Compositions, devices and methods for treating CNS disorders
By designing BBB transport fusion proteins containing HSA and IGF1R binding domains, the problem of macromolecular proteins passing through the blood-brain barrier is solved, and the therapeutic effect of central nervous system diseases has been improved.
Patent Information
- Application Number
- CN202380021666.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-28
- Filing Date
- 2023-01-27
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to effectively pass macromolecular proteins through the blood-brain barrier, limiting protein treatment methods for central nervous system diseases.
A BBB transport fusion protein has been developed, containing the binding domain of human serum albumin (HSA) and insulin growth factor-1 receptor (IGF1R), as well as cargo moieties and linker moieties, enhanced by specific amino acid sequences and structural designs. The ability of protein to pass through.
It achieves efficient crossing of the blood-brain barrier, improves the delivery ability of therapeutic proteins in the central nervous system, and enhances the therapeutic effect on certain diseases such as lysosomal storage diseases.
Smart Images

Figure CN118984840A_ABST
Abstract
Description
[0001] Priority claim
[0002] This application claims priority to U.S. Patent Application No. 63 / 304,377, filed on January 28, 2022. The entire contents of the foregoing application are incorporated herein by reference in their entirety. Background Art
[0003] In theory, many neurodegenerative diseases and other central nervous system (CNS) disorders can be treated by proteins such as enzymes, cytokines and antibodies. However, the prospect of using protein-based therapy to treat CNS disorders is limited by the difficulty of transporting molecules greater than 500 daltons across the blood-brain barrier (BBB), which is formed by lining blood vessels and brain endothelial cells (BEC) connected to each other by tight junctions. Receptor-mediated transcytosis (RMT) is one of the various methods explored to increase the delivery of proteins across the BBB. The RMT method generally uses intravenous or subcutaneous administration of fusion proteins, which connect therapeutic proteins to molecules of one of the endogenous receptors expressed on the BEC surface. After receptor binding, the RMT process requires the internalization of receptor-fusion protein complexes and the exocytosis of fusion proteins on the near-cavity side of the cell. Candidate target receptors for RMT include transferrin receptor, insulin receptor, insulin-like growth factor-1 receptor (IGF1R), low-density lipoprotein (LDL) receptor-related proteins 1 and 2 (LRP-1 and LRP-2), diphtheria toxin receptor, and TMEM30A. Results obtained in preclinical and clinical studies indicate that multiple factors can affect the amount and / or activity of therapeutic proteins that cross the BBB (including the plasma half-life of the fusion protein and its binding affinity to the RMT target receptor). Summary of the invention
[0004] BBB transport fusion proteins are described herein, comprising a cargo portion located at the C-terminus of a separate domain that binds to human serum albumin (HSA) and to the extracellular portion of human IGF1R (hIGF1R), such as a molecule having activity that can be used to treat or diagnose a target central nervous system (CNS) disorder or condition. In one embodiment, the IGF1R binding domain is disposed between the HSA binding domain and the cargo portion. In another embodiment, the HSA binding domain is disposed between the IGF1R binding domain and the cargo portion. In one embodiment, a linker portion is disposed between the two binding domains and / or between the hIGF1 binding domain and the cargo portion. In one embodiment, one or both of the HSA binding domain and the hIGF1R binding domain have a molecular weight of less than about any one of 75 kDa, 50 kDa, or 25 kDa. In one embodiment, the amino acid sequence of each of the HSA binding domain and the hIGF1R binding domain is from a single-chain Fab (scFab), a single-chain Fv (scFv), or a single-domain antibody (sdAb). In one embodiment, the cargo moiety (molecule) has a molecular weight of about 1 kD to about 200 kD, or about 2 kD to about 100 kD. In one embodiment, the cargo moiety (molecule) consists essentially of or consists of the amino acid sequence of a polypeptide (e.g., a cytokine, an enzyme, or an antibody). In one embodiment, the linker moiety is a linker peptide less than 50 amino acids in length.
[0005] In one aspect, the disclosure features a BBB transport fusion protein comprising a primary structure defined by Formula I: AB-L1-RB-L2-C or by Formula II: RB-L1-AB-L2-C, wherein in each formula, AB comprises an HSA binding domain, L1 comprises a first linker amino acid sequence, RB comprises a hIGF1R binding domain, L2 comprises a second linker amino acid sequence, and C comprises an amino acid sequence of a cargo polypeptide.
[0006] In one embodiment, the fusion protein binds to domain 1 (DI) or domain 2 (DII) of HSA via AB and does not substantially inhibit the binding of human FcRn (h-FcRn) to HSA. ... domain with a K of less than about 1 nM to about 100 nM in the pH range of about 5.0 to about 7.4 as determined by surface plasmon resonance at 25°C. D Affinity binds to HSA. In some embodiments, the fusion protein also binds to at least one mammalian serum albumin ortholog via AB at 25°C in the pH range of about 5.5 to about 7.4. In one embodiment, the albumin ortholog is from mouse, rat, hamster, rabbit, guinea pig, pig, cat, dog, or non-human primate (e.g., cynomolgus monkey or rhesus monkey).
[0007] In one embodiment, the AB comprises a first, second and third amino acid sequence corresponding to the three complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region of an anti-HSA antibody (e.g., a conventional antibody having two heavy chains and two light chains, a scFab, a scFv, an sdAb). In one embodiment, the amino acid sequences of CDR1, CDR2 and CDR3 in the AB are: GRTFIAYA (SEQ ID NO: 1) or a conservatively substituted variant thereof; ITNFAGGTT (SEQ ID NO: 2) or a conservatively substituted variant thereof; and AADRSAQTMRQVRPVLPY (SEQ ID NO: 3) or a conservatively substituted variant thereof.
[0008] In one embodiment, AB consists essentially of or consists of QVQLVESGGGLVQAGGSLRLSCVASGRTFIAYAMGWFRQAPGKEREFVAAITNFAGGTTYYADSVKGRFTISRDNAKTTVYLQMNSLKPEDTALYYCAADRSAQTMRQVRPVLPYWGQGTQVTVSS (SEQ ID NO: 4), or a conservatively substituted variant thereof. In one embodiment, AB consists essentially of or consists of QVQLVESGGGLVQPGGSLRLSCAASGRTFIAYAMGWFRQAPGKEREFVAAITNFAGGTTYYADSVKGRFTISRDNAKTTVYLQMNSLRAEDTAVYYCAADRSAQTMRQVRPVLPYWGQGTLVTVSS (SEQ ID NO: 5), or a conservatively substituted variant thereof. In one embodiment, the AB consists essentially of or consists of the amino acid sequence of the heavy chain variable region of an antibody that cross-competes with the sdAb consisting of SEQ ID NO:4 or SEQ ID NO:5 for binding to HSA.
[0009] The fusion protein binds to hIGF1R expressed on the surface of human brain endothelial cells via the RB domain. In some embodiments, the fusion protein does not substantially bind to the human insulin receptor (h-IR). In some embodiments, the fusion protein does not substantially inhibit the binding of insulin, insulin growth factor 1 (IGF1) or insulin growth factor 2 (IGF2) to hIGF1R. In one embodiment, the fusion protein binds to an epitope in the extracellular domain of hIGF1R comprising FENFLHNSIFVPR (SEQ ID NO: 6) via RB. In one embodiment, as determined by surface plasmon resonance at 25°C, the fusion protein binds to the hIGF1R via RB with a K of about 0.5nM to about 50nM in the pH range of about 5.0 to about 7.4. D Affinity binds to hIGF1R. In some embodiments, the fusion protein also binds to at least one mammalian IGF1R ortholog via RB at 25°C and in a pH range of about 5.0 to about 7.4. In one embodiment, the IGF1R ortholog is from a mouse, rat, hamster, rabbit, guinea pig, dog, cat, or non-human primate (e.g., cynomolgus monkey or rhesus monkey). In one embodiment, RB comprises the first, second, and third amino acid sequences of the three complementary determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region corresponding to an anti-hIGF1R antibody (e.g., a conventional antibody, scFab, scFv, sdAb having two heavy chains and two light chains). In one embodiment, the CDR1, CDR2 and CDR3 amino acid sequences in RB are GRTIDNYA (SEQ ID NO: 7) or conservatively substituted variants thereof; IDWGDGGX, wherein X is A or T (SEQ ID NO: 8) or conservatively substituted variants thereof; and AMARQSRVNLDVARYDY (SEQ ID NO: 9) or conservatively substituted variants thereof. In one embodiment, the CDR2 sequence in RB is IDWGDGGA (SEQ ID NO: 10).
[0010] In one embodiment, RB consists essentially of or consists of: QVKLEESGGGLVQAGGSLRLSCAASGRTIDNYAMAWSRQAPGKDREFVATIDWGDGGARYANSVKGRFTISRDNAKGTMYLQMNNLEPEDTAVYSCAMARQSRVNLDVARYDYWGQGTQVTVSS (SEQ ID NO: 11) or a conservatively substituted variant thereof. In another embodiment, RB consists essentially of or consists of: QVQLVESGGGLVQPGGSLRLSCAASGRTIDNYAMAWVRQAPGKGLEWVATIDWGDGGTRYANSVKGRFTISRDNSKNTMYLQMNSLRAEDTAVYYCAMARQSRVNLDVARYDYWGQGTLVTVSS (SEQ ID NO: 12) or a conservatively substituted variant thereof. In one embodiment, RB consists essentially of or consists of the amino acid sequence of the heavy chain variable region of an antibody that cross-competes with a sdAb consisting of SEQ ID NO:11 or SEQ ID NO:12 for binding to hIGF1R.
[0011] In some embodiments, the cargo portion in the fusion protein comprises, consists essentially of, or consists of the amino acid sequence of an enzyme deficient in lysosomal storage diseases (LSDs), such as α-L-iduronidase (IDUA), iduronate-2-sulfatase (IDS), arylsulfatase B (ARSB), N-sulfoglucosamine sulfohydrolase (SGSH), glucosylceramidase (GBA), α-galactosidase A (GLA), and α-1,4-glucosidase (GAA). In one embodiment, the cargo portion is not IDS. In other embodiments, the cargo portion (molecule) comprises, consists essentially of, or consists of the amino acid sequence of an antibody or antigen-binding fragment thereof that binds to a target protein in the brain (e.g., β-secretase 1 (BACE1), an immunotherapy target (e.g., programmed death receptor 1 (PD-1)).
[0012] The L1 and L2 amino acid sequences in the BBB transport fusion proteins of the present disclosure may be the same or different. In some embodiments, the length of each of L1 and L2 is 3 to about 35 amino acids, 4 to about 30 amino acids, or 5 to about 20 amino acids. In one embodiment, each of L1 and L2 is essentially composed of or consists of (GGGGS) n(SEQ ID NO: 13), wherein n is equal to 3, 4 or 5. In one embodiment, each of L1 and L2 consists essentially of or consists of (GGGGS)4(SEQ ID NO: 14). In one embodiment, the cargo moiety in the BBB transport fusion protein is an IDUA protein. In one embodiment, the BBB transport IDUA fusion protein comprises Figure 6 The amino acid sequence shown in (SEQ ID NO: 38) consists essentially of or consists of the amino acid sequence.
[0013] In another aspect, the present disclosure provides a polynucleotide (e.g., an isolated polynucleotide) comprising a nucleotide sequence encoding a BBB transport fusion protein as described herein. In one embodiment, the nucleotide sequence is operably linked to a promoter sequence and a polyA signal sequence. In one embodiment, the promoter sequence is identical or substantially identical to one of the promoter sequences (SEQ ID NO:32, SEQ ID NO:33, or SEQ ID NO:34) in Figure 4. In one embodiment, the polyA signal sequence is identical or substantially identical to one of the polyA signal sequences (SEQ ID NO:35, SEQ ID NO:36, or SEQ ID NO:37) shown in Figure 5. In one embodiment, the BBB transport fusion protein is composed of Figure 6 The polynucleotide comprises the amino acid sequence shown in Figure 7 The nucleotide sequence shown in, consists essentially of or consists of the nucleotide sequence.
[0014] In yet another aspect, the present disclosure provides a mammalian cell (e.g., mouse cell, Chinese hamster ovary (CHO) cell, monkey cell, human cell (e.g., RPE cell) genetically modified to express and secrete a BBB transport fusion protein described herein. In one embodiment, the mammalian cell is genetically modified by transfection with a polynucleotide (e.g., expression vector) encoding a BBB transport fusion protein described herein. In one embodiment, the cargo portion in the fusion protein is an IDUA protein. In one embodiment, the cargo portion is transfected with a polynucleotide (e.g., expression vector) encoding a BBB transport fusion protein described herein. Figure 7 The mammalian cells were derived from ARPE-19 cells by transfection with an expression vector containing the nucleotide sequence shown in .
[0015] The present disclosure also provides a composition comprising multiple genetically modified cells as described herein and a method for manufacturing the composition. In one embodiment, the composition comprises cell culture medium or storage medium. In one embodiment, the composition comprises a polymer solution wherein suspended with cells, such as a polymer solution as described herein, for example, a polymer solution comprising alginate and a cell binding material such as defined herein. In one embodiment, the method for manufacturing the composition includes cultivating multiple genetically modified cells as described herein, until the desired number of cultured cells has been produced, and the desired number of cultured cells is combined with cell culture medium, storage medium or polymer solution.
[0016] In yet another aspect, the present disclosure is characterized by a device comprising at least one cell-containing compartment comprising a genetically modified mammalian cell or a plurality of such cells as described herein. The device is configured to protect one or more cells from the recipient's immune system and mitigate foreign body response (FBR) (as defined herein) to the implanted device. In one embodiment, the surface of the device comprises a compound or polymer (e.g., a defibrotic compound or a defibrotic polymer) that mitigates the FBR (as defined herein) of the device. In one embodiment, the defibrotic polymer includes a biocompatible zwitterionic polymer, for example, as described in WO 2017 / 218507, WO 2018 / 140834 or Liu et al., Zwitterionically modified alginates mitigate cellular overgrowth for cell encapsulation, Nature Communications (2019) 10: 5262. In one embodiment, the compound is a compound of formula (III):
[0017]
[0018] or a pharmaceutically acceptable salt thereof, wherein variables A, L 1 , M, L 2 , P, L 3and Z and related subvariables are defined herein. In some embodiments, the compound of formula (III) or a pharmaceutically acceptable salt thereof (e.g., formula (III-a), (III-b), (III-bi), (III-b-ii), (III-c), (III-d), (III-e), (III-f), (IV), (IV-a), (V), (Va), (Vb), (Vc), (Vd), (VI-a), (VI-b), (VI-c), (VI-d) or (VI-e)) is a compound described herein, including, for example, one of the compounds shown in Table 6 herein. In one embodiment, the compound of formula (III) is a compound selected from Compound 100, Compound 101, Compound 102 or Compound 122 shown in Table 6.
[0019] In one aspect, the device of the present disclosure is a two-compartment hydrogel capsule (e.g., a microcapsule (less than 1 mm in diameter) or a millicapsule (at least 1 mm in diameter)), wherein a cell-containing compartment (e.g., an inner compartment) comprising a plurality of living genetically modified cells described herein (and optionally one or more cell-binding substances) is surrounded by a barrier compartment (e.g., an outer compartment, such as a hydrogel layer) comprising a defibrotizing polymer. In one embodiment, the defibrotizing polymer comprises a defibrotizing compound. In one embodiment, the defibrotizing compound is a compound of formula (III).
[0020] In another aspect, the disclosure features a formulation (e.g., a composition) comprising a plurality (at least any of 3, 6, 12, 25, 50 or more) of the cell-containing devices described herein, e.g., a formulation of hydrogel capsules encapsulating genetically modified ARPE-19 cells. In some embodiments, the formulation is a pharmaceutically acceptable composition.
[0021] In another aspect, the present disclosure is characterized by a method for preparing or manufacturing a device comprising genetically modified cells as described herein. In some embodiments, the method includes providing a genetically modified cell or a plurality of such cells, and one or more cells are arranged in a closed component (e.g., a cell-containing compartment of a device as described herein). In some embodiments, the closed component includes a flexible polymer (e.g., PLA, PLG, PEG, CMC or a polysaccharide, such as alginate). In some embodiments, the closed component includes a non-flexible polymer or a metal shell. In some embodiments, the surface of the device is chemically modified, for example, with a compound of formula (III) as described herein.
[0022] In one embodiment, equipment as herein described or multiple equipment are combined with a pharmaceutically acceptable excipient to prepare equipment preparation or composition, the equipment preparation or composition can be applied to the subject (for example, being administered to the intraperitoneal cavity) of the BBB transport fusion protein treatment that needs to be produced by the equipment. In one embodiment, genetically modified cells are derived from human cells (for example, RPE cells, ARPE-19 cells), and the equipment preparation or composition can be continuously delivered to the subject in a continuous time period (for example, at least any one of the following: 3 months, 6 months, 1 year, 2 years or longer).
[0023] In another aspect, the feature of the present disclosure is a method for evaluating a composition, device or device preparation as described herein. In some embodiments, the method includes providing a composition, device or device preparation and evaluating a functional parameter of the composition, device or device preparation. In one embodiment, the functional parameter is the amount of BBB transport fusion protein produced by cells in a composition, device or device preparation in vitro (e.g., when placed in a suitable culture medium) and / or in vivo (e.g., after being implanted in a subject, such as a non-human subject or a human subject).
[0024] In another aspect, the present disclosure is characterized by a method for treating a subject who needs to use a therapy for BBB transport fusion protein as described herein. In one embodiment, the method includes applying an implantable element (e.g., a device or a device preparation) to the subject, the implantable element comprising a genetically modified cell expressing and secreting the fusion protein, or a plurality of such cells. In some embodiments, the application step includes placing a pharmaceutically acceptable preparation in a subject, the preparation comprising a plurality of devices, each of which has the ability to produce BBB transport fusion protein. In some embodiments, the implantable element is applied to, placed in or injected into the peritoneal cavity (e.g., a cyst), omentum or subcutaneous fat of the subject. In one embodiment, the method further includes measuring the amount of BBB transport fusion protein present in a tissue sample removed from the subject (e.g., plasma separated from a blood sample or a tissue sample obtained from a CNS or a target organ). In one embodiment, a tissue sample is removed from a patient 15, 30, 60 or 120 days after applying, implanting or placing a device or a device preparation. In some embodiments, the subject is a person. In one embodiment, the subject is a human patient diagnosed with neuronopathy MPS disease, and the fusion protein is included in the glycosaminoglycan metabolic enzyme lacking in neuronopathy MPS disease. In one embodiment, implantable elements produce the BBB transport fusion protein of the amount that is enough to reduce one or more symptoms of neuronopathy MPS disease. In one embodiment, the treatment reduces the heparan sulfate level in the brain and one or more other organs or tissues (such as liver, spleen, kidney, lung and heart) outside the CNS optionally. In one embodiment, the patient has been diagnosed with mucopolysaccharidosis type I (MPS I), and the BBB transport fusion protein includes people IDUA protein.
[0025] The details of one or more embodiments of the present disclosure are set forth herein. Other features, objects, and advantages of the present disclosure will be apparent from the detailed description, drawings, examples, and claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figures 1A-1J The amino acid sequence of a wild-type human precursor polypeptide of an exemplary LSD enzyme that can be included as a cargo polypeptide in a BBB transport fusion protein described herein is shown: GAA ( Figure 1A , SEQ ID NO: 15); GBA ( Figure 1B , SEQ ID NO: 16); GLA ( Figure 1C , SEQ ID NO: 17); GNS ( Figure 1D , SEQ ID NO: 18); GUSB ( Figure 1E , SEQ ID NO: 19); HGSNAT ( Figure 1F , SEQ ID NO:20); IDS( Figure 1G , SEQ ID NO:21); IDUA( Figure 1H , SEQ ID NO:22); NAGLU( Fig. 1I , SEQ ID NO:23); and SGSH ( Figure 1J , SEQ ID NO:24).
[0027] Figure 2A-2B An exemplary amino acid sequence of a precursor form of a human protein to which the BBB transport fusion proteins described herein bind is shown, wherein Figure 2A (SEQ ID NO:25) shows the amino acid sequence of the precursor human IGF1R monomer (UniProtKB-P08069), wherein the signal peptide is italicized, the furin cleavage site is shown in lowercase italics, and the underlined bold font indicates amino acids that are contact points in the putative binding site of certain hIGF1R binding domains described herein, and Figure 2B (SEQ ID NO:95) shows the amino acid sequence of precursor human serum albumin, with the signal peptide underlined.
[0028] Figures 3A-3F The amino acid sequence of an exemplary BBB transport IDUA fusion protein of the present disclosure is shown, wherein Figure 3A (SEQ ID NO:26), Figure 3B (SEQ ID NO:27) and Figure 3C The fusion protein in (SEQ ID NO:28) comprises the parent anti-HSA and one of three different parent anti-IGF1R sdAb sequences; Figure 3D (SEQ ID NO: 29), Figure 3E (SEQ ID NO:30) and Figure 3F The fusion protein in (SEQ ID NO: 31) comprises Figure 3A , 3B and humanized variants of the anti-HSA and anti-IGF1R sdAb sequences shown in 3C and 3D; and each of these fusion proteins comprises two linker sequences having 4 or 5 repeats of GGGGS (SEQ ID NO: 92).
[0029] Figures 4A-4C An exemplary promoter sequence that can be used in the expression construct of the BBB transport fusion protein of the present disclosure is shown: pCAG promoter sequence ( Figure 4A , SEQ ID NO:32); EF1α promoter sequence ( Figure 4B , SEQ ID NO:33); and EFS promoter sequence ( Figure 4C , SEQ ID NO:34).
[0030] Figures 5A-5C Exemplary polyA signal sequences that can be used in expression constructs for BBB transport fusion proteins of the present disclosure are shown: rBG poly A signal sequence ( Figure 5A , SEQ ID NO:35); SV40 late poly A signal sequence ( Figure 5B , SEQ ID NO:36) and BGH poly A signal sequence ( Figure 5C , SEQ ID NO:37).
[0031] Figure 6 The amino acid sequence of an exemplary BBB transporting IDUA fusion protein is shown (SEQ ID NO:38), wherein underlining indicates the VHH consensus signal peptide, bold font indicates the anti-HSA sdAb, italics indicate the anti-IGF1R sdAb, bold italics indicate the wild-type human mature IDUA amino acid sequence, and dash-dot underlining indicates the flexible linker sequence.
[0032] Figure 7 Show that it can be used to express Figure 6 , wherein the wavy underline indicates the EF1A promoter sequence, the straight underline indicates the exemplary coding sequence of the VHH consensus signal peptide, the bold font indicates the exemplary coding sequence of the anti-HSA sdAb, the italics indicate the exemplary coding sequence of the anti-IGF1R sdAb, the bold italics indicate the exemplary coding sequence of the wild-type human mature IDUA amino acid sequence, the dotted underline indicates the coding sequence of the flexible linker sequence, the dotted underline indicates the stop codon, and the underlined italic font indicates the rBG poly A signal sequence.
[0033] Figures 8A-8B The IDUA activity in a single IDUA fusion protein containing an exemplary anti-IGF1R sdAb fused to hIDUA via an amino acid linker is shown, wherein Fig. 8A shows in vitro IDUA activity in culture of cells expressing one of six different fusion constructs based on sdAb orientation and linker length, and Figure 8B Comparison of the results from transplantation of cells expressing wild-type hIDUA (light grey bars) or Fig. 8A In vivo hIDUA activity in liver and plasma samples of MPS-1 mice encapsulated with cells expressing the fusion construct that produces the highest in vitro hIDUA activity (IGF1rR-hIDUA, dark grey bars).
[0034] Fig. 9A is a graph showing in vitro IDUA activity in conditioned media of cells expressing one of six different dual IDUA fusion proteins containing hIDUA in various orientations, an exemplary anti-IGF1R sdAb (IGF1R5), and an exemplary anti-HSA sdAb (R28).
[0035] Fig. 9B is a graph comparing in vitro IDUA activity in conditioned media from cells expressing an exemplary anti-IGF1R-hIDUA fusion enzyme (IGF1R4-hIDUA, light grey bars) versus cells expressing an exemplary anti-HSA-anti-IGF1R-hIDUA fusion enzyme (R28-IGF1R5-hIDUA, dark grey bars).
[0036] Fig.10 is a graph comparing in vivo hIDUA activity in plasma and systemic (non-brain) tissues of MPS-1 mice implanted with encapsulated cells expressing wild-type hIDUA (light gray bars) or an exemplary anti-HSA-anti-IGF1R-hIDUA fusion enzyme (R28-IGF1R5-hIDUA, dark gray bars).
[0037] Fig.11 is a graph comparing heparan sulfate levels in brain tissue samples from untreated MPS-1 mice (light grey bars) and MPS-1 mice implanted with encapsulated cells expressing an exemplary anti-HSA-anti-IGF1R-hIDUA fusion enzyme (R28-IGF1R5-hIDUA, dark grey bars).
[0038] Fig. 12A and 12B are the amino acid sequences of exemplary BBB transport IDS fusion proteins of the present disclosure (SEQ ID NO:93 and SEQ ID NO:94).
[0039] Fig.13 is a graph illustrating a comparison of enzyme activity levels produced with exemplary constructs described herein as outlined in Example 5.
[0040] Fig.14 is a graph comparing heparan sulfate levels in liver, spleen, kidney, lung, and heart tissue samples from untreated MPS-1 mice (grey bars) and MPS-1 mice implanted with encapsulated cells expressing an exemplary anti-HSA-anti-IGF1R-hIDUA fusion enzyme (R28-IGF1R5-hIDUA, black bars).
[0041] Fig.15is a graph comparing heparan sulfate levels in brain tissue samples from untreated MPS-1 mice (solid black bars) and MPS-1 mice implanted with encapsulated cells expressing an exemplary hIDUA fusion enzyme (grey bars). DETAILED DESCRIPTION
[0042] The feature of the present disclosure is the BBB transport fusion protein comprising HSA and hIGF1R binding domain and cargo part, is genetically modified to express and secrete mammalian cells (for example, human RPE cells) of these fusion proteins, and the composition and equipment comprising genetically modified cells. In some embodiments, the equipment includes a cell-containing compartment, and the cell-containing compartment includes cell binding material and genetically modified cells. In some embodiments, the equipment is configured to alleviate FBR when placed in a subject (for example, a human subject). In some embodiments, fusion protein, genetically modified cells, compositions and equipment can be used to treat CNS disorders or illnesses, such as lysosomal storage diseases. Various embodiments will be described below.
[0043] Abbreviations and definitions
[0044] Throughout the detailed description and examples of the present disclosure, the following abbreviations will be used.
[0045] CNS Central Nervous System
[0046] CS Chondroitin Sulfate
[0047] DS Dermatan Sulfate
[0048] GAA acid alpha-glucosidase
[0049] GAG Glycosaminoglycan
[0050] GBA β-glucosidase
[0051] GLA α-galactosidase A
[0052] GNS N-acetylgalactosamine-6-sulfatase
[0053] GUSB β-glucoronidase
[0054] HS Heparan Sulfate
[0055] HGSNAT Heparan-α-glucosamine N-acetyltransferase protein
[0056] IDS Iduronate-2-sulfatase protein
[0057] IDUA α-L-iduronidase protein
[0058] MPS Mucopolysaccharidosis
[0059] NAGLU α-N-acetyl-glucosaminidase
[0060] SGSH N-sulfoglucosamine sulfohydrolase
[0061] In order to more easily understand the present disclosure, some technical and scientific terms used herein are specifically defined below. Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by ordinary technicians in the field to which the present disclosure belongs.
[0062] As used herein, including the appended claims, singular forms such as "a," "an," and "the" include their corresponding plural referents unless the context clearly dictates otherwise.
[0063] "About" or "approximately", when used herein to modify a numerically defined parameter (e.g., the amount of fusion protein secreted by an engineered cell, a physical description of a device (e.g., a hydrogel capsule) such as diameter, sphericity, the number of cells encapsulated therein, the number of devices in a formulation), means that the recited value is within an acceptable functional range of the defined parameter as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, such as the limitations of the measurement system, including the acceptable error range for the measurement system. For example, "about" can mean a range of 20% above and below the recited value. As a non-limiting example, a hydrogel capsule defined as having a diameter of about 1.5 millimeters (mm) and encapsulating about 5 million (M) cells can have a diameter of 1.2 to 1.8 mm and can encapsulate 4M to 6M cells. As another non-limiting example, a formulation of about 100 devices (e.g., hydrogel capsules) includes a formulation having 80 to 120 devices. In some embodiments, the term "about" means that the modified parameter may vary by as much as 15%, 10%, or 5% above and below the stated value of that parameter.
[0064] As used herein, the term "acquire" or "acquiring" refers to the process of obtaining a value (e.g., a numerical value) or a physical entity (e.g., a sample) by "directly obtaining" or "indirectly obtaining" the value or image or the physical entity. "Directly obtaining" means performing a process (e.g., performing an analytical method or protocol) to obtain a value or a physical entity. "Indirectly obtaining" refers to receiving the value or physical entity from another party or source (e.g., a third-party laboratory that directly obtains a physical entity or a value). Directly obtaining a value or a physical entity includes performing a process that includes a physical change of a physical substance or the use of a machine or device. Examples of directly obtaining a value include obtaining a sample from a human subject. Directly obtaining a value includes performing a process that uses a machine or device, such as using a fluorescence microscope to obtain fluorescence microscopy data.
[0065] As used herein, "Administer," "administering," or "administration" refers to implanting, absorbing, ingesting, injecting, placing, or otherwise introducing an entity described herein (e.g., a device or a formulation of a device) into a subject, or providing such an entity to a subject for administration.
[0066] As used herein, "defibrotic" refers to a compound or material that reduces the foreign body response (FBR). For example, the amount of FBR induced in a biological tissue by implanting a device (e.g., a hydrogel capsule) comprising a defibrotic compound (e.g., a hydrogel capsule comprising a polymer covalently modified with a compound listed in Table 6) into the tissue is lower than the FBR induced by implanting a reference device without defibrotic (afibrotic-null), i.e., a device lacking any defibrotic compound but having substantially the same composition (e.g., one or more of the same cell types) and structure (e.g., size, shape, number of compartments). In one embodiment, the FBR is induced using an assay known in the art, such as described in WO 2017 / 075630 or using Vegas, A. et al., Nature 2017 / 075630. One or more of the assays / methods described in Biotechnol (supra) (e.g., measurement of subcutaneous tissue proteases of implanted capsules, Masson's trichrome staining (MT), hematoxylin or eosin staining of tissue sections, quantification of collagen density, cell staining and confocal microscopy of macrophages (CD68 or F4 / 80), myofibroblasts (α-muscle actin, SMA), or general cell deposition, quantification of 79 RNA sequences for known inflammatory factors and immune cell markers, or FACS analysis of macrophages and neutrophils on the device (e.g., capsule) retrieved after 14 days in the intraperitoneal space of a suitable test subject (e.g., immunocompetent mouse)) assess the extent of FBR through an immune response in tissue containing an implanted device (e.g., hydrogel capsule), which may include, for example, protein adsorption, macrophages, multinucleated foreign body giant cells, fibroblasts, and angiogenesis. In one embodiment, the FBR is assessed by measuring the level of one or more immune response biomarkers (e.g., cathepsin, TNF-α, IL-13, IL-6, G-CSF, GM-CSF, IL-4, CCL2, or CCL4) in the tissue containing the implant. In some embodiments, the FBR induced by the device of the present invention (e.g., a hydrogel capsule comprising a defibrotic compound disposed on its outer surface) is at least about 80%, about 85%, about 90%, about 95%, about 99%, or about 100% lower than the FBR induced by a reference device without FBR, such as a device substantially identical to the device tested or claimed except for the lack of a device for reducing FBR (e.g., a hydrogel capsule that does not comprise a defibrotic compound but is otherwise substantially identical to the claimed capsule). In some embodiments, the FBR (e.g., the level of one or more biomarkers) is measured after about 30 minutes, about 1 hour, about 6 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 1 week, about 2 weeks, about 1 month, about 2 months, about 3 months, about 6 months, or more.
[0067] "Acid alpha-glucosidase protein," "acid maltase protein," "alpha-1,4-glucosidase protein," and "GAA protein" are used interchangeably herein and refer to a protein comprising the mature amino acid sequence encoded by a wild-type mammalian (e.g., human) GAA gene, or any fragment, mutant, variant, or derivative thereof, having GAA enzyme activity within 80%-120%, 85%-115%, 90%-110%, or 95%-105% of the corresponding wild-type mammalian mature GAA protein as measured by any art-recognized GAA activity assay. GAA enzyme catalyzes the hydrolysis of alpha(1,4) and alpha(1,6) linkages in glycogen, thereby producing free glucose and shortened glycogen polymers. GAA enzyme activity can be measured using any art-recognized assay. The wild-type human GAA gene encodes a 952 amino acid precursor propeptide, of which the N-terminal 27 amino acids constitute a signal peptide and amino acids 28-69 constitute a propeptide (UniProtKB-P10253). In some embodiments, the GAA amino acid sequence in the BBB transport fusion proteins described herein comprises Figure 1A In one embodiment, the amino acid sequence of human GAA in the BBB transport fusion protein consists essentially of amino acids 70-952 of the human precursor GAA sequence shown in Figure 1A The sequence shown in is composed of amino acids 28-952.
[0068] "α-galactosidase A protein," "α-Gal A protein," and "GLA protein" are used interchangeably herein and refer to a protein comprising the mature amino acid sequence encoded by a wild-type mammalian (e.g., human) GLA gene, or any fragment, mutant, variant, or derivative thereof, having GLA enzyme activity within 80%-120%, 85%-115%, 90%-110%, or 95%-105% of the corresponding wild-type mammalian mature GLA protein as measured by any art-recognized GLA activity assay. GLA enzyme hydrolyzes terminal α-D-galactose residues in glycosphingolipids, particularly ceramide trihexosylceramide (Gb3). GLA enzyme activity can be measured using any art-recognized assay. The wild-type human GLA gene encodes a 429 amino acid polypeptide, of which the N-terminal 31 amino acids constitute a signal peptide (UniProtKB-P06280). In some embodiments, the human GLA amino acid sequence in the BBB transport fusion protein described herein consists essentially of Figure 1C The amino acid sequence of human precursor GLA is shown in Figure 3.
[0069] "α-L-iduronidase protein" and "IDUA protein" are used interchangeably herein and refer to a protein comprising the mature amino acid sequence encoded by a wild-type mammalian (e.g., human) IDUA gene, or any fragment, mutant, variant, or derivative thereof, having an IDUA enzyme activity within 80%-120%, 85%-115%, 90%-110%, or 95%-105% of the corresponding wild-type mammalian mature IDUA protein as measured by any art-recognized IDUA activity assay (e.g., hydrolysis of the substrate 4-methylumbelliferyl-α-L-iduronide (4MU-iduronide), see, e.g., Ou, L. et al., Mol Genet Metab. 2014 Feb: 111(2): 113-115) or any IDUA activity assay described herein. IDUA proteins hydrolyze non-reducing terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs), such as dermatan sulfate and heparan sulfate. The wild-type human IDUA gene encodes a 653-amino acid precursor protein, of which the N-terminal 26 or 27 amino acids constitute a signal peptide (GenBAnk Accession No. AAA81589.1, GenBAnk Accession No. AAA51698.1; UniProtKB-P35475). In some embodiments, the mature human IDUA amino acid sequence in the BBB transport fusion protein described herein comprises Figure 1H In one embodiment, the mature human IDUA amino acid sequence in the BBB transport fusion protein consists essentially of amino acids 26, 27 or 28 to amino acid 653 of the precursor human IDUA amino acid sequence shown in Figure 1H The amino acid sequence shown in is composed of amino acids 27-653.
[0070] "α-N-acetyl-glucosaminidase protein", "N-acetyl-α-glucosaminidase" and "NAGLU protein" are used interchangeably herein to refer to a protein comprising a mature amino acid sequence encoded by a wild-type mammalian (e.g., human) NAGLU gene, or any fragment, mutant, variant or derivative thereof, having an enzymatic activity within 80%-120%, 85%-115%, 90%-110% or 95%-105% of the corresponding wild-type mammalian mature NAGLU protein as measured by any art-recognized NAGLU assay. NAGLU catalyzes the hydrolysis of terminal non-reducing N-acetyl-D-glucosamine residues in N-acetyl-α-D-aminoglucosides. The wild-type human NAGLU gene encodes a 743 amino acid precursor polypeptide, of which the N-terminal 23 amino acids constitute a signal peptide (UniProtKB-P54802). In some embodiments, the mature human NAGLU amino acid sequence in the BBB transport fusion protein described herein consists essentially of Fig. 1I The amino acid sequence shown in is composed of amino acids 24-743.
[0071] "β-glucuronidase protein" and "GUSB protein" are used interchangeably herein to refer to a protein comprising a mature amino acid sequence encoded by a wild-type mammalian (e.g., human) GUSB gene, or any fragment, mutant, variant, or derivative thereof, having an enzymatic activity within 80%-120%, 85%-115%, 90%-110%, or 95%-105% of the corresponding wild-type mammalian mature GUSB protein as measured by any art-recognized GUSB assay. GUSB catalyzes the hydrolysis of β-D-glucuronoside to alcohol and D-glucuronic acid. The wild-type human GUSB gene encodes a 651 amino acid precursor polypeptide, of which the N-terminal 22 amino acids constitute a signal peptide (UniProtKB PO8236). In some embodiments, the mature human GUSB amino acid sequence in the BBB transport fusion protein described herein consists essentially of Figure 1E The sequence shown in is composed of amino acids 23-651.
[0072] "β-glucosidase protein", "acid β-glucocerebrosidase protein", "glucocerebrosidase protein", "glucosylceramidase protein", "lysosomal acid glucosylceramidase protein", "lysosomal acid GCase protein" and "GBA protein" are used interchangeably herein to refer to a protein comprising a mature amino acid sequence encoded by a wild-type mammalian (e.g., human) GBA gene, or any fragment, mutant, variant or derivative thereof, having an enzymatic activity within 80%-120%, 85%-115%, 90%-110% or 95%-105% of the corresponding wild-type mammalian mature GBA protein as measured by any art-recognized GBA assay. GBA in the lysosomal compartment catalyzes the breakdown of the glycolipid glucosylceramide (GlcCer) into ceramide and glucose. The wild-type human GBA gene encodes a 536 amino acid precursor polypeptide, of which the N-terminal 39 amino acids constitute a signal peptide (UniProtKB P04062.3). In some embodiments, the mature human GBA amino acid sequence in the BBB transport fusion proteins described herein consists essentially of Figure 1B The sequence shown in is composed of amino acids 40-536.
[0073] As used herein, "cell" refers to an engineered cell (e.g., a genetically modified cell) or an unengineered cell. In one embodiment, the cell is an immortalized cell or an engineered cell derived from an immortalized cell. In one embodiment, the cell is a living cell, e.g., viable as measured by any technique described herein or known in the art.
[0074] As used herein, "cell binding peptide (CBP)" means a linear or cyclic peptide comprising an amino acid sequence of a cell binding domain of a ligand derived from a cell adhesion molecule (CAM) (e.g., a cell adhesion molecule that mediates cell-matrix connection or cell-cell connection). In one embodiment, CBP is any CBP described in International Patent Publication WO2020069429. In one embodiment, CBP is a linear peptide comprising RGD (SEQ ID NO: 87) and is less than 10 amino acids in length. In one embodiment, CBP is a linear peptide consisting essentially of GRGD (SEQ ID NO: 88) or GRGDSP (SEQ ID NO: 89).
[0075] As used herein, "CBP- polymer " means a polymer comprising at least one cell binding peptide molecule covalently attached to a polymer via a linker. In one embodiment, the polymer in the CBP- polymer is a synthetic or naturally occurring polysaccharide, such as an alginate, such as sodium alginate. In one embodiment, the linker is an amino acid linker (that is, substantially composed of a single amino acid, or a peptide of several identical or different amino acids), which is connected to the N-terminus or C-terminus of CBP via a peptide bond. In one embodiment, the CBP- polymer is any CBP- alginate defined in WO2020069429.
[0076] As used herein, "cell binding substance (CBS)" refers to any chemical, biological or other type of material (e.g., small organic compounds, peptides, polypeptides) that can simulate at least one activity of a ligand of a cell adhesion molecule (CAM) or other cell surface molecule that mediates cell-matrix connection or cell-cell connection or other receptor-mediated signaling. In one embodiment, when present in a polymer composition encapsulating living cells, CBS can form a temporary or permanent bond or contact with one or more cells. In one embodiment, CBS promotes the interaction between two or more living cells encapsulated in a polymer composition. In one embodiment, the presence of CBS in a polymer composition encapsulating multiple cells (e.g., living cells) is related to one or both of the cell productivity (e.g., expression of therapeutic agents) and increased cell viability when the encapsulated cells are implanted in a test subject (e.g., mouse). In one embodiment, CBS is physically attached to one or more polymer molecules in a polymer composition. In one embodiment, CBS is a cell binding peptide as defined herein or in WO2020069429.
[0077] As used herein, "conservatively modified variants" or "conservative substitutions" refer to variants of a reference peptide or polypeptide that are identical to a reference molecule except that they have one or more conservative amino acid substitutions in the amino acid sequence. In one embodiment, the conservatively modified variant consists of an amino acid sequence that is at least 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the reference amino acid sequence. In some embodiments, the conservatively modified variants of the HSA binding domain sequence and / or IGF1R binding domain sequence do not comprise a substitution of any amino acid in the CDRs. Conservative amino acid substitutions refer to substitutions of amino acids with similar characteristics (e.g., charge, side chain size, hydrophobicity / hydrophilicity, main chain conformation and rigidity, etc.) and that have minimal effect on the biological activity of the resulting substituted peptide or polypeptide. Conservative substitution tables of functionally similar amino acids are well known in the art, and exemplary substitutions grouped by functional characteristics are listed in Table 1 below.
[0078] Table 1. Exemplary conservative amino acid substitution groups.
[0079]
[0080] As used throughout the specification and claims, "consisting essentially of" and variations such as "consist essentially of" or "consisting essentially of" means including any recited elements or groups of elements, and optionally including other elements of similar or different properties to the recited elements, which other elements do not substantially alter the basic or novel characteristics of the specified molecule, composition, device, or method. As a non-limiting example, an HSA binding domain or IGF1R binding domain consisting essentially of a recited amino acid sequence may further comprise one or more amino acids (including substitutions of one or more amino acid residues in the recited amino acid sequence) that do not substantially affect the relevant biological activity of the HSA binding domain or IGF1R binding domain, respectively.
[0081] "Derived from" as used herein with respect to one or more cells refers to cells obtained from a tissue, cell line, or cells that are then optionally cultured, passaged, immortalized, differentiated, and / or induced, etc. to produce one or more derived cells.
[0082] As used herein, a "device" refers to any implantable object (e.g., a particle, a hydrogel capsule, an implant, a medical device) that contains one or more engineered cells (e.g., living cells) capable of expressing and secreting a fusion protein after implantation in the device and has a structure that supports the viability of the cells by allowing cellular nutrients to enter the device.
[0083] As used herein, "effective amount" refers to the amount of any of the following: genetically modified cells that secrete BBB transport fusion proteins, device preparations that produce fusion proteins, the number of genetically modified cells in the device, the amount of CBS and / or defibrotic compounds in the device sufficient to cause the desired biological response. In some embodiments, the term "effective amount" refers to the amount of a component of the device (e.g., the number of cells in the device, the density of defibrotic compounds disposed on the surface of the device and / or in the barrier compartment, the density of CBS in the cell-containing compartment).
[0084] In one embodiment, the desired biological response is an increase in the level of a cargo molecule (e.g., a cargo polypeptide) in a tissue sample removed from a subject treated with (e.g., implanted with) a genetically modified cell, a device containing such a cell, or a device formulation. As will be appreciated by one of ordinary skill in the art, an effective amount can vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the secreted BBB transport fusion protein, composition, or device, the condition being treated, the mode of administration, and the age and health of the subject. An effective amount encompasses both therapeutic and prophylactic treatments.
[0085] In one embodiment, an effective amount of a compound of formula (III) disposed on or in a device is an amount that reduces the FBR to the implanted device compared to a reference device, such as reducing the amount of fibrosis or fibrotic tissue on or near the implanted device.
[0086] In one embodiment, the effective amount of CBS disposed with engineered cells in a cell-containing compartment is an amount that enhances the viability of the cell (e.g., the number of viable cells) compared to a reference device and / or increases the production of a BBB transport fusion protein by the cell (e.g., increasing the level of fusion protein in the plasma of a subject implanted with the device) compared to a reference device. The effective amount of a device, composition, or component (e.g., a defibrotic compound, CBS, engineered cells) can be determined by any technique known in the art as described herein.
[0087] As used herein, "engineered cells" or "genetically modified cells" are mammalian cells (e.g., human cells, such as RPE cells, cells derived from cell lines (e.g., ARPE-19 or other cell lines), stem cells, cells differentiated by iPSC) with non-natural changes, and generally include exogenous nucleotide sequences (e.g., vectors or altered chromosomal sequences) encoding BBB transport fusion proteins as described herein. In one embodiment, the exogenous nucleotide sequence is chromosomal (e.g., an exogenous sequence is disposed in an endogenous chromosomal sequence) or extrachromosomal (e.g., a non-integrated expression vector). In one embodiment, the exogenous nucleotide sequence in the genetically modified cell includes a codon-optimized coding sequence for one, two, or all three of the AB, BBB, or C domains, which achieves a higher fusion protein expression than the naturally occurring coding sequence of each of these domains. Codon-optimized sequences can be commercially available algorithms such as GeneOptimizer (ThermoFisher Scientific), OptimumGene TM (GenScript,Piscataway,NJ USA)、 (ATUM, Newark, CA USA) or Java Codon Adaptation Tool (JCat, www.jcat.de, Grote, A. et al., Nucleic Acids Research, Vol. 33, Supplement No. 2, pp. W526-W531 (2005) produce. In one embodiment, the cell is also genetically modified to reduce or eliminate the expression of one or more proteins naturally expressed by the parental cell. In one embodiment, the genetically modified cell (e.g., modified RPE cell, modified ARPE-19 cell) is cultivated from a cell colony or monoclonal cell line through stably transfected.
[0088] As used herein, an "exogenous nucleotide sequence" is a nucleotide sequence that does not naturally occur in the cells of a subject.
[0089] As used herein, "exogenous polypeptide" is a polypeptide that does not naturally occur in a subject cell (e.g., an engineered cell). Reference to an amino acid position of a particular sequence refers to the position of the amino acid in a reference amino acid sequence, e.g., the sequence of a full-length mature (after signal peptide cleavage) wild-type protein (unless otherwise indicated), and does not exclude the presence of variations (e.g., deletions, insertions, and / or substitutions) at other positions in the reference amino acid sequence.
[0090] As used herein, "expression vector" refers to a recombinant polynucleotide comprising one or more expression constructs encoding one or more proteins to be expressed. Each expression construct contains an expression control sequence operably linked to one or more nucleotide sequences to be expressed. The expression vector contains enough cis-acting elements for expression; other elements for expression can be provided by a host cell or in an in vitro expression system. The vector may contain additional sequence elements for expressing and / or integrating one or more expression cassettes into the genome of a mammalian cell. Expression vectors include all expression vectors known in the art that incorporate recombinant polynucleotides, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., slow viruses, retroviruses, adenoviruses, and adeno-associated viruses). Expression vectors suitable for engineering mammalian cells to express any fusion protein described herein may also contain nucleotide sequences encoding markers for selecting cells containing such vectors. Examples of suitable markers are genes encoding resistance to antibiotics such as ampicillin, chloramphenicol, kanamycin, nourseothricin, or bleomycin.
[0091] "Fabry disease", "GLA deficiency", "α-galactosidase A deficiency" and "Anderson-Fabry disease" are used interchangeably herein to refer to an X-linked LSD caused by a lack of activity of the enzyme α-galactosidase A (GLA or GALA), which results in the destructive accumulation of the glycosphingolipid ceramide trihexosyl (Gb3) in various tissues and organs. More than 370 different mutations located in the human GLA gene have been identified in people with Fabry disease, many of which are unique to a single family. Mutations that eliminate GLA activity lead to a severe, classical form of Fabry disease, which usually begins in childhood. Milder, late-onset forms of Fabry disease are associated with mutations that reduce but do not eliminate GLA activity. A Fabry disease patient refers to an individual diagnosed with or suspected of having Fabry disease. Any method known in the art can be used to diagnose a Fabry disease patient. In one embodiment, a human Fabry disease patient has a GLA gene mutation associated with a lack of GLA enzyme activity and / or Fabry disease.
[0092] As used herein, "Gaucher disease" refers to an autosomal recessive LSD caused by a lack of activity of β-glucocerebrosidase, which results in the accumulation of the glycolipid glucocerebroside in cells throughout the body. At least five forms of Gaucher disease have been identified; the forms associated with CNS complications are named Gaucher disease type 2 and Gaucher disease type 3. The type 2 form is also called acute neuropathic Gaucher disease, which occurs in newborns and infants, and they usually die within the first three years of life. Type 3 Gaucher disease, also known as chronic neuropathic Gaucher disease, usually occurs in the first decade of life, where the occurrence and progression of CNS complications are slower than in type 2 patients. Many mutations located in the GBA gene have been associated with type 2 and type 3 Gaucher disease, of which the L483P substitution is the most common mutation associated with type 3. A Gaucher disease patient refers to an individual who has been diagnosed with or is suspected of having Gaucher disease. In one embodiment, a human Gaucher disease patient has a GBA gene mutation associated with a lack of GBA enzyme activity and / or type 3 Gaucher disease.
[0093] "Heparan-α-glucosaminide N-acetyltransferase protein", "heparan acetyl-CoA:α-glucosaminide N-acetyltransferase protein", "HGSNAT protein" and "N-acetyltransferase protein" are used interchangeably herein to refer to a protein comprising a mature amino acid sequence encoded by a wild-type mammalian (e.g., human) gene, or any fragment, mutant, variant or derivative thereof, having HGSNAT enzyme activity within 80%-120%, 85%-115%, 90%-110% or 95%-105% of the corresponding wild-type mammalian mature HGSNAT protein as measured by any art-recognized HGSNAT assay. HGSNAT catalyzes the acetylation of the terminal glucosamine residue of heparan or heparan sulfate within lysosomes, thereby converting it into a substrate for NAGLU hydrolysis. The wild-type human HGSNAT gene encodes a 663 amino acid polypeptide comprising a predicted signal sequence (UniProtKB-Q68CP4) that is not cleaved after translocation to the endoplasmic reticulum. In some embodiments, the HGSNAT amino acid sequence in the BBB transport fusion proteins described herein consists essentially of Figure 1F The human HGSNAT sequence shown in FIG.
[0094] "High molecular weight alginate" or "HMW-Alg" as used herein means alginate having an approximate molecular weight of 150 kDa-250 kDa.
[0095] "Iduronate-2-sulfatase protein," "IDS protein," "I2S protein," and "α-L-iduronate sulfate sulfatase protein" "IDS" are used interchangeably herein and refer to a protein comprising a mature amino acid sequence encoded by a wild-type mammalian (e.g., human) IDS gene, or any fragment, mutant, variant, or derivative thereof, having IDS enzyme activity within 80%-120%, 85%-115%, 90%-110%, or 95%-105% of the corresponding wild-type mammalian mature IDS protein as measured by any art-recognized IDS assay. IDS hydrolyzes the 2-sulfate group of the L-iduronate 2-sulfate unit of dermatan sulfate, heparan sulfate, and heparan. The wild-type human IDS gene encodes a 550 amino acid precursor polypeptide, of which the N-terminal 25 amino acids constitute a signal peptide and the remaining amino acids constitute a polypeptide, which is processed into a mature polypeptide by removing the propeptide of amino acids 26-33 and then cleaving into two chains formed by amino acids 34-455 and amino acids 456-550. (UniProtKB-P22304). In some embodiments, the IDS amino acid sequence in the BBB transport fusion protein described herein comprises Figure 1GIn one embodiment, the amino acid sequence of the human IDS in the BBB transport fusion protein consists essentially of Figure 1G The sequence shown in is composed of amino acids 26-550.
[0096] "Low molecular weight alginate" or "LMS-Alg" as used herein means alginate with an approximate molecular weight <75 kDa.
[0097] As used herein, "lysosomal storage disease" and "LSD" refer to an inborn error of metabolism caused by a deficiency of an enzyme or its cofactors, which results in defective function of the lysosome and accumulation of one or more glycosaminoglycans (GAGs) in various tissues and organs. GAGs, which are long unbranched polysaccharides composed of repeating disaccharides, include: chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), keratan sulfate (KS), and hyaluronic acid. About 70% of LSDs are caused by enzyme defects, while the rest are due to defects in enzyme activators or related proteins. Known LSDs include enzyme-deficient LSDs and other LSDs listed in Tables 1 and 2 of Pastores et al., Neurol Clin. 31 (4); 1051-1071 (2013). In one embodiment, the LSD is a mucopolysaccharidosis (MPS) or a sphingolipidosis (SP).
[0098] "Medium molecular weight alginate" or "MMW-Alg" as used herein means alginate with an approximate molecular weight of 75 kDa to 150 kDa.
[0099] As used herein, "mucopolysaccharidosis" and "MPS" refer to a disorder caused by a deficiency of enzymes involved in glycosaminoglycan metabolism, which results in accumulation of glycosaminoglycan fragments in lysosomes and can lead to bone, soft tissue and CNS manifestations, particularly for the neuropathic form of MPS. Neuronal damage in neuropathic MPS is associated with the storage of undegraded heparan sulfate (HS) and secondary toxic products such as GM2 and GM3 gangliosides, inflammatory cytokines and reactive oxygen species. Neuropathic MPS includes MPS-1Hurler (MPS-1H), MPS-2, MPS-3 (AD) and MPS-7.
[0100] "Mucopolysaccharidosis type 1" and "MPS1" are used interchangeably herein to refer to LSDs caused by a deficiency in IDUA enzyme activity and the resulting accumulation of GAGs (primarily DS and HS) within the lysosomes of multiple organs and tissues. An MPS1 patient is an individual (e.g., a human) who has been diagnosed with or is suspected of having an MPS1 disease (e.g., severe MPS1 or attenuated MPS1). Patients may be diagnosed using any method known in the art, including clinical, biochemical, and genetic methods for diagnosing MPS1. In one embodiment, a human MPS1 patient has a mutation in the IDUA gene associated with a deficiency in IDUA enzyme activity and / or MPS1 disease.
[0101] "Mucopolysaccharidosis type II," "MPS2," and "Hunter syndrome" are used interchangeably herein to refer to an X-linked LSD caused by a deficiency in IDS enzyme activity and the resulting accumulation of GAGs (primarily DS and HS) within the lysosomes of multiple organs and tissues. An MPS2 patient is an individual (e.g., human) who has been diagnosed with or is suspected of having an MPS2 disease, such as severe early-onset MPS2 (symptoms becoming apparent within 2-4 years of age) or mild, late-onset MPS2. Patients may be diagnosed using any method known in the art, including clinical, biochemical, and genetic methods for diagnosing MPS2. In one embodiment, a human MPS2 patient has a mutation in the IDS gene that is associated with a deficiency in IDS activity and / or MPS2 disease.
[0102] "Mucopolysaccharidosis type IIIA," "MPS 3A," and "Sanfilippo syndrome type A" are used interchangeably herein to refer to an autosomal recessive LSD caused by a deficiency in SGSH activity and the resulting accumulation of heparan sulfate in the CNS. MPS 3A is characterized by severe CNS degeneration. More than 80 different mutations in the SGSH gene have been identified in MPS 3A patients. An MPS 3A patient is an individual (e.g., a human) who has been diagnosed with or is suspected of having MPS3A disease. Patients may be diagnosed using any method known in the art, including clinical, biochemical, and genetic methods for diagnosing MPS 3A. In one embodiment, a human MPS 3A patient has a mutation in the SGSH gene associated with a deficiency in SGSH enzyme activity and / or MPS 3A disease.
[0103] "Mucopolysaccharidosis type IIIB," "MPS 3B," and "Sanfilippo syndrome type B" are used interchangeably herein to refer to an autosomal recessive LSD caused by a deficiency in NAGLU enzyme activity and the resulting accumulation of HS in the CNS. More than 100 different mutations in the human NAGLU gene are associated with the MPS 3B phenotype. An MPS 3B patient is an individual (e.g., a human) who has been diagnosed with or is suspected of having MPS 3B disease. Patients may be diagnosed using any method known in the art, including clinical, biochemical, and genetic methods for diagnosing MPS 3B. In one embodiment, a human MPS 3B patient has a NAGLU gene mutation associated with a deficiency in NAGLU enzyme activity and / or MPS 3B disease.
[0104] "Mucopolysaccharidosis type IIIC," "MPS 3C," and "Sanfilippo syndrome type C" are used interchangeably herein to refer to an autosomal recessive LSD caused by a deficiency in HGSNAT enzyme activity and the consequent accumulation of heparan sulfate in the CNS. MPS 3C disease onset is usually before the age of 10 years and is characterized by progressive CNS degeneration. More than 50 different mutations in the HGSNAT gene have been identified in MPS 3C patients. An MPS 3C patient is an individual (e.g., a human) who has been diagnosed with or is suspected of having MPS 3C disease. Patients may be diagnosed using any method known in the art, including clinical, biochemical, and genetic methods for diagnosing MPS 3C. In one embodiment, a human MPS 3C patient has a mutation in the HGSNAT gene associated with a deficiency in HGSNAT enzyme activity and / or MPS 3C disease.
[0105] "Mucopolysaccharidosis type IIID," "MPS 3D," and "Sanfilippo syndrome type D" are used interchangeably herein to refer to an autosomal recessive LSD caused by a deficiency in GNS enzyme activity and the resulting accumulation of HS in the CNS. MPS 3D disease onset is typically between the ages of 2 and 6 years and is characterized by the development of severe neurological degeneration in most patients between the ages of 6 and 10 years. An MPS 3D patient is an individual (e.g., a human) who has been diagnosed with or is suspected of having MPS 3D disease. Patients may be diagnosed using any method known in the art, including clinical, biochemical, and genetic methods for diagnosing MPS-3A. In one embodiment, a human MPS 3D patient has a GNS gene mutation associated with a deficiency in GNS enzyme activity and / or MPS 3D disease.
[0106] "Mucopolysaccharidosis type VII," "MPS7," and "Sly syndrome" are used interchangeably herein to refer to an autosomal recessive LSD caused by a lack of GUSB enzyme activity and the resulting accumulation of CS, DS, and HS in the lysosomes of various tissues. At least 49 different mutations in the GUSB gene have been identified in MPS 7 patients. An MPS 7 patient is an individual (e.g., a human) who has been diagnosed with or is suspected of having MPS 7 disease. Patients may be diagnosed using any method known in the art, including clinical, biochemical, and genetic methods for diagnosing MPS 7. In one embodiment, a human MPS 7 patient has a GUSB gene mutation associated with a lack of GUSB enzyme activity and / or MPS 7 disease.
[0107] "N-acetylgalactosamine-6-sulfatase protein," "glucosamine N-acetyl-6-sulfatase protein," and "GNS protein" are used interchangeably herein to refer to a protein comprising a mature amino acid sequence encoded by a wild-type mammalian (e.g., human) GNS gene, or any fragment, mutant, variant, or derivative thereof, having GNS enzyme activity within 80%-120%, 85%-115%, 90%-110%, or 95%-105% of the corresponding wild-type mammalian mature GNS protein as measured by any art-recognized GNS enzyme assay. GNS catalyzes the hydrolysis of the 6-sulfate group of the N-acetyl-D-glucosamine 6-sulfate unit of heparan sulfate and keratan sulfate. The wild-type human GNS gene encodes a 552 amino acid precursor polypeptide, of which the N-terminal 36 amino acids constitute a signal peptide (UniProtKB-P15586). In some embodiments, the mature human GNS amino acid sequence in the BBB transport fusion protein described herein consists essentially of Figure 1D The human precursor GNS sequence shown in FIG.
[0108] "N-sulfoglucosamine sulfohydrolase," "SGSH," "sulfamidase," and "heparan-N-sulfatase" are used interchangeably herein to refer to a protein comprising a mature amino acid sequence encoded by a wild-type mammalian (e.g., human) SGSH gene, or any fragment, mutant, variant, or derivative thereof, having an enzymatic activity within 80%-120%, 85%-115%, 90%-110%, or 95%-105% of the corresponding wild-type mammalian mature SGSH protein as measured by any art-recognized SGSH assay. SGSH catalyzes the hydrolysis of N-sulfo-D-glucosamine to D-glucosamine and sulfate. The wild-type human SGSH gene encodes a 502 amino acid precursor polypeptide, of which the N-terminal 20 amino acids constitute a signal peptide (UniProtKB-P51688). In some embodiments, the mature human SGSH amino acid sequence in the BBB transport fusion protein described herein consists essentially of Figure 1J The sequence shown in is composed of amino acids 21-502.
[0109] As used herein, a "peptide" is a polypeptide of less than 50 amino acids, typically less than 25 amino acids.
[0110] As used herein, "Poly A signal" refers to any continuous sequence that terminates transcription of a coding sequence into RNA and directs the addition of a poly A tail to the RNA. Examples of poly A signals are rabbit binding globulin (rBG) poly A signal, SV40 late poly A signal, SV50 poly A signal, bovine growth hormone (BGH) poly A signal, human growth hormone (HGH) poly A signal, and synthetic poly A signals known in the art.
[0111] As used herein, a "polymer composition" is a composition (e.g., solution, mixture) comprising one or more polymers. As a class, "polymers" include homopolymers, heteropolymers, copolymers, block polymers, block copolymers and may be natural and synthetic. Homopolymers contain one type of structural unit or monomer, while copolymers contain more than one type of monomer.
[0112] As used herein, a "polypeptide" is a polymer comprising amino acid residues linked by peptide bonds and having at least two, and in some embodiments at least 10, 50, 75, 100, 150, or 200 amino acid residues.
[0113] "Pompe disease (PD)", "acid alpha-glucosidase deficiency" and "glycogen storage disease type II" are used interchangeably herein to refer to an autosomal recessive LSD caused by a lack of GAA enzyme activity and the resulting excess accumulation of lysosomal glycogen, primarily in the heart, bones, smooth muscle and nervous system. PD is broadly classified into infantile PD (IPD) and late-onset PD (LOPD). More than 580 mutations located in the GAA gene have been identified in PD patients. A PD patient refers to an individual (e.g., a human) who has been diagnosed with or is suspected of having a PD disease. Patients may be diagnosed using any method known in the art, including clinical, biochemical and genetic methods for diagnosing PD. In one embodiment, a human PD patient has a GAA gene mutation associated with a lack of GAA enzyme activity and / or PD. In one embodiment, the patient has been diagnosed with LOPD.
[0114] As used herein, "Prevention," "prevent," and "preventing" refer to a treatment that includes administering or applying a BBB transport fusion protein described herein, e.g., administering a device composition encapsulating modified cells expressing a fusion protein (e.g., as described herein), prior to the onset of one or more symptoms of a CNS disorder or disease to prevent physical manifestation of the one or more symptoms. In some embodiments, "Prevention," "prevent," and "preventing" require that signs or symptoms of a CNS disorder / disease have not yet developed or have not been observed. In some embodiments, treatment includes prevention, while in other embodiments, treatment does not include prevention.
[0115] As used herein, " promoter sequence " refers to a nucleotide sequence that can drive expression in mammalian cells, such as human cells (such as RPE cells, such as ARPE-19 cells). In some embodiments, for example, in order to drive the expression of BBB transport fusion protein as described herein, the promoter sequence is from a strong mammalian promoter, such as a human promoter sequence. Non-limiting examples of the strong promoter used in expression cassettes as described herein include EF1A promoter, CAG promoter, PGK (phosphoglycerate kinase) promoter and ACTB (human beta-actin) promoter. In one embodiment, the promoter sequence that can be used to drive the expression of ST protein as described herein can be from a medium strength promoter, such as an EFS promoter sequence, which is a shortened form of the EF1A promoter sequence.
[0116] As used herein, "RPE cells" refer to cells having one or more of the following characteristics: a) they comprise retinal pigment epithelial cells (RPE) (e.g., using the ARPE-19 cell line ( CRL-2302 TM ) culture) or derived or modified therefrom (e.g., derived or modified from cells cultured from the ARPE-19 cell line by stable transfection with an exogenous sequence encoding a BBB transport fusion protein), cells derived from primary cell cultures of RPE cells, cells directly isolated from naturally occurring RPE cells (e.g., from humans or other mammals) (without long-term culture, e.g., less than 5 or 10 generations or rounds of cell division since isolation), cells derived from transformed, immortalized or long-term (e.g., more than 5 or 10 generations or rounds of cell division) RPE cell cultures; b) cells obtained from less differentiated cells, e.g., cells developed, programmed or reprogrammed (e.g., in vitro) into RPE cells, or cells derived from primary or long-term (e.g., more than 5 or 10 generations or rounds of cell division) RPE cell cultures except for any genetic engineering. c) a cell having one or more of the following properties: i) it expresses one or more of the biomarkers CRALBP, RPE-65, RLBP, BEST1, or αB-crystallin; ii) it does not express one or more of the biomarkers CRALBP, RPE-65, RLBP, BEST1, or αB-crystallin; iii) it occurs naturally in the retina and forms a monolayer above the choroidal vessels in Bruch's membrane; or iv) it is responsible for epithelial transport, light absorption, secretion, and immune regulation in the retina; or v) it is synthetically produced, or modified from a naturally occurring cell to have properties similar to an immortalized RPE cell line (e.g., an ARPE-19 cell line ( CRL-2302 TM )) identical or substantially identical genetic content and optional identical or substantially identical epigenetic content.In one embodiment, RPE as herein described is genetically modified to for example have new characteristic, for example cell is genetically modified to express and secrete fusion protein as herein described.In one embodiment, cell is also genetically modified to reduce or eliminate the expression of one or more proteins by the natural expression of parental cells.In other embodiments, RPE cell is without genetic modification.
[0117] When used herein to refer to two nucleotide sequences or two amino acid sequences, "sequence identity" or "percentage identity" means that when two sequences are compared and aligned on a comparison window or a specified region to obtain maximum correspondence, the two sequences are identical in a specified region, or have the same nucleotides or amino acids at a specified percentage of nucleotides or amino acid positions in a specified region. Sequence identity can be determined using standard techniques known in the art (including but not limited to any algorithm described in U.S. Patent Application Publication No. 2017 / 02334455A1). In one embodiment, the specified percentage of the same nucleotide or amino acid position is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher.
[0118] As used herein, "spherical" means a device (e.g., a hydrogel capsule or other particle) having a curved surface that forms a sphere (e.g., a perfectly round sphere) or a sphere-like shape, which may have waves and undulations on the surface, for example. Spheres and sphere-like objects can be mathematically defined by rotating a circle, ellipse, or combination about each of three perpendicular axes a, b, and c. For a sphere, the three axes are the same length. In general, a sphere-like shape is an ellipsoid whose semi-major axes are within 10%, 5%, or 2.5% of each other (with respect to its average surface). The diameter of a sphere or sphere-like shape is the average diameter, such as the average of the semi-major axes.
[0119] As used herein, "sphingolipidosis" and "SP" refer to deficiencies in enzymes involved in sphingolipid metabolism that lead to accumulation of sphingolipids in lysosomes and can result in a variety of manifestations in various organs and tissues, including the visceral and nervous systems. SP diseases include Gaucher disease and Fabry disease.
[0120] As used herein, "subject" refers to a human or non-human animal. In one embodiment, the subject is a human (i.e., male or female) of any age group, such as a pediatric human subject (e.g., infant, child, teenager) or an adult subject (e.g., young, middle-aged, or elderly). In one embodiment, the subject is a non-human animal, such as a mammal (e.g., mouse, dog, primate (e.g., cynomolgus monkey or rhesus monkey). In one embodiment, the subject is a commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog) or bird (e.g., commercially relevant bird, such as chicken, duck, goose, or turkey). In certain embodiments, the animal is a mammal. The animal can be male or female and at any stage of development. The non-human animal can be a transgenic animal.
[0121] As used herein, "treatment", "treat" and "treating" refer to reducing, reversing, alleviating CNS disorders or diseases, delaying the onset of CNS disorders or diseases, or inhibiting the progression of one or more of the symptoms, manifestations or potential causes of CNS disorders or diseases. In one embodiment, treatment includes increasing the activity of a therapeutic protein in the CNS. In one embodiment, treatment includes reducing, reversing, alleviating symptoms associated with a disorder or disease, delaying its onset or inhibiting its progression. In some embodiments, "treatment", "treat" and "treating" require that signs or symptoms associated with a CNS disorder / disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease, such as in preventive treatment. For example, treatment may be administered to susceptible individuals before the onset of symptoms (e.g., based on a history of symptoms and / or based on genetic or other susceptibility factors). Treatment may also continue after symptoms have subsided, for example, to delay or prevent recurrence. In some embodiments, treatment includes prevention, while in other embodiments, treatment does not include prevention.
[0122] "Wild type" (wt) refers to the native form, including sequence, of a polynucleotide, polypeptide or protein in a species. The wild type form is distinguished from a mutant form of a polynucleotide, polypeptide or protein resulting from one or more genetic mutations.
[0123] Selected chemical definitions
[0124] The definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th edition, cover, and specific functional groups are generally defined as described therein. In addition, the general principles of organic chemistry as well as specific functional moieties and reactivity are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd edition, Cambridge University Press, Cambridge, 1987.
[0125] Abbreviations used herein have their conventional meanings in the fields of chemistry and biology.The chemical structures and formulae shown herein are constructed according to standard rules of chemical valency known in the chemical arts.
[0126] When a range of values is listed, it is intended to encompass each value and subrange within that range. For example, "C1-C6 alkyl" is intended to encompass C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6 alkyl.
[0127] As used herein, "alkyl" refers to a straight chain or branched saturated hydrocarbon group having 1 to 24 carbon atoms ("C1-C 24 In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C1-C 12 alkyl”), 1 to 10 carbon atoms (“C1-C 12In some embodiments, the alkyl group has 2 to 6 carbon atoms ("C2-C6 alkyl"). Examples of C1-C6 alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), s-propyl (C4), s-propyl (C5), s-propyl (C6), s-propyl (C7), s-propyl (C8), s-propyl (C9), s-propyl (C10), s-propyl (C11), s-propyl (C12), s-propyl (C13), s-propyl (C14), s-propyl (C15), s-propyl (C16), s-propyl (C17), s-propyl (C18), s-propyl (C19), s-propyl (C21), s-propyl (C22), s-propyl (C23), s-propyl (C24), s-propyl (C25), s-propyl (C26), s-propyl (C27), s-propyl (C28), s-propyl (C29), s-propyl (C31), s-propyl (C32), s-propyl (C33), s-propyl (C34), s-propyl (C35), s-propyl (C36), s-propyl (C37), s-propyl (C38), s-propyl (C39). ), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5) and n-hexyl (C6). Additional examples of alkyl include n-heptyl (C7), n-octyl (C8), etc. Each example of alkyl can independently be optionally substituted, i.e., unsubstituted ("unsubstituted alkyl"), or substituted with one or more substituents, such as 1 to 5 substituents, 1 to 3 substituents, or 1 substituent ("substituted alkyl").
[0128] As used herein, "alkenyl" refers to a straight chain or branched hydrocarbon group having 2 to 24 carbon atoms, one or more carbon-carbon double bonds and no triple bonds ("C2-C 24 In some embodiments, an alkenyl group has 2 to 10 carbon atoms ("C2-C 10 The carbon-carbon double bond(s) may be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-C4 alkenyl groups include vinyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-C6 alkenyl groups include the aforementioned C 2-4 Alkenyl and pentenyl (C5), pentadienyl (C5), hexenyl (C6), etc. Each instance of alkenyl can independently be optionally substituted, i.e., unsubstituted (“unsubstituted alkenyl”) or substituted with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents, or 1 substituent (“substituted alkenyl”).
[0129] As used herein, the term "alkynyl" refers to a straight chain or branched hydrocarbon group having 2 to 24 carbon atoms, one or more carbon-carbon triple bonds ("C2-C24 In some embodiments, an alkynyl group has 2 to 10 carbon atoms ("C2-C 10 The carbon-carbon triple bond(s) may be internal (as in 2-butynyl) or terminal (as in 1-butynyl). Examples of C2-C4 alkynyl groups include ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Each example of an alkynyl group may independently be optionally substituted, i.e., unsubstituted (“unsubstituted alkynyl”), or substituted with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents, or 1 substituent (“substituted alkynyl”).
[0130] As used herein, the term "heteroalkyl" refers to a non-cyclic stable straight or branched chain or a combination thereof including at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si and S, and wherein the nitrogen atom and the sulfur atom may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. One or more heteroatoms O, N, P, S and Si may be placed at any position of the heteroalkyl. Exemplary heteroalkyls include, but are not limited to: -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2, -S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -O-CH3 and -O-CH2-CH3. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. In the description of "heteroalkyl", the specific heteroalkyl group is followed, such as -CH2O, -NR C R D etc., it will be understood that the term heteroalkyl and -CH2O or -NR C R D The terms "heteroalkyl" and "heteroalkyl" are not redundant or mutually exclusive. Rather, specific heteroalkyl groups are described to increase clarity. Therefore, the term "heteroalkyl" should not be interpreted herein to exclude specific heteroalkyl groups, such as -CH2O, -NR C R DEtc. Each instance of heterocyclyl can independently be optionally substituted, i.e., unsubstituted (“unsubstituted heteroalkyl”) or substituted with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents, or 1 substituent (“substituted heteroalkyl”).
[0131] Unless otherwise indicated, the terms "alkylene", "alkenylene", "alkynylene" or "heteroalkylene", alone or as part of another substituent, mean a divalent radical derived from an alkyl, alkenyl, alkynyl or heteroalkylene, respectively. An alkylene, alkenylene, alkynylene or heteroalkylene may be described, for example, as a C1-C6 membered alkylene, a C2-C6 membered alkenylene, a C2-C6 membered alkynylene or a C1-C6 membered heteroalkylene, wherein the term "membered" refers to non-hydrogen atoms within the moiety. In the case of heteroalkylene, heteroatoms may also occupy one or both chain ends (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Further, for alkylene and heteroalkylene linking groups, the orientation of the linking group is not implied by the direction in which the chemical formula of the linking group is written. For example, the formula -C(O)2R'- may represent both -C(O)2R'- and -R'C(O)2-.
[0132] As used herein, "aryl" refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in the ring array) radical having 6-14 ring carbon atoms and zero heteroatoms ("C6-C 14 In some embodiments, an aryl group has 6 ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C 10 In some embodiments, an aryl group has 14 ring carbon atoms ("C 14 Aryl is a "group"; for example, anthracenyl). Aryl can be described as, for example, C6-C 10 The term "aryl" refers to the non-hydrogen ring atoms within the moiety. Aryl includes phenyl, naphthyl, indenyl and tetrahydronaphthyl. Each example of aryl can independently be optionally substituted, i.e., unsubstituted ("unsubstituted aryl"), or substituted ("substituted aryl") with one or more substituents.
[0133] As used herein, "heteroaryl" refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in the ring array) having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-10 membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom when valence permits. Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings. "Heteroaryl" also includes ring systems in which a heteroaryl ring as defined above is fused to one or more aryl groups, wherein the point of attachment is on the aryl or heteroaryl ring, and in such cases, the number of ring members indicates the number of ring members in the fused (aryl / heteroaryl) ring system. Bicyclic heteroaryl groups, where one ring contains no heteroatoms (e.g., indolyl, quinolyl, carbazolyl, etc.), the point of attachment can be on either ring, i.e., the ring bearing the heteroatom (e.g., 2-indolyl) or the ring containing no heteroatoms (e.g., 5-indolyl). Heteroaryl groups can be described, for example, as 6-10 membered heteroaryl groups, where the term "membered" refers to non-hydrogen ring atoms within the moiety.
[0134] In some embodiments, heteroaryl is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In some embodiments, heteroaryl is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In some embodiments, heteroaryl is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In some embodiments, 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Each instance of heteroaryl can independently be optionally substituted, i.e., unsubstituted (an "unsubstituted heteroaryl") or substituted (a "substituted heteroaryl") with one or more substituents.
[0135] Exemplary 5-membered heteroaryls containing 1 heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryls containing 2 heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryls containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryls containing 4 heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryls containing 1 heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryls containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryls containing 3 or 4 heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryls containing 1 heteroatom include, but are not limited to, aza-zepta ... Exemplary 5,6-bicyclic heteroaryls include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothienyl, isobenzothienyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indolizinyl and purinyl. Exemplary 6,6-bicyclic heteroaryls include, but are not limited to, naphthyridinyl, pteridinyl, quinolyl, isoquinolyl, cinnolinyl, quinoxalinyl, phthalazinyl and quinazolinyl. Other exemplary heteroaryls include heme and heme derivatives.
[0136] As used herein, the terms "arylene" and "heteroarylene" by themselves or as part of another substituent refer to a divalent radical derived from an aryl and heteroaryl group, respectively.
[0137] As used herein, "cycloalkyl" refers to a non-aromatic ring system having 3 to 10 ring carbon atoms ("C3-C 10 In some embodiments, the cycloalkyl group has 3 to 8 ring carbon atoms ("C3-C8 cycloalkyl"), 3 to 6 ring carbon atoms ("C3-C6 cycloalkyl"), or 5 to 10 ring carbon atoms ("C5-C8 cycloalkyl"). 10Cycloalkyl"). Cycloalkyl can be described, for example, as a C4-C7 membered cycloalkyl, where the term "membered" refers to the non-hydrogen ring atoms within the moiety. Exemplary C3-C6 cycloalkyls include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3-C8 cycloalkyls include but Not limited to the aforementioned C3-C6 cycloalkyl and cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), cubanyl (C8), bicyclo[1.1.1]pentanyl (C5), bicyclo[2.2.2]octanyl (C8), bicyclo[2.1.1]hexanyl (C6), bicyclo[3.1.1]heptanyl (C7), etc. Exemplary C3-C6 cycloalkyl groups include cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), cubanyl (C8), bicyclo[1.1.1]pentanyl (C5), bicyclo[2.2.2]octanyl (C8), bicyclo[2.1.1]hexanyl (C6), bicyclo[3.1.1]heptanyl (C7), etc. 10 Cycloalkyl includes, but is not limited to, the aforementioned C3-C8 cycloalkyl as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C9), 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthyl (C 10 ), spiro[4.5]decyl (C 10 ) and the like. As illustrated by the foregoing examples, in certain embodiments, the cycloalkyl is monocyclic ("monocyclic cycloalkyl") or contains a fused, bridged or spiro ring system (such as a bicyclic ring system ("bicyclic cycloalkyl")), and may be saturated or may be partially unsaturated. "Cycloalkyl" also includes ring systems in which a cycloalkyl ring as defined above is fused to one or more aryl groups, wherein the point of attachment is on the cycloalkyl ring, and in such cases, the number of carbons continues to refer to the number of carbons in the cycloalkyl ring system. Each example of a cycloalkyl group may independently be optionally substituted, i.e., unsubstituted ("unsubstituted cycloalkyl"), or substituted ("substituted cycloalkyl") with one or more substituents.
[0138] As used herein, "heterocyclyl" refers to a group of a 3-10 membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon ("3-10 membered heterocyclyl"). In heterocyclyls containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as long as valence permits. The heterocyclyl group may be a monocyclic ("monocyclic heterocyclyl") or a fused, bridged or spiro ring system, such as a bicyclic system ("bicyclic heterocyclyl"), and may be saturated or may be partially unsaturated. Heterocyclyl bicyclic ring systems may include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which the heterocyclyl ring as defined above is fused to one or more cycloalkyl groups, wherein the point of attachment is on the cycloalkyl or heterocyclyl ring; or ring systems in which the heterocyclyl ring as defined above is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such cases, the number of ring members continues to represent the number of ring members in the heterocyclyl ring system. Heterocyclyl can be described as, for example, 3-7 membered heterocyclyl, wherein the term "member" refers to the non-hydrogen ring atoms within the moiety, i.e., carbon, nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. Each instance of heterocyclyl can independently be optionally substituted, i.e., unsubstituted ("unsubstituted heterocyclyl"), or substituted ("substituted heterocyclyl") by one or more substituents. In certain embodiments, heterocyclyl is an unsubstituted 3-10 membered heterocyclyl. In certain embodiments, heterocyclyl is a substituted 3-10 membered heterocyclyl.
[0139] In some embodiments, heterocyclyl is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon (“5-10 membered heterocyclyl”). In some embodiments, heterocyclyl is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-8 membered heterocyclyl”). In some embodiments, heterocyclyl is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-6 membered heterocyclyl”). In some embodiments, 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0140] Exemplary 3-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, aziridine, oxirane and thioethane. Exemplary 4-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, azetidinyl, oxetane and thietanyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrophenylthio, dihydrophenylthio, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxathiolanyl, dithiolanyl and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing 3 heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, piperidinyl, piperazinyl, tetrahydropyranyl, dihydropyridinyl and thianyl. Exemplary 6-membered heterocyclic groups containing 2 heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, triazinanyl or thiomorpholinyl-1,1-dioxide. Exemplary 7-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, azepanyl, oxepane and thiepanyl. Exemplary 8-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, azocyclooctanyl, oxoctanyl and thiepanyl. Exemplary 5-membered heterocyclic groups fused to a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocyclic rings) include, but are not limited to, indolyl, isoindolyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinone, etc. Exemplary 6-membered heterocyclic groups fused to an aryl ring (also referred to herein as 6,6-bicyclic heterocyclic rings) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc.
[0141] As used herein, "amino" refers to the group -NR 70 R 71 , where R 70 and R 71 are independently hydrogen, C1-C8 alkyl, C3-C 10 Cycloalkyl, C4-C 10 Heterocyclic group, C6-C 10 Aryl and C5-C 10 In some embodiments, amino refers to NH2.
[0142] As used herein, "cyano" refers to -CN.
[0143]
[0043] As used herein, "halo" or "halogen," by itself or as part of another substituent, means, unless otherwise stated, a fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) atom.
[0144] As used herein, "hydroxy" refers to the group -OH.
[0145] As defined herein, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl, "substituted" or "unsubstituted" heteroalkyl, "substituted" or "unsubstituted" cycloalkyl, "substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl, or "substituted" or "unsubstituted" heteroaryl). In general, the term "substituted", whether preceded by the term "optionally" or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, such as a substituent that, upon substitution, results in a stable compound, such as a compound that does not spontaneously transform, such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise stated, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is the same or different at each position. The term "substituted" is intended to include substitution with all permissible substituents of an organic compound, any substituent that produces the formation of a stable compound as described herein. The present disclosure contemplates any and all such combinations to achieve stable compounds. For purposes of the present disclosure, a heteroatom (such as nitrogen) may have a hydrogen substituent and / or any suitable substituent that satisfies the valence of the heteroatom and produces the formation of a stable moiety as described herein.
[0146] Two or more substituents may be optionally linked to form an aryl, heteroaryl, cycloalkyl or heterocyclyl group. Such so-called ring-forming substituents are usually but not necessarily attached to the cyclic basic structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the basic structure. For example, two ring-forming substituents attached to adjacent members of the cyclic basic structure form a condensed ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the basic structure. For example, two ring-forming substituents attached to a single member of the cyclic basic structure form a spiro ring structure. In another embodiment, the ring-forming substituents are attached to non-adjacent members of the basic structure.
[0147] The compounds of formula (III) described herein and their pharmaceutically acceptable salts may contain one or more asymmetric centers and may therefore exist in various isomeric forms (e.g., enantiomers and / or diastereomers). For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, or geometric isomers, or may be in the form of stereoisomer mixtures (including racemic mixtures and mixtures enriched in one or more stereoisomers). Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis. See, e.g., Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions, p. 268 (ELEliel, ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present disclosure further encompasses the compounds described herein in the form of individual isomers that are substantially free of other isomers, as well as alternatively in the form of mixtures of different isomers.
[0148] As used herein, a pure enantiomer compound is substantially free of other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess). In other words, the "S" form of the compound is substantially free of the "R" form of the compound, and is therefore in enantiomeric excess of the "R" form. The term "enantiomerically pure" or "pure enantiomer" means that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 99% by weight, more than 99.5% by weight, or more than 99.9% by weight of the enantiomer. In certain embodiments, the weight is based on the total weight of all enantiomers or stereoisomers of the compound.
[0149] The compounds of formula (III) described herein may also contain one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H. 2H (D or deuterium) and 3 H (or tritium); C can be in any isotopic form, including 12 C. 13 C and 14 C; O can be in any isotopic form, including 16 O and 18 O etc.
[0150] The term "pharmaceutically acceptable salt" is intended to include salts of active compounds prepared with relatively nontoxic acids or bases, depending on the specific substituents found on the compounds described herein. When the compounds of formula (III) used to prepare the devices of the present disclosure contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base (neat or in a suitable inert solvent). Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino or magnesium salts, or similar salts. When the compounds used in the present disclosure contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid or phosphorous acid, etc.; and salts derived from organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid, etc. Also included are salts of amino acids such as arginine salts, etc.; and salts of organic acids such as glucuronic acid or galacturonic acid, etc. (see, e.g., Berge et al., Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds used in the disclosed devices (e.g., particles, hydrogel capsules) contain both basic and acidic functional groups that allow the compound to be converted into base addition salts or acid addition salts. These salts can be prepared by methods known to those skilled in the art. Other pharmaceutically acceptable carriers known to those skilled in the art are also suitable for use in the present disclosure.
[0151] The devices of the present disclosure may contain compounds of formula (III) in the form of prodrugs. Prodrugs are those compounds that readily undergo chemical changes under physiological conditions to provide compounds that can be used to prepare the devices of the present disclosure. In addition, prodrugs can be converted into useful compounds of formula (III) by chemical or biochemical methods in an ex vivo environment.
[0152] Some of the compounds of formula (III) described herein can exist in non-solvated form and solvated form (including hydrated form). In general, the solvated form is equivalent to the non-solvated form and is included in the scope of the present disclosure. Some of the compounds of formula (III) described herein can exist in multiple crystals or amorphous forms. In general, all physical forms are equivalent for the purposes covered by the present disclosure and are intended to fall within the scope of the present disclosure.
[0153] The term "solvate" refers to a form of a compound associated with a solvent, typically by a solvolysis reaction. Such physical association may include hydrogen bonding. Commonly used solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compounds described herein may be prepared, for example, in crystalline form and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include stoichiometric solvates and non-stoichiometric solvates.
[0154] The term "hydrate" refers to a compound associated with water. Typically, the number of water molecules contained in a hydrate of a compound is in a certain ratio to the number of compound molecules in the hydrate. Thus, a hydrate of a compound can be represented, for example, by the general formula R·x H2O, where R is a compound and where x is a number greater than 0.
[0155] As used herein, the term "tautomer" refers to a compound structure that is an interchangeable form and that varies in hydrogen atom and electron displacement. Thus, by the movement of π electrons and atoms (usually H), the two structures can be in equilibrium. For example, enols and ketones are tautomers because they can be rapidly interconverted by treatment with acid or base. Tautomeric forms can be relevant to obtaining the optimal chemical reactivity and biological activity of the target compound.
[0156] Symbols used in this article Refers to attachment to the surface of an entity, such as a polymer (e.g., a hydrogel-forming polymer such as alginate) or an implantable device (e.g., a particle, a hydrogel capsule). The connection represented can refer to direct attachment to an entity (e.g., a polymer or an implantable element), and can refer to a linkage to an entity through an attachment group. As described herein, an "attachment group" refers to a portion used to link a compound of formula (III) to an entity (e.g., a polymer or an implantable element (e.g., a device) as described herein), and may include any attachment chemistry known in the art. A list of exemplary attachment groups is summarized in Bioconjugate Techniques (3rd Edition, Greg T. Hermanson, Waltham, MA: Elsevier, Inc, 2013), which is incorporated herein by reference in its entirety. In some embodiments, the attachment group includes alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)-, -OC(O)-, -N(R C )-、-N(R C )C(O)-、-C(O)N(R C )-、-N(R C )N(R D )-、-NCN-、-C(=N(R C )(R D ))O-、-S-、-S(O) x -、-OS(O) x -、-N(R C )S(O) x -、-S(O) x N(R C )-、-P(R F )y -、-Si(OR A) 2-、-Si(R G )(OR A )-、-B(OR A )- or metal, where R A , R C , R D , R F , R G Each of x and y is independently as described herein. In some embodiments, the attachment group comprises an amine, a ketone, an ester, an amide, an alkyl group. In some embodiments, the attachment group is a cross-linking agent. In some embodiments, The attached group is -C(O)(C1-C6 1 , and R 1 As described in this article In some embodiments, the attachment group is -C(O)(C1-C6-alkylene)-, wherein the alkylene is substituted with 1-2 alkyl groups (e.g., 1-2 methyl groups). In some embodiments, the attachment group is -C(O)C(CH 3)2-. In some embodiments, the attachment group is -C(O)(methylene)-, wherein the alkylene group is substituted with 1-2 alkyl groups (e.g., 1-2 methyl groups). In some embodiments, the attachment group is -C(O)CH(CH3)-. In some embodiments, the attachment group is -C(O)C(CH3)-.
[0157] Characteristics of BBB transport fusion proteins
[0158] The BBB transport fusion protein of the present disclosure comprises an HSA binding domain (AB) and an IGF1R binding domain (RB) located upstream of a cargo portion (C) (e.g., an amino acid sequence of a therapeutic protein). In some embodiments, a first linker portion (e.g., a linker peptide) is located between AB and RB, and a second linker portion (e.g., a linker peptide) is located between RB and the cargo portion.
[0159] HSA binding domain AB
[0160] The serum half-life of the BBB transport protein is longer than that of an otherwise identical fusion protein without the AB domain. This half-life extension is primarily due to the binding of the fusion protein to HSA via the AB. Mature human serum albumin (HSA) is a monomeric protein of 585 amino acids (GenBank Accession No. AAA98797.1) and contains three homologous domains D1 ( Figure 2B amino acids 25-221); DII( Figure 2B amino acids 213-409 of DIII); and DIII ( Figure 2B 405-609 of (amino acids 405-609 of (Dockal, M. et al., J. Biol. Chem., Vol. 274, No. 41, pp. 29303-29310 (1999). The long half-life of albumin in the blood is driven primarily by two features: (i) the large size of albumin (65 kDa) limits its glomerular filtration rate; and (ii) albumin binds to FcRn at low pH (pH 6), thereby protecting albumin from degradation in lysosomes following passive endocytosis in endothelial and epithelial cells by recycling albumin from early endosomes back to the extracellular environment. In one embodiment, the AB domain confers a BBB transport fusion protein with a serum half-life in humans (expressed as t1 / 2-β) that exceeds any of 6 hours, 12 hours, 24 hours, 72 hours, one week, two weeks, or up to the half-life of HSA in humans (estimated to be about 19 days).
[0161] In some embodiments, the AB domain is specific for serum albumin, i.e., the AB domain does not substantially bind to any non-albumin protein. In some embodiments, the fusion protein does not substantially inhibit the binding of FcRn to HSA, and the binding site of HSA is located in DIII. In one embodiment, in the presence of the fusion protein of the present disclosure, less than about 20%, 15%, 10%, 5% or 1% inhibition of the binding of FcRn to HSA occurs, which can be determined by any competitive binding assay known in the art, such as the SPR competitive binding assay described in
[0095] of WO 2019 / 204925 or Example 3 of US 2019 / 0367596A1. The possibility of interfering with FcRn binding can be reduced by deriving the AB domain from an anti-HSA antibody that does not bind to DIII. In one embodiment, the fusion protein binds to the DI of HSA via the AB domain. In one embodiment, the fusion protein cross-competes for binding to HSA via AB with a single domain antibody (sdAb) described in WO2019 / 204925, i.e., an sdAb consisting of the amino acid sequence of R11, R28, M75 or M79.
[0162] In some embodiments, AB (as part of the fusion protein) also binds (e.g., cross-reacts) to serum albumin from one, two, three, four or more other mammalian species, e.g., mouse, rat, guinea pig, hamster, rabbit, cat, dog, pig, sheep, horse, cow, and monkey (e.g., rhesus and / or cynomolgus monkey) in any combination. In one embodiment, the fusion protein binds to serum albumin from at least mouse, rat, monkey (rhesus or cynomolgus monkey), and human via the AB domain. In one embodiment, the fusion protein binds to serum albumin from at least mouse, dog, and human via the AB domain.
[0163] In some embodiments, the AB domain (as part of a fusion protein) binds to HSA and optionally to at least one other mammalian serum albumin with a desired affinity over a pH range of between about 5.0 or about 5.5 up to about 7.4. In one embodiment, the desired affinity is a dissociation constant (K) in the range of any of about 0.1 nM to about 1,000 nM, about 0.5 nM to about 500 nM, about 1 nM to about 250 nM, about 5 nM to about 50 nM, about 10 nM to about 25 nM, or about 0.5 nM to about 1 nM. D)In one embodiment, the affinity is determined by surface plasmon resonance (SPR) at 25°C and a pH range of about 5.5 to about 7.4. In one embodiment, the affinity of the fusion protein for serum albumin from mouse, rat, and monkey is similar to the affinity for HSA, e.g., at a K of 1.0 for HSA. D within 70% to 130%, 80% to 120% or 90% to 110% of the
[0164] For measuring the K of anti-HSA antibodies and fusion proteins D An exemplary SPR assay for is described in
[0092] of WO 2019 / 204925. Another exemplary SPR assay for measuring affinity in the pH range of 5.0 to 7.4 is described in US 2019 / 0367597A1. K of anti-HSA antibodies and fusion proteins for HSA and mammalian orthologs D It can also be determined essentially as described in WO 2019 / 246003 at
[0994] -
[0995] .
[0165] The AB domain of the BBB transport fusion protein of the present disclosure comprises the amino acid sequence of the heavy chain variable region (HCVR) of an anti-HSA antibody. In order to promote the expression of the fusion protein by genetically modified cells, in some embodiments, the AB domain has a molecular weight of less than about any one of 75 kDa, 50 kDa or 25 kDa. The AB domain can be derived from any anti-HSA antibody molecule known in the art, including conventional 4-chain antibodies, antigen binding fragments, Fab, Fab', F(ab')2, Fv (double-chain and single-chain (scFv)), miniantibodies, diabodies and sdAbs. In one embodiment, AB consists essentially of or consists of the HCVR amino acid sequence of an sdAb.
[0166] In one embodiment, the AB domain comprises a set of three CDR amino acid sequences in one of the anti-HSA sdAbs described in Table I of WO 2006 / 122787. In one embodiment, AB consists essentially of or consists of an amino acid sequence in one of the anti-HSA sdAbs described in Table II of WO 2006 / 22787 (e.g., Alb-1), or an amino acid sequence in one of the humanized variants of Alb-1 described in Table III of WO 2006 / 22787 (e.g., Alb-8). In one embodiment, AB consists essentially of or consists of any one of the Alb-23 sequences described in WO 2012 / 175400 (e.g., Alb-23D). In one embodiment, the BBB transport fusion protein of the present disclosure cross-competes with any of the anti-HSA sdAbs described in WO 2006 / 22787 (e.g., Alb-8) or WO 2012 / 175400 (e.g., Alb-23D) for binding to HSA. In one embodiment, the BBB transport fusion protein does not comprise the amino acid sequence of Alb-1. In one embodiment, the BBB transport fusion protein does not comprise the amino acid sequence of Alb-8.
[0167] In another embodiment, the AB domain consists essentially of or consists of an albumin binding domain (ABD) described in Table 7 of WO 2019 / 246003, such as LAEAKVLANRELD KYGVSDYYKNLINNAKTVEGVKALIDEILAALP (SEQ ID NO: 40) (which is described in WO 2019 / 246003 as having a K for HSA D In one embodiment, the AB domain comprises three CDRs of the anti-HSA P367 antibody described in Table 14 of WO 2019 / 2460003. In one embodiment, the AB consists essentially of or consists of the amino acid sequence of the anti-HSA P367 antibody or its humanized variant P494 (each of which is listed in Table 14 of WO 2019 / 2460003). In one embodiment, the BBB transport fusion protein of the present disclosure cross-competes with the P494 sdAb described in WO 2019 / 2460003 for binding to HSA.
[0168] In another embodiment, the AB domain comprises a set of three heavy chain CDR amino acid sequences in one of the anti-HSA sdAbs described in Table 5 of WO 2021 / 119551. In one embodiment, the AB consists essentially of or consists of a VH amino acid sequence in one of the anti-HSA sdAbs described in Table 5 of WO 2021 / 119551. In one embodiment, the BBB transport fusion protein of the present disclosure cross-competes with one or more of the sdAbs described in Table 5 of WO 2021 / 119551 for binding to HSA.
[0169] In another embodiment, the AB domain comprises a set of three CDR amino acid sequences located in the T0235002C06 sdAb described in Table B of US20190367597A1. In one embodiment, the AB consists essentially of or consists of the amino acid sequence of T0235002C06 described in Table B of US2019 / 0367597A1. In one embodiment, the BBB transport fusion protein of the present disclosure cross-competes with the T0235002C06 sdAb described in Table B of US 20190367597A1 for binding to HSA.
[0170] In another embodiment, the AB domain comprises a set of three CDR amino acid sequences located in the T0235005D04 sdAb described in Table B of US 20190367596A1. In one embodiment, the AB consists essentially of or consists of the amino acid sequence of T0235005D04 described in Table B of US2019 / 0367596A1. In one embodiment, the BBB transport fusion protein of the present disclosure cross-competes with the T0235002D04 sdAb described in Table B of US 20190367596A1 for binding to HSA.
[0171] In another embodiment, the AB domain comprises a set of three CDR amino acid sequences located in T0235005G01 or T023500043sdAb described in Table B of US 20190367598A1. In one embodiment, AB consists essentially of or consists of the amino acid sequence of T0235005G01 or T023500043 described in Table B of US 20190367598A1. In one embodiment, the BBB transport fusion protein of the present disclosure cross-competes with T0235005G01 or T023500043sdAb described in Table B of US 20190367598A1 for binding to HSA.
[0172] In one embodiment, the AB domain comprises a set of three CDR amino acid sequences located in R28, R11, M75 or M79 sdAb described in WO 2019 / 204925. These CDR sequences are listed in Table 2A below.
[0173] Table 2A: Exemplary CDR amino acid sequences of AB domains.
[0174]
[0175]
[0176] In one embodiment, AB is substantially composed of or by the amino acid sequence of R28, R11, M75 or M79sdAb described in WO 2019 / 204925. In one embodiment, AB is substantially composed of or by the amino acid sequence of a humanized variant in the humanized variant of R28, R11, M75 or M79 described in WO 2019 / 204925. The amino acid sequences of the parents and humanized variants of R28, R11, M75 and M79 are shown in the sequence table of pages 46-48 of WO 2019 / 204925. In one embodiment, AB is substantially composed of or by the amino acid sequence of the parent and humanized sequence selected from the following table 2B herein. In one embodiment, AB is substantially composed of or by the parent or humanized amino acid sequence of R28 shown in the following table 2B.
[0177] Table 2B: Exemplary amino acid sequences of AB domains.
[0178]
[0179]
[0180] IGF1R binding domain RB
[0181] The RB domain of the BBB transport fusion protein of the present disclosure gives the fusion protein the ability to pass through the BBB via the transcytosis mediated by IGF1R (also referred to as CD221, IGFIR, IGFR and JTK13). Human IGF1R is synthesized as a pre-proreceptor (pre-proreceptor) of 1367 amino acids of the monomeric signal sequence (UniProtKB-P08069) with 30 amino acids. After the signal peptide cleavage, the former receptor is glycosylated, dimerized and transported to the Golgi apparatus, where furin cleavage produces α and β subunits, which α and β subunits form a tetramer (β-α-α-β) of disulfide linkages, which are transported to plasma membrane. The fully mature cell membrane-bound IGF1R is composed of two 130 to 135kDa α subunits and two 90 to 95kDa β subunits with some α-α and α-β disulfide bonds. The α subunit is located entirely extracellularly and forms the ligand binding domain. The β subunit contains an extracellular domain, a transmembrane domain, and an intracellular domain. Ligand binding induces trans-autophosphorylation and phosphorylation of a variety of downstream signaling molecules.
[0182] The ability of the transcytosis that the RB domain confers to the fusion protein hIGF1R mediation as described herein can be evaluated by any method known in the art. For example, in vitro determination can evaluate the internalization of the fusion protein to IGF1-R expressing cells (such as MCF-7 cells or primary human microvascular brain endothelial cells (HMBEC)), as described in
[0317] -
[0315] of EP3725806A1. Similar determinations that can be used when RB cross-reacts with rat IGF1-R adopt immortalized rat brain endothelial cells (svARBEC) as described in US 10,100,117. In addition, known in vitro and in vivo BBB models can be used to evaluate the BBB transport capacity of the fusion protein combined with human and rat IGF1R, for example, as described in Examples 10 and 12 of US 10,100,117.
[0183] In some embodiments, the RB domain is specific to IGF1R, i.e., the RB domain is substantially not bound to the insulin receptor or any other non-IGF1R protein. Fusion proteins containing RB should not induce signal transduction by IGF1R or IR, and should not inhibit the signal transduction by IGF1R or IR induced by insulin, IGF-1 or IGF-2. The signal transduction influence of BBB transport fusion proteins described herein can be assessed by analyzing the phosphorylation of downstream kinase Akt of IGF1R and IR and / or receptor stimulation. This assessment can be performed using any method known in the art, such as described in Example 14 of US 10,100,117 or in paragraphs
[0325] -
[0327] of EP3725806A1. Any method known in the art can be used, such as by the MCF-7 cell line proliferation assay described in
[0320] -
[0324] of EP3725806A1 to assess any influence of fusion proteins on IGF1 signal transduction by IGF1R.
[0184] The possibility of interfering with ligand binding can be reduced by obtaining the RB domain from an anti-hIGF1R antibody molecule known not to interfere with ligand binding or selecting an antibody that does not bind to the α subunit. In one embodiment, the fusion protein cross-competes for hIGF1R binding via the RB domain with the IGF1R-5sdAb described in US 10,100,117, the IGF1R-3sdAb described in US 10,106,614, or the IGF1R-5sdAb described in US 10,112,998. In one embodiment, the fusion protein cross-competes for hIGF1R binding via the RB domain with any of the 996, 1226 and 1564 antibodies described in EP3725806A1. In one embodiment, the epitope of the RB domain has three binding sites: binding site 1 includes one or more of R650, Y775, P776, F778, E779, S791 and L798; binding site 2 includes one or more of L641, H808, E809 and L813; and binding site 3 includes one or more of V397, W434, D435, Y460 and C488.
[0185] In some embodiments, RB (as part of the fusion protein) also binds (e.g., cross-reacts) to any combination of two, three, four or more IGF1Rs from one, two, three, four or more other mammalian species, such as mice, rats, guinea pigs, hamsters, rabbits, cats, dogs, pigs, sheep, horses, cattle, and monkeys (e.g., rhesus monkeys and / or cynomolgus monkeys). In one embodiment, the fusion protein binds to IGF1Rs from at least mice, rats, monkeys (rhesus monkeys or cynomolgus monkeys), and humans via the RB domain. In one embodiment, the fusion protein binds to IGF1Rs from at least mice, dogs, and humans via the RB domain.
[0186] In some embodiments, the RB domain (as part of a fusion protein) binds to hIGF1R and optionally to at least one other mammalian IGF1R with a desired affinity over a pH range of about 5.0 or about 5.5 up to about 7.4. In one embodiment, the desired affinity is a dissociation constant (K) in the range of D ): (i) about 0.1 nM to about 1,000 nM; (ii) about 0.2 nM to about any of 500 nM, 250 nM, 100 nM, 50 nM, 25 nM, or 10 nM; (iii) about 0.5 nM to about any of 250 nM, 100 nM, 50 nM, 25 nM, 10 nM, or 5 nM; or (iv) about 1 nM to about any of 100 nM, 50 nM, 25 nM, 10 nM, or 5 nM. In one embodiment, the desired affinity is a dissociation constant (K) of 1 nM to 10 nM. D In one embodiment, the affinity is determined by surface plasmon resonance (SPR) at 25°C and a pH range of about 5.5 to about 7.4. In one embodiment, the affinity of the fusion protein for IGF1R from mouse, rat, and monkey is similar to the affinity for hIGF1R, e.g., K D In the K D 70% to 130%, 80% to 120%, or 90% to 110% of the BBB. D An exemplary SPR assay is described in US 10,100,117.
[0187] The RB domain of the BBB transport fusion protein disclosed herein comprises the amino acid sequence of the heavy chain variable region (HCVR) of the anti-hIGF1R antibody. In order to promote the expression of the fusion protein by genetically modified cells, in some embodiments, the RB domain has a molecular weight less than about any one of 75kDa, 50kDa or 25kDa. The RB domain can be derived from any anti-IGF1R antibody molecule known in the art, including conventional 4-chain antibodies, antigen-binding fragments, Fab, Fab', F(ab')2, Fv (double-chain and single-chain (scFv)), mini antibodies, double antibodies and sdAb. In one embodiment, RB is substantially composed of or consists of the HCVR amino acid sequence of sdAb.
[0188] In one embodiment, the RB domain comprises a set of three CDR amino acid sequences in an sdAb selected from the group consisting of: IGF1R-5 sdAb described in US 10,100,117, IGF1R-3 sdAb described in US 10,106,614, and IGF1R-5 sdAb described in US 10,112,998. These CDR sequences are listed in Table 3A below.
[0189] Table 3A: Exemplary CDR amino acid sequences of RB domains
[0190]
[0191] In one embodiment, RB consists essentially of or consists of the parent amino acid sequence of IGF1R-5, IGF1R-3 or IGF1R-4, or a humanized variant of one of these sdAbs. In one embodiment, RB consists essentially of or consists of a sequence selected from the group consisting of:
[0192] (i)X1VX2LX3ESGGGLVQX4GGSLRLSCAASGRTIDNYAMAWX5RQAPGKX6X7EX8VX9TIDWGDGGX 10 RYANSVKGRFTISRDNX 11 KX 12 TX 13 YQ 14 LX 15 X 16 EDTAVYX 17 CAMARQSRVNLDVARYDYWGQGTX 18 VTVSS, where X1 is E or Q; X2 is K or Q; X3 is V or E; X4 is A or P; X5 is V or S; X6 is D or G; X7 is L or R; X5 is F or W; X9 is A or S; X 10 A or T; X11 A or S; X 12 is G or N; X 13 M or L; X 14 is N or R; X 15 is E or R; X 16 Is P or A; X 17 is S or Y; and X 18 is Q or L (SEQ ID NO:64);
[0193] (ii)X1VX2LX3ESGGGLVQX4GGSLRLSCX5ASEYPSNFYAMSWX6RQAPGKX7X8EX9VX 10 GVSRDGLTTLYADSVKGRFTX 11 SRDNX i2 KNTX 13 X 14 LQM 15 X 16 AEDTAVYYCAIVITGVWNKVDVNSRSYHYWGQGTX 17 VTVSS, where X1 is E or Q; X2 is K or Q; X3 is V or E; X4 is A or P; X5 is V or A; X6 is F or V; X7 is E or G; X8 is R or L; X9 is F or W; X 10 A or S; X 11 is M or I; X 12 A or S; X 13 is V or L; X 14 is D or Y; X 15 is V or L; X 16 is K or R; and X 17 is Q or L (SEQ ID NO:65); and
[0194] (iii)X1VX2LX3ESGGGLVQX4GGSLRLSCX5X6SGGTVSPTAMGWX7RQAPGKX8X9EX 10 VX 11 HITWSRGTTRX 12 ASSVKX 13 RFTISRDX 14 X 15 KNTX 16 YLQ 17 X 18 EDTAVYYCAASTFLRILPEESAYTYWGQGTX 19VTVSS, where X1 is E or Q; X2 is K or Q; X3 is V or E; X4 is A or P; X5 is A or E; X6 is V or A; X7 is V or F; X8 is G or E; X3 is L or R; X 10 Is F or W; X 11 is G or S; X 12 is V or Y; X 13 is D or G; X 14 is N or S; X 15 A or S; X 16 L or V; X 17 is K or R; X 18 is A or S; and X 19 is L or Q (SEQ ID NO:66).
[0195] In one embodiment, RB consists essentially of or consists of the amino acid sequence of any one of the humanized variants of IGF1R-5, IGF1R-3 or IGF1R-5 described in US 10,100,117, US 10,106,614 and US 10,112,998, respectively. In one embodiment, RB consists essentially of or consists of an amino acid sequence selected from the parent or humanized sequence shown in Table 3B below herein. In one embodiment, RB consists essentially of or consists of the parent or humanized amino acid sequence of IGF1R-5 shown in Table 3B below.
[0196] Table 3B: Exemplary amino acid sequences of RB domains.
[0197]
[0198] Generation of HSA and hIGF1R binding domains
[0199] The AB and RB domains may be derived from any antibody or antigen-binding fragment thereof having the desired properties described herein. The antibody or antigen-binding fragment may be known in the art or may be identified by any method known in the art.
[0200] In some embodiments, one or both of the AB and RB domains are derived from a single domain Ab. For example, camelid-derived sdAbs lack light chains and therefore their antigen binding sites consist of one domain (referred to as V H H). sdAb has also been observed in sharks, which is called V NAR Other sdAbs can be engineered based on human Ig heavy and light chain sequences. As used herein, the term "sdAb" includes V sequences from any source generated by phage display or other techniques. H 、V H H.V L or VNAR sdAbs isolated directly from the reservoir, recombinantly produced sdAbs, and those produced by further modification of such sdAbs by humanization, affinity maturation, stabilization, solubilization or other antibody engineering methods. The present disclosure also encompasses homologues, derivatives or fragments that retain the antigen binding function and specificity of the parent sdAb.
[0201] In order to generate V that binds to HSA H H sdAb and V binding to hIGF1R H For H sdAbs, a skilled artisan may generate and screen phage-displayed V sdAbs from a heavy chain-only antibody library of a camel or other camelid immunized with a desired antigen using any method known in the art (e.g., essentially as described in WO 2019 / 204925 and US 10,100,117, respectively). H H library. In one embodiment, the IGF1R antigen used to immunize camelids is a fragment of the precursor hIGF1R, for example comprising amino acids 1 to 932 of the sequence shown in Figure 1. In one embodiment, the antigenic hIGF1R fragment does not contain a signal peptide.
[0202] The AB or RB domain derived from an sdAb may include the parental framework regions; alternatively, the parental CDRs may be grafted onto the V domain of another sdAb. NAR 、V H H.V H or V L The CDRs can be grafted onto the framework regions, or onto other types of antibody fragments or antibody-like molecules (Fv, scFv, Fab) of any origin (e.g., human), or onto the framework regions of proteins of similar size and properties onto which the CDRs can be grafted (e.g., see Nicaise, M. et al., Protein Sci 13: 1882-91 2004).
[0203] In some embodiments, the amino acid sequence in one or both of the AB and RB domains is a humanized version (humanized variant) of the parent variable region. Humanization of an antibody or antibody fragment includes replacing the amino acids in the sequence with its human counterpart as found in the human consensus sequence without losing antigen binding ability or specificity; this method reduces the immunogenicity of the antibody or its fragment when introduced into a human subject. The parent sequence can be humanized using any suitable method known in the art (such as, but not limited to, CDR grafting and veneering).
[0204] In the CDR grafting process, one or more than one CDR defined herein can be fused or grafted into a human variable region (V H or V L), another human antibody (IgA, IgD, IgE, IgG and IgM), an antibody fragment framework region (Fv, scFv, Fab), or a protein of similar size and properties to which a CDR can be grafted. CDR grafting is known in the art and is described in at least the following: U.S. Patent Nos. 6,180,370, 5,693,761, 6,054,297 and European Patent No. 626390.
[0205] Veneering, also known in the art as "variable region resurfacing," involves humanizing the solvent-exposed positions of an antibody or antibody fragment; thus, buried non-humanized residues that may be important for CDR conformation are retained while minimizing the potential for immune response to solvent-exposed regions. Veneering is known in the art and is described in at least the following: U.S. Pat. Nos. 5,869,619, 5,766,886, and 5,821,123 and European Patent No. 519596.
[0206] Connectors
[0207] BBB transport fusion proteins may, for example, contain one or more joints between the AB and RB domains and / or between the RB domain and a cargo portion (e.g., a therapeutic polypeptide). Each joint should be of sufficient length to allow the connected polypeptide to be individually folded into a three-dimensional structure with a desired functional activity (e.g., binding or treatment). In addition, each joint should not be cleaved by any protease or other enzyme present in serum.
[0208] In some embodiments, the linker is a peptide linker comprising at least two, three or four amino acids and less than about 30 amino acids (e.g., less than any of about 25, 20, 15 or 10 amino acids). Peptide linkers are known in the art and non-limiting examples are described herein.
[0209] The peptide linker may have a naturally occurring sequence or a non-naturally occurring sequence. For example, a sequence derived from the hinge region of a heavy chain-only antibody may be used as a linker. See, for example, WO 1996 / 34103.
[0210] Suitable linker peptides typically include various forms of G and / or S residues, and exemplary linker peptides include GGGG (SEQ ID NO: 71), TGGGG (SEQ ID NO: 72), GGSSGGSGSSSGSGGSGSSG (SEQ ID NO: 73), (GGSS) n (SEQ ID NO: 74), (GGGGS) n (SEQ ID NO: 13), (SGGGG) n (SEQ ID NO: 75) and GGGG (SGGGG) n (SEQ ID NO: 76), wherein "n" is typically a number between 1 and 10 in each case, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, provided that the maximum length of about 40 amino acids is not exceeded. Another exemplary peptide linker is SKPTCPPPELLGGPSVFIFPPK (SEQ ID NO: 77).
[0211] In one embodiment, the fusion protein comprises two peptide linkers L1 and L2, wherein the peptide linker L1 is located between AB and RB, and L2 is located between RB and the cargo polypeptide. In one embodiment, the length of each of L1 and L2 is between about 15 and 30 amino acids, or between about 20 and 25 amino acids. L1 and L2 may have the same or different amino acid sequences. In one embodiment, each of L1 and L2 is independently substantially composed of or consisting of: (GGGGS)4 (SEQ ID NO: 14) or (GGGGS)5 (SEQ ID NO: 78). In one embodiment, each of L1 and L2 is substantially composed of or consisting of: (GGGGS)4.
[0212] Therapeutic and diagnostic goods
[0213] The cargo moiety can be any therapeutic or diagnostic molecule that can be linked or attached to the hIGF1R binding domain.
[0214] In one embodiment, the therapeutic molecule is a polypeptide, such as a cytokine, an enzyme, a growth factor, or an antibody or an antigen-binding fragment thereof. In one embodiment, the polypeptide has an activity that can be used to treat a nervous system disorder in a mammal (e.g., a human). In one embodiment, the nervous system disorder is selected from the group consisting of: LSD with nervous system manifestations (nLSD), Alzheimer's disease (AD), ataxia (e.g., hereditary ataxias, such as Friedreich's ataxia), Huntington's disease, stroke, dementia, muscular dystrophy (MD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), cystic fibrosis, Angelman's syndrome, Liddle syndrome, Parkinson's disease, Pick's disease, Paget's disease, schizophrenia, depression, encephalitis, prion disease, cancer, and traumatic brain injury.
[0215] In one embodiment, the therapeutic molecule is an enzyme. In one embodiment, the enzyme is deficient in LSD, for example, any of the deficient enzymes listed in Table 1 of Edelman, MJAnd and Maegawa, GHB, Frontiers in Molecular Biosciences, Vol. 7, Article 559804 (November 12, 2020). In one embodiment, the enzyme is IDUA, IDS, SGSH, GLA or GAA. In one embodiment, LSD is MPS-1 and the enzyme is IDUA. In one embodiment, the enzyme is IDS. In one embodiment, the enzyme is not IDS.
[0216] In one embodiment, the therapeutic molecule is an antibody or antigen-binding fragment thereof that specifically binds to a target protein (e.g., an antigen) in the brain. In one embodiment, the target protein is Tau protein (e.g., cis P-tau), Aβ, BACE1 or its splice isoforms, human epidermal growth factor receptor (2) (HER2), apolipoprotein E4 (ApoE4), α-synuclein, CD20, prion protein (PrP), leucine-rich repeat kinase 2 (LRRK2), parkin presenilin 1, presenilin 2, γ-secretase, death receptor 6 (DR6), amyloid precursor protein (APP), p75 neurotrophic factor receptor (p75NTR), interferon γ, white blood cell proliferation factor receptor (WGF-β), leukocyte antigen 2 (LRRK2 ... Interleukin-1 receptor (IL-1R), interleukin-6 (IL-6), interleukin 6 receptor (IL6R), interleukin-12, interleukin-23, TNF receptor (TNFR1), interleukin 1β (IL1β), caspase 6, interleukin-17 (IL-17), CTLA-4, programmed death receptor 1 (PD-1), programmed death ligand 1 (PD-L1), programmed death ligand 2 (PD-L2), TNF-α, vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR).
[0217] In one embodiment, the therapeutic molecule is a cytokine or growth factor, such as an immunomodulatory cytokine, such as granulocyte-macrophage colony stimulating factor (GM-CSF), interferon-β, nerve growth factor, glial cell line-derived neurotrophic factor (GNDF), ciliary neurotrophic factor (CNTF), basic fibroblast growth factor (bFGF), fibroblast growth factor-2 (FGF2), epidermal growth factor (EGF), or transforming growth factor (TGF)-β2.
[0218] Genetically modified cells
[0219] Any of the above-mentioned BBB transport fusion proteins can be expressed by one or more mammalian cells genetically modified to express and secrete fusion proteins. One or more genetically modified cells can be derived from a variety of different mammalian cell types (e.g., human cells), including epithelial cells, endothelial cells, fibroblasts, mesenchymal stem cells, keratinocytes and stem cells, such as embryonic stem cells or induced pluripotent stem cells. Exemplary cell types include the cell types described in WO 2017 / 075631. In some embodiments, the cell is derived from the cell line shown in Table 4 below.
[0220] Table 4: Exemplary cell lines
[0221]
[0222]
[0223] In one embodiment, any of the genetically modified mammalian cells described herein are derived from RPE cells, such as ARPE-19 cells. In one embodiment, the genetically modified ARPE-19 cells comprise any of the expression cassettes, transposons, and polynucleotides described herein.
[0224] Any of a variety of genetic engineering techniques known in the art can be used to genetically modify cells to express and secrete the desired BBB transport fusion protein. For example, cells can be transfected with an expression vector comprising one or more exogenous nucleotide sequences encoding the desired fusion protein, which are operably linked to control elements necessary for or useful for gene expression, such as promoters, ribosome binding sites, enhancers, polyA signals, etc. In some embodiments, the exogenous nucleotide sequence is a part of a transcription unit stably integrated into the genome of the parent cell.
[0225] In one embodiment, the exogenous sequence includes a nucleotide sequence encoding a secretory signal sequence of the fusion protein. In one embodiment, the signal sequence is from a naturally secreted protein. In one embodiment, the signal sequence is MELGLSWVVLAALLQGVQA (SEQ ID NO: 79). In some embodiments, the signal sequence is substantially composed of the amino acid sequence shown in Table 5 below.
[0226] Table 5: Exemplary secretion signal peptide sequences
[0227]
[0228]
[0229] Genetically modified mammalian cells used in the devices, compositions and methods described herein, for example as multiple cells in a hydrogel capsule, may be in various stages of the cell cycle. In some embodiments, at least one of the multiple genetically modified cells is undergoing cell division. Cell division can be measured using any known method in the art, for example, as described in DeFazio A et al. (1987) J Histochem Cytochem 35:571-577 and Dolbeare F et al. (1983) Proc Natl Acad Sci USA 80:5573-5577, each of which is incorporated by reference in its entirety. In one embodiment, at least 1%, 2%, 3%, 4%, 5%, 10% or 20% of the cells are undergoing cell division, for example, as determined by 5-ethynyl-2'deoxyuridine (EdU) assay or 5-bromo-2'-deoxyuridine (BrdU) assay. In some embodiments, cell proliferation is visualized or quantified by microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation) or flow cytometry). In some embodiments, no cells in the plurality of genetically modified cells are undergoing cell division and are in a quiescent state. In one embodiment, less than 1%, 2%, 3%, 4%, 5%, 10%, or 20% of the cells are undergoing cell division, 5-ethynyl-2'deoxyuridine (EdU) assay, 5-bromo-2'-deoxyuridine (BrdU) assay, microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation) or flow cytometry).
[0230] In one embodiment, at least 50%, 60%, 70%, 80%, 90% or more of the genetically modified cells in a plurality of genetically modified cells are viable. Cell viability can be measured using any known method in the art, for example, as described in Riss, T. et al. (2013) "Cell Viability Assays" in Assay Guidance Manual (Sittapalam, GS et al., ed.). For example, cell viability can be measured or quantified by ATP assay, 5-ethynyl-2'deoxyuridine (EdU) assay, 5-bromo-2'-deoxyuridine (BrdU) assay. In some embodiments, cell viability is visualized or quantified by microscopy, such as fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation) or flow cytometry. In one embodiment, at least 80% of the engineered cells in the plurality of genetically modified cells are viable, e.g., as determined by an ATP assay, a 5-ethynyl-2'deoxyuridine (EdU) assay, a 5-bromo-2'-deoxyuridine (BrdU) assay, microscopy (e.g., fluorescence microscopy (e.g., time-lapse or evaluation of spindle formation), or flow cytometry.
[0231] Any of the parameters described herein can be assessed using standard techniques known to those of skill in the art, such as histology, microscopy, and various functional assays.
[0232] Implantable Cell Encapsulation Devices
[0233] The genetically modified cells described herein, or a plurality of such cells, can be incorporated into an implantable device for use in providing a therapeutic or diagnostic cargo to a subject suffering from a CNS disease or disorder, such as a patient suffering from a LSD such as MPS-I.
[0234] The implantable device of the present disclosure includes at least one barrier that prevents immune cells from contacting cells contained inside the device. At least a portion of the barrier needs to be sufficiently porous to allow proteins (e.g., fusion proteins) expressed and secreted by the cells to leave the device. A variety of device configurations known in the art are suitable.
[0235] The device (e.g., particle) may have any configuration and shape suitable for supporting the vitality and productivity of the contained cells after being implanted in the expected target position. As a non-limiting example, the device shape may be cylindrical, rectangular, disc-shaped, oval, star-shaped or spherical. The device may be composed of a mesh or nested structure. In some embodiments, the device can prevent materials exceeding a certain size from passing through a pore or opening. In some embodiments, the device (e.g., particle) can prevent materials greater than 50kD, 75kD, 100kD, 125kD, 150kD, 175kD, 200kD, 250kD, 300kD, 400kD, 500kD, 750kD or 1,000kD from passing through.
[0236] In one embodiment, the device is a macroencapsulation device. Non-limiting examples of macrodevices are described in WO 2019 / 068059, WO 2019 / 169089, U.S. Patents Nos. 9,526,880, 9,724,430, and 8,278,106; European Patent No. EP742818B1, and Sang, S. and Roy, S., Biotechnol. Bioeng. 113(7): 1381-1402 (2016).
[0237] In one embodiment, the device is a macro device having one or more cell-containing compartments. A device having two or more cell-containing compartments can be configured to produce two or more proteins, for example, cells expressing a fusion protein will be placed in one compartment, and cells expressing different proteins (e.g., therapeutic proteins that can alleviate one or more symptoms of a targeted CNS disease or disorder) will be placed in separate compartments. WO 2018 / 232027 describes a device having multiple cell-containing compartments formed in a micro-fabricated body and covered by a porous membrane.
[0238] In one embodiment, the device is constructed as a thin, flexible strand, as described in U.S. Pat. No. 10,493,107. The strand includes a substrate, an inner polymer coating surrounding the substrate, and an outer hydrogel coating surrounding the inner polymer coating. Cells expressing the protein are located in the outer coating.
[0239] In some embodiments, the device (e.g., particle) has a maximum linear dimension (LLD), such as an average diameter or size of at least about 0.5 millimeters (mm), preferably about 1.0 mm, about 1.5 mm, or more. In some embodiments, the diameter or size of the device can be as large as 10 mm. For example, the devices or particles described herein have a range of 0.5 mm to 10 mm, 1 mm to 10 mm, 1 mm to 8 mm, 1 mm to 6 mm, 1 mm to 5 mm, 1 mm to 4 mm, 1 mm to 3 mm, 1 mm to 2 mm, 1 mm to 1.5 mm, 1.5 mm to 8 mm, 1.5 mm to 6 mm, 1.5 mm to 5 mm, 1.5 mm to 4 mm, 1.5 mm to 3 mm, 1.5 mm to 2 mm, 2 mm to 8 mm, 2 mm to 7 mm, 2 mm to 6 mm, 2 mm to 5 mm, 2 mm to 4 mm, 2 mm to 3 mm, 2.5 mm to 8 mm, 2.5 mm to 7 mm, 2.5 mm to 6 mm, 2.5 mm to 5 mm, 2.5 mm to 4 mm, 2.5 mm to 3 mm, 3 mm to 8 mm, 3mm to 7mm, 3mm to 6mm, 3mm to 5mm, 3mm to 4mm, 3.5mm to 8mm, 3.5mm to 7mm, 3.5mm to 6mm, 3.5mm to 5mm, 3.5mm to 4mm, 4mm to 8mm, 4mm to 7mm, 4mm to 6mm, 4mm to 5mm, 4.5mm to 8mm, 4.5mm to 7mm, 4.5mm to 6mm, 4.5mm to 5mm, 5mm to 8mm, 5mm to 7mm, 5mm to 6mm, 5.5mm to 8mm, 5.5mm to 7mm, 5.5mm to 6mm, 6mm to 8mm, 6mm to 7mm, 6.5mm to 8mm, 6.5mm to 7mm, 7mm to 8mm or 7.5mm to 8mm.
[0240] In some embodiments, the device (e.g., particle, capsule) of the present disclosure includes at least one pore or opening, such as to allow material to flow freely. In some embodiments, the average pore size of the device is between about 0.1 μm and about 10 μm. For example, the average pore size can be between 0.1 μm and 10 μm, 0.1 μm and 5 μm, 0.1 μm and 2 μm, 0.15 μm and 10 μm, 0.15 μm and 5 μm, 0.15 μm and 2 μm, 0.2 μm and 10 μm, 0.2 μm and 5 μm, 0.25 μm and 10 μm, 0.25 μm and 5 μm, 0.5 μm and 10 μm, 0.75 μm and 10 μm, 1 μm and 10 μm, 1 μm and 5 μm, 1 μm and 2 μm, 2 μm and 10 μm, 2 μm and 5 μm or 5 μm and 10 μm. In some embodiments, the average pore size of the device is between about 0.1 μm and 10 μm. In some embodiments, the average pore size of the device is between about 0.1 μm and 5 μm. In some embodiments, the average pore size of the device is between about 0.1 μm and 1 μm.
[0241] In some embodiments, equipment includes semipermeability, biocompatible membrane, and this membrane is around the genetically modified cell that is encapsulated in polymer composition (for example, alginate hydrogel).Select membrane pore size to allow oxygen and other important molecules for cell survival and function to move through semipermeable membrane, while preventing immune cells from passing through hole.In one embodiment, semipermeable membrane has less than 1000kD or between 50-700kD, between 70-300kD, or between 70-150kD, or molecular weight cut-off between 70 and 130kD.
[0242] In one embodiment, the device may contain a cell-containing compartment surrounded by a barrier compartment formed of a cell-free biocompatible material, such as a core-shell microcapsule described in Ma, M et al., Adv. Healthc Mater., 2(5): 667-672 (2012). Such a barrier compartment may be used with or without a semipermeable membrane.
[0243] The cells in one or more cell-containing compartments of the device of the present disclosure may be encapsulated in a polymer composition. The polymer composition may include one or more polymers that form a hydrogel. In addition to the polymer composition in one or more cell-containing compartments, the device (e.g., macro device, particle, hydrogel capsule) may also include or be formed of materials such as metals, metal alloys, ceramics, polymers, fibers, inert materials, and combinations thereof. The device may be made entirely of one type of material, or may include other materials in the cell-containing compartment and any other compartment.
[0244] In some embodiments, the device comprises a metal or a metal alloy. In one embodiment, one or more of the compartments in the device (e.g., the first compartment, the second compartment, or all compartments) comprise a metal or a metal alloy. Exemplary metals or metal alloys include titanium and titanium group alloys (e.g., nitinol, nickel titanium alloys, heat memory alloy materials), platinum, platinum group alloys, stainless steel, tantalum, palladium, zirconium, niobium, molybdenum, nickel-chromium, chromium-molybdenum alloys, or certain cobalt alloys (e.g., cobalt-chromium and cobalt-chromium-nickel alloys, such as and ). For example, the metal material can be 316 grade stainless steel (SS 316L) (including Fe, <0.3% C, 16%-18.5% Cr, 10%-14% Ni, 2%-3% Mo, <2% Mn, <1% Si, <0.45% P and <0.03% S). In the metal-containing device, the amount of metal (e.g., in weight %, actual weight) can be at least 5%, such as at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or more, such as w / w; less than 20%, such as less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1% or less.
[0245] In some embodiments, the device includes ceramics. In one embodiment, one or more compartments (e.g., the first compartment, the second compartment, or all compartments) in the compartments in the device include ceramics. Exemplary ceramic materials include oxides, carbides, or nitrides of transition elements, such as titanium oxide, hafnium oxide, iridium oxide, chromium oxide, aluminum oxide, and zirconium oxide. Silicon-based materials such as silicon dioxide can also be used. In a device containing ceramics, the amount of ceramics (e.g., in wt%, actual weight) can be at least 5%, such as at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or more, such as w / w; less than 20%, such as less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1% or less.
[0246] In some embodiments, the device has two hydrogel compartments, wherein the inner cell-containing compartment is completely surrounded by the second outer (e.g., barrier) compartment. In one embodiment, the inner boundary of the second compartment forms an interface with the outer boundary of the first compartment. In such embodiments, the thickness of the second (outer) compartment means the average distance between the outer boundary of the second compartment and the interface between the two compartments, for example, the average value of the distance measured at each of the thinnest point and the thickest point visually observed in the outer compartment. In some embodiments (e.g., the diameter of the device is about 1.5mm), the thinnest distance and the thickest distance of the outer compartment are respectively between 25 and 110 microns (μm) and between 270 μm and 480 μm. In some embodiments, the thickness of the outer compartment is greater than about 10 nanometers (nm), preferably 100nm or larger, and can be as large as 1 millimeter (mm). For example, the thickness (e.g., average distance) of the outer compartment in the hydrogel capsule device described herein can be 10nm to 1mm, 100nm to 1mm, 500nm to 1 millimeter, 1 micrometer (μm) to 1mm, 1μm to 1mm, 1μm to 500μm, 1μm to 250μm, 1μm to 1mm, 5μm to 500μm, 5μm to 250μm, 10μm to 1mm, 10μm to 500μm or 10μm to 250μm. In some embodiments, the thickness (e.g., average distance) of the outer compartment is 100nm to 1mm, between 1μm and 1mm, between 1μm and 500μm or between 5μm and 1mm. In some embodiments, the thickness (e.g., average distance) of the outer compartment is between about 50μm and about 100μm. In some embodiments (eg, the diameter of the device is about 1.5 mm), the thickness (eg, average distance) of the outer compartment is between about 180 μm and 260 μm or between about 310 μm and 440 μm.
[0247] In some embodiments of the dual compartment hydrogel capsule device, the average pore size of the cell-containing inner compartment and the outer compartment is substantially the same. In some embodiments, the average pore size of the inner compartment and the second compartment differs by about 1.5%, 2%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or more. In some embodiments, the average pore size of the device (e.g., the average pore size of the first compartment and / or the average pore size of the second compartment) depends on many factors, such as the presence and density of one or more materials in each compartment and the compound of formula (III).
[0248] In some embodiments, one or more polymer compositions containing cell compartments include polysaccharides or other polymers (for example, alginate, hyaluronate or chondroitin) forming hydrogels. In some embodiments, polymer is alginate, which is a polysaccharide made of β-D-mannuronic acid (M) and α-L-guluronic acid (G). In some embodiments, alginate has low molecular weight (for example, <75kD approximate molecular weight) and ≥1.5 G:M ratio, (ii) medium molecular weight alginate, for example, with 75-150kDa approximate molecular weight about and ≥1.5 G:M ratio, (iii) high molecular weight alginate, for example, with 150kDa-250kDa approximate MW and ≥1.5 G:M ratio, (iv) or two or more mixtures in these alginates. In some embodiments, one or more cell compartments further include at least one cell binding material (CBS), such as cell binding peptide (CBP) or cell binding polypeptide (CBPP) described in WO2020069429.
[0249] In some embodiments, one or more cell-containing compartments include alginate covalently modified with a joint-cell binding peptide moiety (e.g., GRGD or GRGDSP). In one embodiment, the cell binding peptide density (such as nitrogen % determined by combustion analysis such as described in WO2020198695) in one or more cell-containing compartments is at least 0.05%, 0.1%, 0.2% or 0.3%, but less than 4%, 3%, 2% or 1%. In one embodiment, the total density of joint-CBP in the cell-containing compartment is about 0.1 to about 1.0 micromolar CBP / g CBP- polymer (e.g., MMW- alginate covalently modified with GRGD (SEQ ID NO: 88) or GRGDSP (SEQ ID NO: 89) in solution), such as determined by quantitative peptide conjugation, such as determined by the determination described in WO2020198695. In one embodiment, the linker-CBP is GRGDSP and the alginate has a molecular weight of 75 kDa to 150 kDa and a G:M ratio greater than or equal to 1.5. In one embodiment, the cell-containing compartment further comprises unmodified alginate having a molecular weight of 75 kDa to 150 kDa and a G:M ratio greater than or equal to 1.5.
[0250] The device may form part of a plurality of substantially identical devices in a formulation (e.g., a composition). In some embodiments, the device (e.g., particle, hydrogel capsule) in the formulation has an average diameter or size between about 0.5 mm and about 8 mm. In some embodiments, the average diameter or size of the device in the formulation is between about 0.5 mm and about 4 mm or between about 0.5 mm and about 2 mm. In some embodiments, the device in the formulation is a two-compartment hydrogel capsule and has an average diameter or size of about 0.7 mm to about 1.3 mm, or about 1.2 mm to about 1.8 mm.
[0251] In some embodiments, the surface of the device comprises a compound capable of reducing FBR after implantation in a subject, such as a defibrotic compound as described herein below. For devices comprising a barrier compartment surrounding a cell-containing compartment, the defibrotic compound can covalently modify a polymer disposed throughout the barrier compartment and optionally throughout the cell-containing compartment.
[0252] In some embodiments, one or more compartments in the device include a defibrotizing polymer, e.g., a defibrotizing compound of formula (III) covalently attached to a polymer. In one embodiment, some or all monomers in the defibrotizing polymer are modified with the same compound of formula (III). In some embodiments, some or all monomers in the defibrotizing polymer are modified with different compounds of formula (III). In some embodiments where the device is a 2-compartment hydrogel capsule, the defibrotizing polymer is present only in the outer barrier compartment.
[0253] One or more compartments in the device may include an unmodified polymer that is the same or different than the polymer in any defibrillating polymer present in the device. In one embodiment, the first compartment, the second compartment, or all compartments in the device include an unmodified polymer.
[0254] Each of the modified polymers and the unmodified polymers in the device can be a linear, branched or cross-linked polymer, or a polymer with a selected molecular weight range, degree of polymerization, viscosity or melt flow rate. Branched polymers can include one or more of the following types: star polymers, comb polymers, brush polymers, dendritic polymers, ladder polymers and dendrimers. The polymer can be a thermosensitive polymer, such as a gel (e.g., a solid or liquid after exposure to heat or a certain temperature) or a photocross-linkable polymer. Exemplary polymers include polystyrene, polyethylene, polypropylene, polyacetylene, poly(vinyl chloride) (PVC), polyolefin copolymers, poly(polyurethane), polyacrylates and polymethacrylates, polyacrylamides and polymethacrylamides, poly(methyl methacrylate), poly(2-hydroxyethyl methacrylate), polyesters, polysiloxanes, polydimethylsiloxanes (PDMS), polyethers, poly(orthoesters), poly(carbonates), poly(hydroxyalkanoates), polyfluorocarbons, (polytetrafluoroethylene, PTFE), PEEK, silicone, epoxy resin, (condensation polymer obtained from ethylene glycol and terephthalic acid), polyethylene glycol, nylon, polyolefins, phenolic resins, natural and synthetic elastomers, adhesives and sealants, polyolefins, polysulfones, polyacrylonitrile, biopolymers such as polysaccharides and natural latex, collagen, cellulosic polymers (e.g., alkyl cellulose, etc.), polyethylene glycol and 2-hydroxyethyl methacrylate (HEMA), polysaccharides, poly(glycolic acid), poly(L-lactic acid) (PLLA), poly(lactic-glycolic acid) (PLGA), polydioxanone (PDA), or racemic poly(lactic acid), polycarbonates (e.g., polyamides (e.g., nylon)), fluoroplastics, carbon fibers, agarose, alginate, chitosan, and blends or copolymers thereof. In a polymer-containing device, the amount of polymer (e.g., actual weight of polymer as a % by weight of the device) can be at least 5%, such as at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or more, such as w / w; less than 20%, such as less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1% or less.
[0255] In some embodiments, one or more of the modified polymer and the unmodified polymer in the device comprises polyethylene. Exemplary polyethylenes include ultra low density polyethylene (ULDPE) (e.g., having a density in the range of 0.890 to 0.905 g / cm 3 Very low density polyethylene (VLDPE) (e.g., having a density in the range of 0.905 to 0.915 g / cm 3A polymer having a density of 0.915 to 0.935 g / cm 3 A polymer having a density of about 0.915 to 0.935 g / m 3 medium density polyethylene (MDPE) (e.g., having a density in the range of 0.926 to 0.940 g / cm 3 Polymers with a density of 0.940 to 0.970 g / cm 3 A polymer having a density of , which may or may not contain a comonomer) and polyethylene glycol.
[0256] In some embodiments, one or more of the modified polymer and the unmodified polymer in the device comprises polypropylene. Exemplary polypropylenes include homopolymers, random copolymers (homophase copolymers) and impact copolymers (heterogeneous copolymers), for example, as described in McKeen, Handbook of Polymer Applications in Medicine and Medical Devices, 3-Plastics Used in Medical Devices, (2014): 21-53.
[0257] In some embodiments, one or more of the modified polymer and the unmodified polymer in the device comprises polypropylene.Exemplary polystyrenes include general purpose or crystalline polystyrene (PS or GPPS), high impact polystyrene (HIPS), and syndiotactic polystyrene (SPS).
[0258] In some embodiments, one or more of the modified polymer and the unmodified polymer comprises a thermoplastic elastomer (TPE). Exemplary TPEs include (i) TPA-polyamide TPEs, which comprise block copolymers of alternating hard segments and soft segments, wherein there are amide chemical linkages in the hard blocks and ether and / or ester linkages in the soft blocks; (ii) TPC-copolyester TPEs, which consist of block copolymers of alternating hard segments and soft segments, wherein the chemical linkages in the backbone are esters and / or ethers; (iii) TPO-olefin TPEs, which consist of a blend of polyolefins and conventional rubbers, wherein the rubber phase in the blend has little or no crosslinking; (iv) TPS-styrenic TPEs, which consist of at least a triblock copolymer of styrene and a specific diene, wherein the two end blocks (hard blocks) are polystyrene, and and the interior blocks (soft block(s)) are polydiene or hydrogenated polydiene; (v) TPU - urethane TPE, which consists of block copolymers of alternating hard segments and soft segments with urethane chemical linkages in the hard blocks and ether, ester or carbonate linkages or mixtures thereof in the soft blocks; (vi) TPV - thermoplastic rubber vulcanizate, which consists of a blend of thermoplastic material and conventional rubber, wherein the rubber is crosslinked by a dynamic vulcanization process during the blending and mixing steps; and (vii) TPZ - unclassified TPE, which contains any composition or structure other than those grouped in TPA, TPC, TPO, TPS, TPU and TPV.
[0259] In some embodiments, the unmodified polymer is an unmodified alginate. In some embodiments, alginate is a high guluronic acid (G) alginate, and comprises greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more guluronic acid (G). In some embodiments, alginate is a high mannuronic acid (M) alginate, and comprises greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or more mannuronic acid (M). In some embodiments, the ratio of M:G is about 1. In some embodiments, the ratio of M:G is less than 1. In some embodiments, the ratio of M:G is greater than 1. In one embodiment, unmodified alginate has a molecular weight of 150kDa-250kDa and a G:M ratio of ≥1.5.
[0260] In some embodiments, defibration polymer comprises alginate chemically modified with formula (III) compound. The alginate in defibration polymer can be identical or different with any unmodified alginate present in equipment. In one embodiment, the density (e.g., amount conjugated) of formula (III) compound in defibration alginate is between about 4.0% and about 8.0% nitrogen, between about 5.0% and about 7.0% nitrogen or between about 6.0% and about 7.0% nitrogen (e.g., as determined by combustion analysis for nitrogen percentage). In one embodiment, the amount of compound 101 produces about 0.5% to 2%2% to 4% N, about 4% to 6% N, about 6% to 8% or about 8% to 10% N) N% increase (compared with unmodified alginate), wherein N% is determined by combustion analysis and corresponds to the amount of compound 101 in modified alginate.
[0261] In other embodiments, the density (e.g., concentration) of the compound of formula (III) (e.g., Compound 101) in the defibrotized alginate is defined as % w / w, for example, as a % of the weight of amine in a solution (e.g., saline) / weight of the defibrotized alginate as determined by a suitable quantitative amine conjugation assay (e.g., by the assay described in WO2020069429), and in certain embodiments, the density of the compound of formula (III) (e.g., Compound 101) is between about 1.0% w / w and about 3.0% w / w, between about 1.3% w / w and about 2.5% w / w, or between about 1.5% w / w and 2.2% w / w.
[0262] In an alginate-containing device, the amount of modified and unmodified alginate (e.g., actual weight of alginate as a % by weight of the device) can be at least 5%, such as at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or more, such as w / w; less than 20%, such as less than 20%, 15%, 10%, 5%, 1%, 0.5%, 0.1% or less.
[0263] The alginate in the defibration polymer can be chemically modified with a compound of formula (III) using any suitable method known in the art. For example, the alginate carboxylic acid moiety can be activated for coupling with one or more amine-functionalized compounds to obtain alginate modified with a compound of formula (III). The alginate polymer can be dissolved in water (30mL / gram of polymer) and treated with an activator (e.g., 2-chloro-4,6-dimethoxy-1,3,5-triazine (0.5 equivalent)) and a base (e.g., N-methylmorpholine (1 equivalent)). A solution of the compound of formula (III) in acetonitrile (0.3M) can be added to this mixture. The reactant can be warmed to 55°C for 16 hours, then cooled to room temperature and gently concentrated by rotary evaporation, and then the residue can be dissolved in, for example, water. The mixture can then be filtered, for example, by filtering through a cyano-modified silica gel (Silicycle) bed, and the filter cake can be washed with water. The resulting solution can then be dialyzed with water (10,000MWCO membrane) for 24 hours, for example, changing water twice. The obtained solution can be concentrated, for example, by lyophilization, to obtain the desired chemically modified alginate.Any suitable method as known in the art, for example, as described in any one of WO 2021 / 119522, WO 2019 / 195055, WO 2018 / 067615, WO 2017 / 075631, WO 2016 / 019391 and WO 2012 / 167223 can be used to chemically modify the alginate in the defibrotized polymer with a compound of formula (III).
[0264] In one embodiment, the device includes at least one cell-containing compartment, and in some embodiments contains two, three, four or more cell-containing compartments. In one embodiment, each cell-containing compartment includes a plurality of cells (e.g., living cells), and when the device is implanted in a subject, the cells in at least one of these compartments are capable of expressing and secreting the BBB transport fusion protein.
[0265] In one embodiment, all cells in the cell-containing compartment are derived from a single parent cell type or a mixture of at least two different parent cell types. In one embodiment, all cells in the cell-containing compartment are derived from the same parent cell type, but the first plurality of derived cells are engineered to express BBB transport fusion proteins, and the second plurality of derived cells are engineered to express different therapeutic proteins. In a device with two or more cell-containing compartments, cells and one or more proteins produced therefrom may be the same or different in each cell-containing compartment. In some embodiments, all cell-containing compartments are surrounded by a single barrier compartment. In some embodiments, the barrier compartment is substantially free of cells.
[0266] In one embodiment, cells to be incorporated into a device described herein (e.g., a hydrogel capsule) are prepared in the form of a cell suspension prior to being encapsulated in the device. The cells in the suspension may be in the form of a single cell (e.g., from a monolayer cell culture), or provided in another form, such as disposed on a microcarrier (e.g., a bead or matrix) or as a three-dimensional aggregate of cells (e.g., a cell cluster or spheroid). The cell suspension may contain a plurality of cell clusters (e.g., as spheroids) or microcarriers.
[0267] In addition to the fusion protein secreted by the encapsulated cells, the device (e.g., capsule, particle) may also contain one or more exogenous agents that are not expressed by the cells, and may contain, for example, nucleic acids (e.g., RNA or DNA molecules), proteins (e.g., hormones, enzymes (e.g., glucose oxidase, kinase, phosphatase, oxygenase, hydrogenase, reductase), antibodies, antibody fragments, antigens or epitopes)), active or inactive fragments of proteins or polypeptides, small molecules, or drugs. In one embodiment, the device is configured to release such exogenous agents.
[0268] Defiberizing – (i.e., FBR-mitigating) compounds
[0269] In some embodiments, the devices described herein include at least one compound of formula (III):
[0270]
[0271] or a pharmaceutically acceptable salt thereof, wherein:
[0272] A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, -C(O)O-, -C(O)-, -OC(O)-, -N(R C )-、-N(R C )C(O)-、-C(O)N(R C )-、-N(R C )C(O)(C1-C6-alkylene)-, -N(R C )C(O)(C1-C6-alkenylene)-, -N(R C )N(R D )-、-NCN-、-C(=N(R C )(R D ))O-、-S-、-S(O) x -、-OS(O) x -、-N(R C )S(O) x -、-S(O) x N(R C )-、-P(R F )y -、-Si(OR A )2-、-Si(R G )(OR A )-、-B(OR A )- or a metal, each of which is optionally linked to a linker group (e.g., a linker group described herein) and optionally supported by one or more R 1 replace;
[0273] L 1 and L 3 Each of the R is independently a bond, an alkyl group or a heteroalkyl group, wherein each alkyl group and heteroalkyl group is optionally substituted by one or more R 2 replace;
[0274] L 2 is the key;
[0275] M is absent, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally replaced by one or more R 3 replace;
[0276] P is absent, cycloalkyl, heterocyclyl, or heteroaryl, each of which is optionally replaced by one or more R 4 replace;
[0277] Z is hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, -OR A 、-C(O)R A 、-C(O)OR A 、-C(O)N(R C )(R D )、-N(R C )C(O)R A 、-N(R C )(R D ), cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted by one or more R 5 replace;
[0278] Each R A , R B , R C , R D , R E , R F and R G are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, azido, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted by one or more R 6 replace;
[0279] or R C and R D Together with the nitrogen atom to which they are attached, they form a 6 substituted rings (e.g., 5-7 membered rings);
[0280] Each R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, –OR A1 , –C(O)OR A1 , –C(O)R B1 、–OC(O)R B1 , –N(R C1 )(R D1 ),–N(R C1 )C(O)R B1 , –C(O)N(R C1 ), SR E1 、S(O) x R E1 、–OS(O) x R E1 , –N(R C1 )S(O) x R E1 , –S(O) x N(R C1 )(R D1 ),–P(R F1 ) y , cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally replaced by one or more R 7 replace;
[0281] Each R A1 , R B1 , R C1 , R D1 , R E1 and R F1 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted by one or more R 7 replace;
[0282] Each R 7are independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxy, cycloalkyl or heterocyclyl;
[0283] x is 1 or 2; and
[0284] y is 2, 3, or 4.
[0285] In some embodiments, the compound of formula (III) is a compound of formula (III-a):
[0286]
[0287] or a pharmaceutically acceptable salt thereof, wherein:
[0288] A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, -C(O)O-, -C(O)-, -OC(O)-, -N(R C )-、-N(R C )C(O)-、-C(O)N(R C )-、-N(R C )N(R D )-、N(R C )C(O)(C1-C6-alkylene)-, -N(R C )C(O)(C1-C6-alkenylene)-, -NCN-, -C(=N(R C )(R D ))O-、-S-、-S(O) x -、-OS(O) x -、-N(R C )S(O) x -、-S(O) x N(R C )-、-P(R F ) y -、-Si(OR A )2-、-Si(R G )(OR A )-、-B(OR A )- or a metal, each of which is optionally linked to an attachment group (e.g., an attachment group described herein) and optionally substituted by one or more R 1 replace;
[0289] L 1 and L 3 Each of the R is independently a bond, an alkyl group or a heteroalkyl group, wherein each alkyl group and heteroalkyl group is optionally substituted by one or more R 2 replace;
[0290] L 2 is the key;
[0291] M is absent, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally replaced by one or more R 3 replace;
[0292] P is optionally replaced by one or more R 4 substituted heteroaryl;
[0293] Z is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted by one or more R 5 replace;
[0294] Each R A , R B , R C , R D , R E , R F and R G are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, azido, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted by one or more R 6 replace;
[0295] or R C and R D Together with the nitrogen atom to which they are attached, they form a 6 substituted rings (e.g., 5-7 membered rings);
[0296] Each R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, –OR A1 , –C(O)OR A1 , –C(O)R B1 、–OC(O)R B1 , –N(R C1 )(R D1 ),–N(R C1 )C(O)R B1 , –C(O)N(R C1 ), SR E1 、S(O) x R E1 、–OS(O) x R E1 , –N(R C1 )S(O)x R E1 , –S(O) x N(R C1 )(R D1 ),–P(R F1 ) y , cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally replaced by one or more R 7 replace;
[0297] Each R A1 , R B1 , R C1 , R D1 , R E1 and R F1 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted by one or more R 7 replace;
[0298] Each R 7 are independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxy, cycloalkyl or heterocyclyl;
[0299] x is 1 or 2; and
[0300] y is 2, 3, or 4.
[0301] In some embodiments, for Formula (III) and (III-a), A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, -C(O)O-, -C(O)-, -OC(O)-, -N(R C )C(O)-、-N(R C )C(O)(C1-C6-alkylene)-, -N(R C )C(O)(C1-C6-alkenylene)-or-N(R C )-. In some embodiments, A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, -C(O)O-, -C(O)-, -OC(O)-, or -N(R C )-. In some embodiments, A is alkyl, alkenyl, alkynyl, heteroalkyl, -O-, -C(O)O-, -C(O)-, -OC(O)-, or -N(R C )-. In some embodiments, A is alkyl, -O-, -C(O)O-, -C(O)-, -OC(O), or -N(R C )-. In some embodiments, A is -N(RC )C(O)-、-N(R C )C(O)(C1-C6-alkylene)-or-N(R C )C(O)(C1-C6-alkenylene)-. In some embodiments, A is -N(R C )-. In some embodiments, A is -N(R C )-, and R C and R D is independently hydrogen or alkyl. In some embodiments, A is -NH-. In some embodiments, A is -N(R C )C(O)(C1-C6-alkylene)-, wherein the alkylene is R 1 In some embodiments, A is -N(R C )C(O)(C1-C6-alkylene)-, and R 1 is alkyl (eg, methyl). In some embodiments, A is -NH C(O)C(CH 3 ) 2 -. In some embodiments, A is -N(R C )C(O)(methylene)-, and R 1 is alkyl (eg, methyl). In some embodiments, A is -NHC(O)CH(CH3)-. In some embodiments, A is -NHC(O)C(CH3)-.
[0302] In some embodiments, for Formula (III) and (III-a), L 1 is a bond, alkyl or heteroalkyl. 1 is a bond or an alkyl group. In some embodiments, L 1 is a bond. In some embodiments, L 1 In some embodiments, L 1 is C1-C6 alkyl. 1 is -CH2-, -CH(CH3)-, -CH2CH2CH2 or -CH2CH2-. In some embodiments, L 1 It is -CH2- or -CH2CH2-.
[0303] In some embodiments, for Formula (III) and (III-a), L 3 is a bond, alkyl or heteroalkyl. 3 is a bond. In some embodiments, L 3 In some embodiments, L 3 It is C1-C 12 In some embodiments, L 3 is C1-C6 alkyl.3 is -CH2-. In some embodiments, L 3 In some embodiments, L 3 is optionally replaced by one or more R 2 (e.g., oxo) substituted C1-C 12 In some embodiments, L 3 is optionally replaced by one or more R 2 In some embodiments, L 3 is -C(O)OCH2-, -CH2(OCH2CH2)2-, -CH2(OCH2CH2)3-, CH2CH2O- or -CH2O-. In some embodiments, L 3 It is –CH2O–.
[0304] In some embodiments, for formula (III) or (III-a), M is absent, alkyl, heteroalkyl, aryl, or heteroaryl. In some embodiments, for formula (III) or (III-a), M is absent, alkyl, heteroalkyl, aryl, or heteroaryl. In some embodiments, M is heteroalkyl, aryl, or heteroaryl. In some embodiments, M is absent. In some embodiments, M is alkyl (e.g., C1-C6 alkyl). In some embodiments, M is -CH2-. In some embodiments, M is heteroalkyl (e.g., C1-C6 heteroalkyl). In some embodiments, M is (-OCH2CH2-) z , wherein z is an integer selected from 1 to 10. In some embodiments, z is an integer selected from 1 to 5. In some embodiments, M is -(OCH2)2-, (-OCH2CH 2- )2、(-OCH2CH 2- )3、(-OCH2CH2-)4 or (-OCH2CH2-) 5。 In some embodiments, M is -OCH2CH 2- 、(-OCH2CH 2-)2 , (-OCH2CH2-)3 or (-OCH2CH 2- )4. In some embodiments, M is -(-OCH2-)3. In some embodiments, M is aryl. In some embodiments, M is phenyl. In some embodiments, M is unsubstituted phenyl. In some embodiments, M is In some embodiments, M is In some embodiments, M is replaced by 1-4 R 3 (For example, 1 R 3 ) substituted phenyl. In some embodiments, R 3 It's CF3.
[0305] In some embodiments, for formula (III) and (III-a), P is absent, heterocyclyl, or heteroaryl. In some embodiments, for formula (III) and (III-a), P is absent, heterocyclyl, or heteroaryl. In some embodiments, P is absent. In some embodiments, for formula (III) and (III-a), P is a tricyclic, bicyclic, or monocyclic heteroaryl. In some embodiments, P is a monocyclic heteroaryl. In some embodiments, P is a nitrogen-containing heteroaryl. In some embodiments, P is a monocyclic nitrogen-containing heteroaryl. In some embodiments, P is a 5-membered heteroaryl. In some embodiments, P is a 5-membered nitrogen-containing heteroaryl. In some embodiments, P is a tetrazolyl, imidazolyl, pyrazolyl, or triazolyl or pyrrolyl. In some embodiments, P is imidazolyl. In some embodiments, P is 1,2,3-triazolyl. In some embodiments, P is In some embodiments, P is In some embodiments, P is
[0306] In some embodiments, P is heterocyclyl. In some embodiments, P is heterocyclyl. In some embodiments, P is 5-membered heterocyclyl. In some embodiments, P is imidazolidinone. In some embodiments, P is In some embodiments, P is thiomorpholinyl-1,1-dioxide. In some embodiments, P is
[0307] In some embodiments, for formula (III) and (III-a), Z is alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. In some embodiments, for formula (III) and (III-a), Z is alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. In some embodiments, Z is heterocyclyl. In some embodiments, Z is monocyclic or bicyclic heterocyclyl, 5-membered heterocyclyl or 6-membered heterocyclyl. In some embodiments, Z is 6-membered oxygen-containing heterocyclyl. In some embodiments, Z is tetrahydropyranyl. In some embodiments, Z is In some embodiments, Z is a 4-membered oxygen-containing heterocyclic group. In some embodiments, Z is
[0308] In some embodiments, Z is a bicyclic oxygen-containing heterocyclic group. In some embodiments, Z is a bicyclic oxygen-containing heterocyclic group. In some embodiments, Z is a phthalic anhydride group. In some embodiments, Z is a sulfur-containing heterocyclic group. In some embodiments, Z is a 6-membered sulfur-containing heterocyclic group In some embodiments, Z is a 6-membered heterocyclic group containing a nitrogen atom and a sulfur atom. In some embodiments, Z is thiomorpholinyl-1,1-dioxyl. In some embodiments, Z is In some embodiments, Z is a nitrogen-containing heterocyclic group. In some embodiments, Z is a 6-membered nitrogen-containing heterocyclic group. In some embodiments, Z is
[0309] In some embodiments, Z is a bicyclic heterocyclyl. In some embodiments, Z is a bicyclic heterocyclyl. In some embodiments, Z is optionally substituted with one or more R 5 In some embodiments, Z is 2-oxa-7-azaspiro[3.5]nonyl. In some embodiments, Z is In some embodiments, Z is 1-oxa-3,8-diazaspiro[4.5]decan-2-one. In some embodiments, Z is
[0310] In some embodiments, for formula (III) and (III-a), Z is aryl. In some embodiments, Z is monocyclic aryl. In some embodiments, Z is phenyl. In some embodiments, Z is (e.g., with 1 R 5 ) is a monosubstituted phenyl. In some embodiments, Z is a monosubstituted phenyl, wherein 1 R 5 In some embodiments, Z is a monosubstituted phenyl group, wherein one R 5 is NH2. In some embodiments, Z is a monosubstituted phenyl group wherein one R 5 In some embodiments, Z is a monosubstituted phenyl group, wherein one R 5 In some embodiments, Z is a monosubstituted phenyl group, wherein one R 5 In some embodiments, Z is a monosubstituted phenyl group, wherein one R 5 In some embodiments, Z is a monosubstituted phenyl group, wherein one R 5 In some embodiments, Z is a monosubstituted phenyl group, wherein one R 5 Located in the opposite position.
[0311] In some embodiments, for Formula (III) and (III-a), Z is alkyl. In some embodiments, Z is C1-C 12 In some embodiments, Z is C1-C 10 In some embodiments, Z is C1-C8 alkyl. In some embodiments, Z is substituted by 1-5 R 5In some embodiments, Z is replaced by 1 R 5 In some embodiments, Z is replaced by 1 R 5 Substituted C1-C8 alkyl, wherein R 5 is alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 、-C(O)R B1 、-OC(O)R B1 or -N(R C1 )(R D1 In some embodiments, Z is replaced by 1 R 5 Substituted C1-C8 alkyl, wherein R 5 Yes-OR A1 or-C(O)OR A1 In some embodiments, Z is replaced by 1 R 5 Substituted C1-C8 alkyl, wherein R 5 Yes-OR A1 or -C(O)OH. In some embodiments, Z is -CH3.
[0312] In some embodiments, for Formula (III) and (III-a), Z is heteroalkyl. In some embodiments, Z is C1-C 12 In some embodiments, Z is C1-C 10 In some embodiments, Z is C1-C8 heteroalkyl. In some embodiments, Z is C1-C6 heteroalkyl. In some embodiments, Z is optionally substituted with one or more R 5 In some embodiments, Z is substituted with 1-5 R 5 Substituted nitrogen and sulfur containing heteroalkyl. In some embodiments, Z is N-methyl-2-(methylsulfonyl)eth-1-amino free radical (aminyl).
[0313] In some embodiments, Z is -OR A or-C(O)OR A In some embodiments, Z is -OR A (e.g., -OH or -OCH3). In some embodiments, Z is -OCH3. In some embodiments, Z is -C(O)OR A (e.g., -C(O)OH).
[0314] In some embodiments, Z is hydrogen.
[0315] In some embodiments, L 2 is a key and P and L 3In some embodiments, L 2 is a bond, P is a heteroaryl, L 3 is a bond, and Z is hydrogen. In some embodiments, P is heteroaryl, L 3 is heteroalkyl, and Z is alkyl.
[0316] In some embodiments, the compound of formula (III) is a compound of formula (III-b):
[0317]
[0318] or a pharmaceutically acceptable salt thereof, wherein ring M 1 is cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted by 1-5 R 3 Substitution; Ring Z 1 is optionally replaced by 1-5 R 5 Substituted cycloalkyl, heterocyclyl, aryl or heteroaryl; R 2a , R 2b , R 2c and R 2d Each of is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halo, cyano, nitro, amino, cycloalkyl, heterocyclyl, aryl or heteroaryl, or R 2a and R 2b or R 2c and R 2d Each of the above forms an oxo group; X is absent, N(R 10 )(R 11 ), O or S; R C is hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by 1-6 R 6 Replace; each R 3 , R 5 and R 6 are independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 、-C(O)OR A1 、-C(O)R B1 、-OC(O)R B1 、-N(R C1 )(R D1 )、-N(R C1 )C(O)R B1 、-C(O)N(R C1 ), SR E1 , cycloalkyl, heterocyclyl, aryl or heteroaryl; R 10 and R 11Each of the above is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, -C(O)OR A1 、-C(O)R B1 、-OC(O)R B1 、-C(O)N(R C1 ), cycloalkyl, heterocyclyl or heteroaryl; each R A1 , R B1 , R C1 , R D1 and R E1 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted by 1-6 R 7 Replace; each R 7 are independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxy, cycloalkyl or heterocyclyl; each m and n are independently 1, 2, 3, 4, 5 or 6; and Refers to a connection to an attachment group or polymer described herein. In some embodiments, for each R 3 and R 5 , each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally and independently substituted with halogen, oxo, cyano, cycloalkyl or heterocyclyl.
[0319] In some embodiments, the compound of formula (III-b) is a compound of formula (III-bi):
[0320]
[0321] or a pharmaceutically acceptable salt thereof, wherein ring M 2 is optionally replaced by one or more R 3 Substituted aryl or heteroaryl; Ring Z 2 is a cycloalkyl group, a heterocyclyl group, an aryl group or a heteroaryl group; R 2a , R 2b , R 2c and R 2d Each of R is independently hydrogen, alkyl or heteroalkyl, or R 2a and R 2b or R 2c and R 2d Each of the groups together form an oxo group; X is absent, O or S; each R 3 and R 5 are independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1, wherein each alkyl and heteroalkyl is optionally substituted with halogen; or two R 5 Together with ring Z 2 A fused 5-6 membered ring; each R A1 and R B1 is independently hydrogen, alkyl or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3, 4, 5 or 6; and Refers to linkage to an attachment group or polymer as described herein.
[0322] In some embodiments, the compound of formula (III-bi) is a compound of formula (III-b-ii):
[0323]
[0324] or a pharmaceutically acceptable salt thereof, wherein ring Z 2 is a cycloalkyl group, a heterocyclyl group, an aryl group or a heteroaryl group; R 2c and R 2d Each of R is independently hydrogen, alkyl or heteroalkyl, or R 2c and R and together form an oxo group; each R 3 and R 5 are independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1 , wherein each alkyl and heteroalkyl is optionally substituted with halogen; each R A1 and R B1 are independently hydrogen, alkyl or heteroalkyl; each of p and q is independently 0, 1, 2, 3, 4, 5 or 6; and Refers to linkage to an attachment group or polymer as described herein.
[0325] In some embodiments, the compound of formula (III) is a compound of formula (III-c):
[0326]
[0327] or a pharmaceutically acceptable salt thereof, wherein ring Z 2 is a cycloalkyl group, a heterocyclyl group, an aryl group or a heteroaryl group; R 2c and R 2d Each of R is independently hydrogen, alkyl or heteroalkyl, or R 2c and R 2d together to form an oxo group; each R 3 and R 5 are independently alkyl, heteroalkyl, halogen, oxo, -OR, -C(O)OR or -C(O)R B1, wherein each alkyl and heteroalkyl is optionally substituted with halogen; each R A1 and R B1 are each independently hydrogen, alkyl or heteroalkyl; m is 1, 2, 3, 4, 5 or 6; each of p and q is independently 0, 1, 2, 3, 4, 5 or 6; and Refers to linkage to an attachment group or polymer as described herein.
[0328] In some embodiments, the compound of formula (III) is a compound of formula (III-d):
[0329]
[0330] or a pharmaceutically acceptable salt thereof, wherein ring Z 2 is cycloalkyl, heterocyclyl, aryl or heteroaryl; X is absent, O or S; R 2a , R 2b , R 2c and R 2d Each of R is independently hydrogen, alkyl or heteroalkyl, or R 2a and R 2b or R 2c and R 2d Each of the R 5 are independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1 , wherein each alkyl and heteroalkyl is optionally substituted with halogen; each R A1 and R are each independently hydrogen, alkyl or heteroalkyl; each of m and n is independently 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3, 4, 5 or 6; and Refers to linkage to an attachment group or polymer as described herein.
[0331] In some embodiments, the compound of formula (III) is a compound of formula (III-e):
[0332]
[0333] or a pharmaceutically acceptable salt thereof, wherein ring Z 2 is cycloalkyl, heterocyclyl, aryl or heteroaryl; X is absent, O or S; R 2a , R 2b , R 2c and R 2d Each of R is independently hydrogen, alkyl or heteroalkyl, or R 2a and R 2b or R 2c and R2d Each of the R 5 are independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1 ; Each R A1 and R B1 are each independently hydrogen, alkyl or heteroalkyl; each of m and n is independently 1, 2, 3, 4, 5 or 6; p is 0, 1, 2, 3, 4, 5 or 6; and Refers to linkage to an attachment group or polymer as described herein.
[0334] In some embodiments, the compound of formula (III) is a compound of formula (III-f):
[0335]
[0336] or a pharmaceutically acceptable salt thereof, wherein M is optionally replaced by one or more R 3 substituted alkyl; ring P is optionally substituted with one or more R 4 Substituted heteroaryl; L 3 is optionally replaced by one or more R 2 substituted alkyl or heteroalkyl; Z is alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted by one or more R 5 Replacement; R 2a and R 2b Each of R is independently hydrogen, alkyl or heteroalkyl, or R 2a and R 2b together to form an oxo group; each R 2 , R 3 , R 4 and R 5 are independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1 ; Each R A1 and R B1 are independently hydrogen, alkyl or heteroalkyl; n is independently 1, 2, 3, 4, 5 or 6; and Refers to linkage to an attachment group or polymer as described herein.
[0337] In some embodiments, the compound of formula (III) is a compound of formula (IV):
[0338]
[0339] or a pharmaceutically acceptable salt thereof, wherein M is a bond, an alkyl group or an aryl group, wherein the alkyl group and the aryl group are optionally replaced by one or more R 3 Replacement; L 3 is optionally replaced by one or more R 2 substituted alkyl or heteroalkyl; Z is hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or -OR, wherein alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted by one or more R 5 Replacement; R A is hydrogen; R 2a and R 2b Each of R is independently hydrogen, alkyl or heteroalkyl, or R 2a and R 2b together to form an oxo group; each R 2 , R 3 and R 5 are independently alkyl, heteroalkyl, halogen, oxo, -OR A1 or -C(O)R B1 ; Each R A1 and R B1 are independently hydrogen, alkyl or heteroalkyl; n is independently 1, 2, 3, 4, 5 or 6; and Refers to linkage to an attachment group or polymer as described herein.
[0340] In some embodiments, the compound of formula (IV) is a compound of formula (IV-a):
[0341]
[0342] or a pharmaceutically acceptable salt thereof, wherein L 3 is alkyl or heteroalkyl, each of which is optionally substituted by one or more R 2 substituted; Z is hydrogen, alkyl, heteroalkyl or -OR A , heteroalkyl is optionally replaced by one or more R 5 Replacement; R 2a and R 2b Each of R is independently hydrogen, alkyl or heteroalkyl, or R 2a and R 2b Each of the R 2 , R 3 and R 5 are independently heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 ; R A is hydrogen; each R A1 and R B1 is independently hydrogen, alkyl or heteroalkyl; n is independently 1, 2, 3, 4, 5 or 6; and Refers to linkage to an attachment group or polymer as described herein.
[0343] In some embodiments, the compound of formula (III) is a compound of formula (V):
[0344]
[0345] or a pharmaceutically acceptable salt thereof, wherein Z 1 is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted by 1-5 R 5 Replacement; R 2a , R 2b , R 2c and R 2d Each of R is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halo, cyano, nitro, amino, cycloalkyl, heterocyclyl, aryl or heteroaryl; or R 2a and R 2b or R 2c and R 2d Each of the R C is hydrogen, alkyl, alkenyl, alkynyl or heteroalkyl, wherein each of the alkyl, alkenyl, alkynyl or heteroalkyl is optionally substituted with 1-6 R 6 Replacement; R 3 , R 5 and R 6 Each of the above is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1 ; Each R 12 are independently deuterium, alkyl, heteroalkyl, haloalkyl, halogen, cyano, nitro or amino; each R A1 and R B1 are each independently hydrogen, alkyl or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5 or 6; q is an integer from 0 to 25; w is 0 or 1; and Refers to linkage to an attachment group or polymer as described herein.
[0346] In some embodiments, the compound of formula (V) is a compound of formula (Va):
[0347]
[0348] or a pharmaceutically acceptable salt thereof, wherein ring Z 1 is cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted by 1-5 R 5 Replacement; R 2a , R2b , R 2c and R 2d Each of which is independently hydrogen, alkyl, heteroalkyl, halo; or R 2a and R 2b or R 2c and R 2d Together they form an oxo group; R C is hydrogen, alkyl, alkenyl, alkynyl or heteroalkyl, wherein each of the alkyl, alkenyl, alkynyl or heteroalkyl is optionally substituted with 1-6 R 6 Replacement; R 3 , R 5 and R 6 Each of the above is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1 ; Each R 12 are independently deuterium, alkyl, heteroalkyl, haloalkyl, halogen, cyano, nitro or amino; each R A1 and R B1 are each independently hydrogen, alkyl or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5 or 6; o and p are each independently 0, 1, 2, 3, 4 or 5; q is an integer from 0 to 25; w is 0 or 1; and Refers to linkage to an attachment group or polymer as described herein.
[0349] In some embodiments, the compound of formula (V) is a compound of formula (Vb):
[0350]
[0351] or a pharmaceutically acceptable salt thereof, wherein ring Z 1 is cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted by 1-5 R 5 Replacement; R C is hydrogen, alkyl, -N(R C )C(O)R B 、-N(R C )C(O)(C1-C6-alkyl) or -N(R C )C(O)(C1-C6-alkenyl), wherein each of the alkyl and alkenyl groups is optionally substituted with 1-6 R 6 Replacement; R 2a , R 2b , R 2c and R 2d Each of R is independently hydrogen or alkyl; or 2a and R 2b or R 2c and R2d Together they form an oxo group; R 3 , R 5 and R 6 Each of the above is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1 ; R 12 is hydrogen, deuterium, alkyl, heteroalkyl, haloalkyl, halogen, cyano, nitro or amino; each R A1 , R B1 and R E1 are each independently hydrogen, alkyl or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5 or 6; q is an integer from 0 to 25; x is 0, 1 or 2; and Refers to linkage to an attachment group or polymer as described herein.
[0352] In some embodiments, the compound of formula (V) is a compound of formula (Vc):
[0353]
[0354] or a pharmaceutically acceptable salt thereof, wherein R C is hydrogen, alkyl, -N(R C )C(O)R B 、-N(R C )C(O)(C1-C6-alkyl) or -N(R C )C(O)(C1-C6-alkenyl), wherein each of the alkyl and alkenyl groups is optionally substituted with 1-6 R 6 Replacement; R 2a , R 2b , R 2c and R 2d Each of R is independently hydrogen or alkyl; or 2a and R 2b or R 2c and R 2d Together they form an oxo group; R 3 , R 5 and R 6 Each of the above is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1 ; R 12 is hydrogen, deuterium, alkyl, heteroalkyl, haloalkyl, halo, cyano, nitro, or amino; each R A1 , R B1 and R E1are each independently hydrogen, alkyl or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5 or 6; q is an integer from 0 to 25; x is 0, 1 or 2; z is 0, 1, 2, 3, 4, 5 or 6, and Refers to linkage to an attachment group or polymer as described herein.
[0355] In some embodiments, the compound of formula (V) is a compound of formula (Vd):
[0356]
[0357] or a pharmaceutically acceptable salt thereof, wherein X is C(R')(R"), N(R') or S(O) x ; R' and R" are each independently hydrogen, alkyl or halogen; R C is hydrogen, alkyl, -N(R C )C(O)R B 、-N(R C )C(O)(C1-C6-alkyl) or -N(R C )C(O)(C1-C6-alkenyl), wherein each of the alkyl and alkenyl groups is optionally substituted with 1-6 R 6 Replacement; R 2a , R 2b , R 2c and R 2d Each of R is independently hydrogen or alkyl; or 2a and R 2b or R 2c and R 2d Together they form an oxo group; R 3 , R 5 and R 6 Each of the above is independently alkyl, heteroalkyl, halogen, oxo, -OR A1 、-C(O)OR A1 or -C(O)R B1 ; R 12 is hydrogen, deuterium, alkyl, heteroalkyl, haloalkyl, halo, cyano, nitro, or amino; each R A1 , R B1 and R E1 are each independently hydrogen, alkyl or heteroalkyl; m and n are each independently 1, 2, 3, 4, 5 or 6; q is an integer from 0 to 25; x is 0, 1 or 2; z is 0, 1, 2, 3, 4, 5 or 6, and Refers to linkage to an attachment group or polymer as described herein.
[0358] In some embodiments, X is S(O) xIn some embodiments, x is 2. In some embodiments, X is S(O)2.
[0359] In some embodiments, R 2a , R 2b , R 2c and R 2d Each of is independently hydrogen.
[0360] In some embodiments, R C is hydrogen, -C(O)(C1-C6-alkyl) or -C(O)(C1-C6-alkenyl). In some embodiments, each of the alkyl and alkenyl groups is replaced by 1 R 6 (e.g., -CH3) substitution. In some embodiments, R C It's hydrogen.
[0361] In some embodiments, n is 1. In some embodiments, q is 2, 3, 4, or 5. In some embodiments, q is 3. In some embodiments, m is 1. In some embodiments, p is 0. In some embodiments, R 12 is a halogen group (eg, Cl).
[0362] In some embodiments, the compound is a compound of formula (III). In some embodiments, L 2 is a key and P and L 3 Does not exist independently.
[0363] In some embodiments, the compound is a compound of formula (III-a). In some embodiments of formula (IV-a), L 2 is a bond, P is a heteroaryl, L 3 is a bond, and Z is hydrogen. In some embodiments, P is heteroaryl, L 3 is heteroalkyl, and Z is alkyl. 2 is a key and P and L 3 In some embodiments, L 2 is a bond, P is a heteroaryl, L 3 is a bond, and Z is hydrogen. In some embodiments, P is heteroaryl, L 3 is heteroalkyl, and Z is alkyl.
[0364] In some embodiments, the compound is of formula (III-b). In some embodiments, P is absent, L 1 Yes -NHCH2, L 2 is a bond, M is an aryl group (e.g., phenyl), L 3is -CH2O, and Z is a heterocyclic group (eg, a nitrogen-containing heterocyclic group, such as thiomorpholinyl-1,1-dioxide). In some embodiments, the compound of formula (Ib) is Compound 116.
[0365] In some embodiments of Formula (III-b), P is absent, L 1 Yes -NHCH2, L 2 is a key, M does not exist, L 3 is a bond, and Z is a heterocyclyl (eg, an oxygen-containing heterocyclyl, such as tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, or oxiranyl). In some embodiments, the compound of formula (III-b) is Compound 105.
[0366] In some embodiments, the compound is a compound of formula (III-bi). In some embodiments of formula (III-bi), R 2a and R 2b Each of R is independently hydrogen or CH3, 2c and R 2d Each of the above is independently hydrogen, m is 1 or 2, n is 1, X is O, p is 0, M 2 is optionally replaced by one or more R 3 Substituted phenyl, R 3 is -CF3, and Z 2 is a heterocyclic group (eg, an oxygen-containing heterocyclic group, such as tetrahydropyranyl, tetrahydrofuranyl, oxetanyl or oxirane). In some embodiments, the compound of formula (III-bi) is Compound 100, Compound 106, Compound 107, Compound 108, Compound 109 or Compound 111.
[0367] In some embodiments, the compound is a compound of formula (III-b-ii). In some embodiments of formula (III-b-ii), R 2a , R 2b , R 2c and R 2d Each of is independently hydrogen, q is 0, p is 0, m is 1, and Z 2 In some embodiments, the compound of formula (III-b-ii) is compound 100.
[0368] In some embodiments, the compound is a compound of formula (III-c). In some embodiments of formula (III-c), R 2c and R 2d Each of the above is independently hydrogen, m is 1, p is 1, q is 0, R 5is -CH3, and Z is a heterocyclic group (eg, a nitrogen-containing heterocyclic group, such as piperazinyl). In some embodiments, the compound of formula (Ic) is compound 113.
[0369] In some embodiments, the compound is a compound of formula (III-d). In some embodiments of formula (III-d), R 2a , R 2b , R 2c and R 2d Each of the above is independently hydrogen, m is 1, n is 3, X is O, p is 0, and Z is a heterocyclic group (e.g., an oxygen-containing heterocyclic group, such as tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, or oxirane). In some embodiments, the compound of formula (III-d) is Compound 110 or Compound 114.
[0370] In some embodiments, the compound is a compound of formula (III-f). In some embodiments of formula (III-f), R 2a and R 2b Each of the above is independently hydrogen, n is 1, M is -CH2-, P is a nitrogen-containing heteroaryl group (eg, imidazolyl), L 3 is -C(O)OCH2-, and Z is CH3. In some embodiments, the compound of formula (III-f) is Compound 115.
[0371] In some embodiments, the compound is a compound of formula (IV-a). In some embodiments of formula (IV-a), R 2a and R 2b Each of the above is independently hydrogen, n is 1, q is 0, L 3 is -CH2(OCH2CH2)2, and Z is -OCH3. In some embodiments, the compound of formula (IV-a) is Compound 112.
[0372] In some embodiments of Formula (IV-a), R 2a and R 2b Each of the above is independently hydrogen, n is 1, L 3 is a bond or -CH2, and Z is hydrogen or -OH. In some embodiments, the compound of formula (IV-a) is Compound 103 or Compound 104.
[0373] In some embodiments, the compound is of formula (V). In some embodiments of formula (V), R 2a , R 2b , R 2c and R 2d Each of the above is independently hydrogen, m is 1, n is 2, q is 3, p is 0, R C is hydrogen, and Z1 is optionally replaced by R 5 Substituted heteroalkyl (e.g., -N(CH3)(CH2CH2)S(O)2CH3). In some embodiments, the compound of Formula (V) is Compound 120.
[0374] In some embodiments, the compound is of formula (Vb). In some embodiments of formula (Vb), R 2a , R 2b , R 2c and R 2d Each of the above is independently hydrogen, m is 0, n is 2, q is 3, p is 0, and Z 2 It is 1 R 5 (eg, -NH2) substituted aryl (eg, phenyl). In some embodiments, the compound of formula (III-b) is compound 102.
[0375] In some embodiments, the compound is of formula (Vb). In some embodiments of formula (Vb), R 2a , R 2b , R 2c and R 2d Each of the above is independently hydrogen, m is 1, n is 2, q is 3, p is 0, R C is hydrogen, and Z 2 is a heterocyclyl (eg, a nitrogen-containing heterocyclyl, such as a nitrogen-containing spiro heterocyclyl, such as 2-oxa-7-azaspiro[3.5]nonyl). In some embodiments, the compound of formula (Vb) is Compound 121.
[0376] In some embodiments, the compound is of formula (Vd). In some embodiments of formula (Vd), R 2a , R 2b , R 2c and R 2d Each of is independently hydrogen, m is 1, n is 2, q is 1, 2, 3 or 4, p is 0, and X is S(O)2. In some embodiments of Formula (Vd), R 2a and R 2b Each of the above is independently hydrogen, m is 1, n is 2, q is 1, 2, 3 or 4, p is 0, and X is S(O)2. In some embodiments, the compound of formula (Vd) is Compound 101, Compound 117, Compound 118 or Compound 119.
[0377] In some embodiments, the compound is a compound of formula (III-b), (III-d) or (III-e). In some embodiments, the compound is a compound of formula (III-b), (III-d) or (IV). In some embodiments, the compound is a compound of formula (III-b), (III-d) or (III-f). In some embodiments, the compound is a compound of formula (III-b), (III-d) or (V).
[0378] In some embodiments, the compound of formula (I) is not a compound disclosed in WO2012 / 112982, WO2012 / 167223, WO2014 / 153126, WO2016 / 019391, WO 2017 / 075630, US 2012-0213708, US 2016-0030359, or US 2016-0030360.
[0379] In some embodiments, the compound of formula (III) comprises a compound shown in Table 6 herein below, or a pharmaceutically acceptable salt thereof. In some embodiments, the external surface and / or one or more compartments within the device described herein comprise a small molecule compound shown in Table 6, or a pharmaceutically acceptable salt thereof.
[0380] Table 6: Exemplary Defiberizing (FBR Reducing) Compounds
[0381]
[0382]
[0383]
[0384]
[0385]
[0386]
[0387]
[0388] Conjugation of any of the compounds in Table 6 to a polymer (e.g., alginate) can be performed as described in Example 2 of WO 2019 / 195055 or in any other suitable chemical reaction.
[0389] In some embodiments, the compound is a compound of formula (III) or a pharmaceutically acceptable salt thereof and is selected from:
[0390]
[0391] or a pharmaceutically acceptable salt thereof.
[0392] In some embodiments, the devices described herein comprise a compound
[0393] or a pharmaceutically acceptable salt of either compound.
[0394] In some embodiments, the compound of formula (III) (e.g., compound 101 in Table 6) is covalently attached to alginate (e.g., alginate having an approximate MW <75 kDa, a G:M ratio ≥1.5) with a conjugation density of at least 2.0% and less than 9.0%, or 3.0% to 8.0%, 4.0-7.0, 5.0 to 7.0, or 6.0 to 7.0, or about 6.8, as determined by combustion analysis of nitrogen percentage as described in WO 2020 / 069429. In one embodiment, the conjugation density of compound 101 in the modified alginate is determined by quantitative free amine analysis, for example as described in WO2020198695, wherein the determined conjugation density is 1.0% w / w to 3.0% w / w, 1.3% w / w to 2.8% w / w, 1.3% w / w to 2.6% w / w, 1.5% w / w to 2.4% w / w, 1.5% w / w to 2.2% w / w, or 1.7% w / w to 2.2% w / w.
[0395] The device, device preparation, or device composition may be configured for implantation, or implanted or disposed in or on any part or portion of the body. In some embodiments, the implantable device or device preparation is configured for implantation in the peritoneal cavity (e.g., the omentum, also known as the omental bursa or bursalis omentum). The device, device preparation, or device composition may be implanted in the peritoneal cavity (e.g., the omentum, such as the omentum) or disposed on a surface within the peritoneal cavity (e.g., the omentum, such as the omentum) via injection or catheter. Additional considerations for implanting or disposing a device, device preparation, or device composition in the omentum (e.g., the omentum) are provided in M. Pellicciaro et al. (2017) Cell R45(3):e2410.
[0396] Equipment Manufacturing
[0397] Genetically modified ARPE-19 cells for use in making the devices described herein can be produced and cultured using methods known in the art. For example, stably transfected ARPE-19 cells can be cultured in vitro essentially as described in WO2020198695.
[0398] Compounds of formula (III) and alginates modified with such compounds may be obtained using procedures known in the art, for example substantially as described in WO2020198695.
[0399] The alginate solution used to prepare the defibrotized two-compartment hydrogel capsules can be obtained using procedures known in the art, for example essentially as described in WO2020198695.
[0400] Two-compartment hydrogel capsules encapsulating genetically modified mammalian cells in an inner compartment and defibrotized alginate in an outer layer (“shielded capsule”) can be produced using procedures known in the art, for example essentially as described in WO2020198696.
[0401] Treatment
[0402] Described herein is a method for preventing or treating a subject's CNS disease or illness (e.g., lysosomal storage disease, such as MPS-1) by administering or implanting a pharmaceutical composition as described herein or a genetically modified cell. In one embodiment, the pharmaceutical composition comprises a BBB transport fusion protein and is formulated for intravenous or subcutaneous administration. In another embodiment, the pharmaceutical composition comprises a plurality of cells genetically modified to express BBB transport fusion proteins. In one embodiment, the cell is encapsulated in a hydrogel capsule as described herein. In another embodiment, the cell is encapsulated in a macro device as described herein. In some embodiments, the method described herein directly or indirectly reduces or alleviates at least one symptom of a CNS disease or illness, or prevents or slows down the onset of a disease. In one embodiment, the method includes administering (e.g., implanting) an effective amount of a two-compartment alginate hydrogel capsule composition, the capsule comprising genetically modified RPE cells and cell binding polymers as described herein in an inner compartment, and on the outer capsule surface and optionally in the outer compartment comprising a compound of formula (III), such as compound 101.
[0403] Treatment of MPS-1
[0404] The present disclosure provides a method for treating a patient with MPS-1 by administering a BBB transport IDUA fusion protein as described herein to a human patient. In one embodiment, the administering step includes implanting cells engineered to express and secrete BBB transport IDUA fusion proteins, which can be encapsulated in a macro device or in a two-compartment alginate hydrogel capsule as described herein. In one embodiment, encapsulated cells expressing BBB transport IDUA fusion proteins are implanted into the peritoneal cavity (e.g., a small sac, also referred to as an omental sac or a bursa omentum of Fabricius). In one embodiment, the BBB transport IDUA fusion protein expressed and secreted by the implanted cells comprises SEQ ID NO: 28 or SEQ ID NO: 29.
[0405] The therapeutic efficacy of treatment with BBB transport IDUA fusion protein can be evaluated using one or more efficacy measurements that have been used for approved and experimental MPS1 therapies. Such efficacy measurements typically include: reduced levels of urinary glycosaminoglycans (e.g., heparan sulfate); reduced liver volume; stable forced vital capacity; increased 6-minute walk distance; improved apnea / hypopnea index; increased shoulder flexion; improved Children's Health Assessment Questionnaire / Health Assessment Questionnaire Disability Index. In one embodiment, efficacy measurements are taken at the desired time point after implantation of cells expressing GGG transport IDUA fusion proteins and compared with baseline levels before implantation. In one embodiment, the desired time point is any one or more of 15 days, 30 days, 60 days, 120 days, one year, or longer.
[0406] In one embodiment, treating a subject with a BBB transport IDUA fusion protein as described herein results in a reduction in the heparan sulfate level in the subject's brain and optionally in one or more non-CNS organs and tissues (e.g., liver, spleen, kidney, heart, and lungs). In one embodiment, the heparan sulfate level is reduced by at least 10%, 25%, 50% or more at a desired time point.
[0407] Exemplary embodiments listed
[0408] 1. A fusion protein comprising an N-terminal to C-terminal structure defined by Formula I: AB-L1-RB-L2-C or by Formula II: RB-L1-AB-L2-C, wherein in each of Formula I and Formula II:
[0409] AB contains a domain that binds to human serum albumin (HSA);
[0410] L1 may be present or absent and comprises a first linker amino acid sequence;
[0411] RB contains a domain that binds to the extracellular domain of human IGF1R (hIGF1R);
[0412] L2 may be present or absent, and comprises a second linker amino acid sequence that is identical to or different from the first linker amino acid sequence; and
[0413] C is the cargo part.
[0414] 2. The fusion protein as described in embodiment 1, which is defined by formula I: AB-L1-RB-L2-C.
[0415] 3. The fusion protein as described in embodiment 1 is defined by formula II: RB-L1-AB-L2-C.
[0416] 4. The fusion protein of any one of the above embodiments, wherein AB has a molecular weight of less than about any one of 75 kDa, 50 kDa or 25 kDa.
[0417] 5. The fusion protein of any one of the above embodiments, wherein RB has a molecular weight of less than about any one of 75 kDa, 50 kDa or 25 kDa.
[0418] 6. The fusion protein of any one of the above embodiments, wherein the cargo portion has a molecular weight of about 1 kD to about 200 kD, or about 2 kD to about 100 kD.
[0419] 7. The fusion protein of any one of the above embodiments, wherein the cargo portion consists essentially of or consists of the amino acid sequence of a polypeptide.
[0420] 8. The fusion protein of any one of the above embodiments, wherein (i) AB comprises a first amino acid sequence, a second amino acid sequence, and a third amino acid sequence corresponding to three complementarity determining regions CDR1, CDR2, and CDR3 of a heavy chain variable region of an anti-HSA antibody, or (ii) AB comprises the CDR1, CDR2, and CDR3 sequences of R11 sdAb, R28 sdAb, M75 sdAb, or M79 sdAb shown in Table 2A.
[0421] 9. A fusion protein as described in any of the above embodiments, wherein AB comprises, consists essentially of or consists of an amino acid sequence from a single domain antibody (sdAb), optionally wherein the amino acid sequence is selected from the group consisting of the R11, R28, M75 and M79 amino acid sequences disclosed in Table 2B above, the Alb-1 and Alb-8 amino acid sequences described in Table II and Table III of WO 2006 / 22787, and the Alb-23 amino acid sequence described in WO 2012 / 175400.
[0422] 10. The fusion protein of claim 7, wherein the AB CDR1 sequence is GRTFIAYA (SEQ ID NO: 1) or a conservatively substituted variant thereof; the AB CDR2 sequence is ITNFAGGTT (SEQ ID NO: 2) or a conservatively substituted variant thereof; and the AB CDR3 sequence is AADRSAQTMRQVRPVLPY (SEQ ID NO: 3) or a conservatively substituted variant thereof.
[0423] 11. The fusion protein of any one of the above embodiments, wherein AB comprises, consists essentially of, or consists of an amino acid sequence from sdAb.
[0424] 12. The fusion protein of any one of the above embodiments, wherein AB consists essentially of or consists of the parent or humanized sequence shown in Table 2B above.
[0425] 13. The fusion protein of any one of embodiments 1 to 12, wherein AB consists essentially of or consists of:
[0426] QVQLVESGGGLVQAGGSLRLSCVASGRTFIAYAMGWFRQAPGKEREFVAAITNFAGGTTYYADSVKGRFTISRDNAKTTVYLQMNSLKPEDTALYYCAADRSAQTMRQVRPVLPYWGQGTQVTVSS (SEQ ID NO: 4) or a conservatively substituted variant thereof.
[0427] 14. The fusion protein of any one of embodiments 1 to 12, wherein AB consists essentially of or consists of:
[0428] QVQLVESGGGLVQPGGSLRLSCAASGRTFIAYAMGWFRQAPGKEREFVAAITNFAGGTTYYADSVKGRFTISRDNAKTTVYLQMNSLRAEDTAVYYCAADRSAQTMRQVRPVLPYWGQGTLVTVSS (SEQ ID NO: 5), or a conservatively substituted variant thereof.
[0429] 15. The fusion protein of any one of embodiments 1 to 10, wherein AB consists essentially of or consists of the amino acid sequence of the heavy chain variable region of an antibody that cross-competes with the sdAb consisting of SEQ ID NO: 4 or SEQ ID NO: 5 for binding to HSA.
[0430] 16. The fusion protein of any one of the above embodiments, wherein the fusion protein binds to domain 1 (DI) or domain 2 (DII) of HSA via AB and does not substantially inhibit the binding of human FcRn to HSA.
[0431] 17. A fusion protein as described in any of the above embodiments, wherein the fusion protein dissociates via the AB domain with a dissociation constant (K) of less than about 0.1 nM to about 1,000 nM in the pH range of about 5.0 to about 7.4 as determined by surface plasmon resonance at 25°C. D ) binds to HSA with high affinity.
[0432] 18. The fusion protein of embodiment 17, wherein the fusion protein is expressed via the AB domain at a pH range of about 5.5 to about 7.4 with a K of about 0.5 nM to about 500 nM, about 1 nM to about 250 nM, about 5 nM to about 50 nM, about 10 nM to about 25 nM, or about 0.5 nM to about 1 nM. D Binds to HSA.
[0433] 19. The fusion protein of any one of the above embodiments, wherein the fusion protein binds to at least one mammalian serum albumin ortholog via AB at a pH range of about 5.5 to about 7.4 at 25°C.
[0434] 20. A fusion protein as described in any of the above embodiments, wherein the fusion protein is bound via AB to two or more mammalian serum albumins selected from the group consisting of mouse serum albumin, rat serum albumin, hamster serum albumin, rabbit serum albumin, guinea pig albumin, porcine albumin, cat albumin, dog albumin and non-human primate serum albumin, optionally wherein the non-human primate serum albumin is cynomolgus monkey serum albumin or rhesus monkey serum albumin.
[0435] 21. The fusion protein of any one of the above embodiments, wherein the fusion protein binds to hIGF1R expressed on the surface of human brain endothelial cells via the RB domain.
[0436] 22. The fusion protein of any one of the above embodiments, wherein the fusion protein does not substantially bind to human insulin receptor (h-IR).
[0437] 23. The fusion protein of any one of the above embodiments, wherein the fusion protein does not substantially inhibit the binding of insulin, insulin growth factor 1 (IGF1) or insulin growth factor 2 (IGF2) to hIGF1R.
[0438] 24. The fusion protein of any one of the above embodiments, wherein the fusion protein binds to an epitope in the extracellular domain of hIGF1R comprising FENFLHNSIFVPR (SEQ ID NO: 6) via RB.
[0439] 25. The fusion protein of any one of the above embodiments, wherein the fusion protein has a K of about 0.1 nM to about 1,000 nM via RB in the pH range of about 5.0 to about 7.4 as determined by surface plasmon resonance at 25°C. D Binds with affinity to hIGF1R.
[0440] 26. A fusion protein as described in embodiment 24, wherein the fusion protein is synthesized via RB with a K of (i) about 0.2 nM to about 500 nM, 250 nM, 100 nM, 50 nM, 25 nM, or 10 nM; (ii) about 0.5 nM to about 250 nM, 100 nM, 50 nM, 25 nM, 10 nM, or 5 nM; or (iii) about 1 nM to about 100 nM, 50 nM, 25 nM, 10 nM, or 5 nM. D Binds to hIGF1R.
[0441] 27. The fusion protein of embodiment 25, wherein the fusion protein is synthesized via RB with a K of 1 nM to 10 nM. D Binds to hIGF1R.
[0442] 28. The fusion protein of any one of the above embodiments, wherein the fusion protein binds to at least one mammalian IGF1R ortholog via RB at 25°C and in the pH range of about 5.0 to about 7.4.
[0443] 29. A fusion protein as described in any of the above embodiments, wherein the fusion protein is bound via RB to two or more mammalian IGF1R proteins selected from the group consisting of mouse IGF1R, rat IGF1R, hamster IGF1R, rabbit IGF1R, guinea pig IGF1R, dog IGF1R, cat IGF1R and non-human primate IGF1R, optionally wherein the non-human primate IGF1R is cynomolgus monkey IGF1R or rhesus monkey IGF1R.
[0444] 30. A fusion protein as described in any of the above embodiments, wherein (i) RB comprises a first amino acid sequence, a second amino acid sequence, and a set of third amino acid sequences corresponding to the three complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region of an anti-hIGF1R antibody, or (ii) RB comprises a first amino acid sequence, a second amino acid sequence, and a set of third amino acid sequences selected from the CDR1, CDR2 and CDR3 amino acid sequences of IGF1R-5sdAb, IGF1R-3sdAb and IGF1R-4sdAb shown in Table 3A above.
[0445] 31. A fusion protein as described in embodiment 30, wherein the RB CDR1 sequence is GRTIDNYA (SEQ ID NO: 7) or a conservatively substituted variant thereof; the RB CDR2 sequence is IDWGDGGX, wherein X is A or T (SEQ ID NO: 8), or a conservatively substituted variant thereof; and the B3 CDR3 sequence is AMARQSRVNLDVARYDY (SEQ ID NO: 9) or a conservatively substituted variant thereof.
[0446] 32. The fusion protein of embodiment 31, wherein the RB CDR2 sequence is IDWGDGGA (SEQ ID NO: 10).
[0447] 33. A fusion protein as described in embodiment 30, wherein RB consists essentially of or consists of the parent or humanized sequence shown in Table 3B above.
[0448] 34. A fusion protein as described in embodiment 30, wherein RB consists essentially of or consists of the following: QVKLEESGGGLVQAGGSLRLSCAASGRTIDNYAMAWSR QAPGKDREFVATIDWGDGGARYANSVKGRFTISRDNAKGTMYL QMNNLEPEDTAVYSCAMARQSRVNLDVARYDYWGQGTQVTVS S (SEQ ID NO: 11) or a conservatively substituted variant thereof.
[0449] 35. A fusion protein as described in embodiment 30, wherein RB consists essentially of or consists of the following: QVQLVESGGGLVQPGGSLRLSCAASGRTIDNYAMAWVR QAPGKGLEWVATIDWGDGGTRYANSVKGRFTISRDNSKNTMYL QMNSLRAEDTAVYYCAMARQSRVNLDVARYDYWGQGTLVTVSS S (SEQ ID NO: 12) or a conservatively substituted variant thereof.
[0450] 36. A fusion protein as described in any of embodiments 1 to 30, wherein RB consists essentially of or consists of the amino acid sequence of the heavy chain variable region of an antibody that (i) cross-competes with a sdAb consisting of SEQ ID NO: 11 or SEQ ID NO: 12 for binding to hIGF1R, or (ii) cross-competes with any of the 996, 1226 and 1564 antibodies described in EP3725806A1.
[0451] 37. The fusion protein of any one of the above embodiments, wherein L1 and L2 are present.
[0452] 38. A fusion protein as described in embodiment 37, wherein each of L1 and L2 is a linker peptide with a length of less than 50 amino acids, optionally wherein the length of each of L1 and L2 is between about 15 and 30 amino acids, or between about 20 and 25 amino acids.
[0453] 39. The fusion protein of embodiment 38, wherein L1 consists essentially of or consists of (GGGGS)m, wherein m is 4 or 5.
[0454] 40. The fusion protein of any one of embodiments 37 to 39, wherein L2 consists essentially of or consists of (GGGGS)n, wherein n is 4 or 5.
[0455] 41. The fusion protein of embodiment 39, wherein each of L1 and L2 consists essentially of or consists of: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 14).
[0456] 42. The fusion protein of any one of the above embodiments, wherein the cargo moiety is a cargo polypeptide selected from the group consisting of an enzyme, a growth factor, a cytokine, or an antibody or an antigen-binding fragment thereof.
[0457] 43. A fusion protein as described in embodiment 42, wherein the cargo polypeptide comprises a mature amino acid sequence encoded by a wild-type human gene.
[0458] 44. The fusion protein of embodiment 42 or 43, wherein the cargo polypeptide is an enzyme.
[0459] 45. A fusion protein as described in any one of embodiments 42 to 44, wherein the cargo polypeptide is an acid α-glucosidase protein (GAA), an α-galactosidase A (GLA) protein, an α-L-iduronidase (IDUA) protein, an α-N-acetyl-glucosaminidase (NAGLU), a β-glucuronidase (GUSB) protein, a β-glucosidase (GBA) protein, an iduronate-2-sulfatase (IDS) protein, heparan-α-aminoglucoside N-acetyltransferase (HGSNAT) protein, N-acetylgalactosamine-6-sulfatase (GNS) protein or an N-sulfoglucosamine sulfohydrolase (SGSH) protein, optionally wherein the cargo polypeptide is not an IDS protein.
[0460] 46. The fusion protein of embodiment 45, wherein the cargo polypeptide is an IDUA protein, optionally wherein the cargo polypeptide comprises, consists essentially of, or consists of a mature amino acid sequence encoded by a wild-type human IDUA gene.
[0461] 47. A fusion protein as described in any one of embodiments 42 to 46, wherein the cargo polypeptide is an IDUA protein and comprises Figure 1H amino acid 26, 27 or 28 to amino acid 653 of the precursor human IDUA amino acid sequence shown in .
[0462] 48. A fusion protein as described in any one of embodiments 42 to 47, wherein the cargo polypeptide is an IDUA protein and consists essentially of Figure 1H The amino acid sequence shown in is composed of amino acids 27-653.
[0463] 49. The fusion protein of any one of embodiments 46 to 48, having an IDUA enzyme activity within 80%-120% of the corresponding enzyme activity of the wild-type human IDUA protein.
[0464] 50. A fusion protein as described in any one of embodiments 42 to 45, wherein the cargo polypeptide is an IDS protein, optionally wherein the cargo polypeptide comprises Fig. 12A or Fig. 12B The amino acid sequence shown in , consists essentially of or consists of the amino acid sequence.
[0465] 51. The fusion protein of embodiment 50, which has an IDS enzyme activity within 80%-120% of the corresponding enzyme activity of the wild-type human IDS protein.
[0466] 52. The fusion protein as described in embodiment 1, comprising Figure 3A , Figure 3B , Figure 3C , Figure 3D , Figure 3E or Figure 3F The amino acid sequence of the hIDUA fusion protein shown in , consisting essentially of or consisting of said amino acid sequence, optionally wherein the fusion protein consists essentially of or consists of the amino acid sequence shown in SEQ ID NO:29, wherein each of m and n=4.
[0467] 53. A fusion protein as described in embodiment 1, comprising Formula I: AB-L1-RB-L2-C, wherein AB comprises, consists essentially of, or consists of SEQ ID NO:4 or SEQ ID NO:5, L1 comprises, consists essentially of, or consists of (GGGGS)n, wherein n is 4 or 5, RB comprises SEQ ID NO:11 or SEQ ID NO:12, L1 comprises, consists essentially of, or consists of (GGGGS)n, wherein n is 4 or 5, C comprises, consists essentially of, or consists of amino acids 27-653 of SEQ ID NO:22, and L2 comprises, consists essentially of, or consists of (GGGGS)n, wherein n is 4 or 5.
[0468] 54. A fusion protein as described in embodiment 1, comprising formula II: RB-L1-AB-L2-C, wherein AB comprises, consists essentially of, or consists of SEQ ID NO:4 or SEQ ID NO:5, L1 comprises, consists essentially of, or consists of (GGGGS)n, wherein n is 4 or 5, RB comprises SEQ ID NO:11 or SEQ ID NO:12, L1 comprises, consists essentially of, or consists of (GGGGS)n, wherein n is 4 or 5, comprises amino acids 27-653 of SEQ ID NO:22, consists essentially of, or consists of amino acids 27-653 of SEQ ID NO:22, and L2 comprises, consists essentially of, or consists of (GGGGS)n, wherein n is 4 or 5.
[0469] 55. The fusion protein of embodiment 53 or 54, wherein AB consists essentially of SEQ ID NO:5 and RB consists essentially of SEQ ID NO:12.
[0470] 56. A polynucleotide comprising a first nucleotide sequence encoding the fusion protein of any one of the above embodiments.
[0471] 57. The polynucleotide of embodiment 56, wherein the first nucleotide sequence is operably linked to a nucleotide sequence encoding a secretion signal sequence of the fusion protein, optionally wherein the secretion signal sequence consists essentially of or consists of (i) MELGLSWVVLAAL LQGVQA (SEQ ID NO: 79) or (ii) one of the amino acid sequences shown in Table 5.
[0472] 58. The polynucleotide of embodiment 57, wherein the secretion signal sequence consists essentially of or consists of MELGLSWVVLAALLQGVQA (SEQ ID NO: 79).
[0473] 59. The polynucleotide of any one of embodiments 56 to 58, wherein the first nucleotide sequence is operably linked to a promoter sequence and a polyA signal sequence.
[0474] 60. The polynucleotide of embodiment 59, wherein the promoter sequence is Figure 4A The pCAG promoter sequence shown in Figure 4B The EF1α promoter sequence shown in Figure 4C The EFS promoter sequence shown in .
[0475] 61. The polynucleotide of embodiment 60, wherein the promoter sequence is Figure 4B The EF1α promoter sequence shown in .
[0476] 62. The polynucleotide of any one of embodiments 59 to 61, wherein the polyA signal sequence is Figure 5A The rBG poly A signal sequence shown in Figure 5B The SV40 late poly A signal sequence shown in Figure 5C The BGH poly A signal sequence shown in .
[0477] 63. The polynucleotide of embodiment 62, wherein the polyA signal sequence is Figure 5A The rBGpoly A signal sequence is shown in .
[0478] 64. The polynucleotide of embodiment 56, comprising Figure 7 The nucleotide sequence shown in .
[0479] 65. The polynucleotide of any one of embodiments 56 to 64, which is one strand of an isolated double-stranded DNA molecule.
[0480] 66. A genetically modified mammalian cell transiently or stably transfected with the polynucleotide of any one of embodiments 56 to 65.
[0481] 67. A genetically modified mammalian cell as described in embodiment 66, wherein the polynucleotide is inserted into at least one location in the genome of the mammalian cell.
[0482] 68. The genetically modified mammalian cell of embodiment 66 or 67, wherein the cell is derived from a human cell.
[0483] 69. The genetically modified mammalian cell of embodiment 68, which is derived from a RPE cell, optionally an ARPE-19 cell.
[0484] 70. The genetically modified mammalian cell of embodiment 68, which is derived from an induced pluripotent stem cell (iPSC) or a mesenchymal stem cell.
[0485] 71. A composition comprising a plurality of genetically modified cells, wherein each cell of the plurality of genetically modified cells is a genetically modified cell as defined by any one of embodiments 68 to 70.
[0486] 72. The composition of embodiment 71, wherein the plurality of genetically modified cells are obtained from a culture of a monoclonal cell line.
[0487] 73. An implantable device comprising at least one cell-containing compartment comprising the genetically modified cells of any one of embodiments 66 to 70 or the composition of embodiment 71 or 72; and further comprising at least one device for reducing a foreign body reaction (FBR) when the device is implanted in a subject.
[0488] 74. An implantable device as described in embodiment 74=3, wherein the cell-containing compartment comprises a polymer composition, wherein the polymer composition comprises alginate covalently modified with a peptide, wherein the peptide essentially consists of or consists of GRGDSP (SEQ ID NO:89), GGRGDSP (SEQ ID NO:90) or GGGRGDSP (SEQ ID NO:91).
[0489] 75. An implantable device as described in embodiment 73 or 74, wherein the cell-containing compartment is surrounded by a barrier compartment, which comprises an alginate hydrogel and optionally a compound of formula (III) disposed on the outer surface of the barrier compartment.
[0490] 76. An implantable device as described in embodiment 74 or 75, wherein the polymer composition comprises alginate covalently modified with a peptide, wherein the peptide consists essentially of or consists of GRGDSP, and wherein the barrier compartment comprises
[0491] Or a chemically modified alginate or a pharmaceutically acceptable salt thereof.
[0492] 77. The implantable device of any one of embodiments 73 to 76, which is a spherical two-compartment hydrogel capsule having a diameter of about 0.75 mm to about 2 mm.
[0493] 78. A preparation of devices, wherein each device in the preparation is a device as described in any one of embodiments 73 to 77.
[0494] 79. A hydrogel capsule comprising:
[0495] (a) an internal compartment comprising the genetically modified cell of any one of embodiments 66 to 70 encapsulated in a first polymer composition, wherein the first polymer composition comprises a hydrogel-forming polymer; and
[0496] (b) a barrier compartment surrounding the inner compartment and comprising a second polymer composition, wherein the second polymer composition comprises alginate covalently modified with at least one compound of formula (III) or a pharmaceutically acceptable salt thereof.
[0497] 80. The hydrogel capsule of embodiment 79, wherein the compound of formula (III) is selected from the compounds provided in the following table:
[0498]
[0499] 81. The hydrogel capsule of embodiment 75 or 76, wherein the selected compound is
[0500]
[0501] 82. The hydrogel capsule of any one of embodiments 79-81, wherein the concentration of the genetically modified cells in the interior compartment is at least 40 million cells / ml of the first polymer composition.
[0502] 83. A capsule composition comprising the hydrogel capsule of any one of embodiments 79 to 82 in a pharmaceutically acceptable carrier.
[0503] 84. The capsule composition of embodiment 83, wherein the genetically modified cells in the plurality of hydrogel capsules express and secrete the IDUA fusion protein of embodiment 51.
[0504] 85. A pharmaceutical composition comprising the fusion protein of any one of embodiments 1 to 55 and a pharmaceutically acceptable carrier.
[0505] 86. The pharmaceutical composition of embodiment 81, wherein the fusion protein is the IDUA fusion protein of embodiment 48.
[0506] 87. A method of preventing or treating a disease or disorder of the central nervous system (CNS) of a subject, the method comprising:
[0507] (i) administering to the subject the pharmaceutical composition of embodiment 85 or 86;
[0508] (ii) implanting the device or device formulation of any one of embodiments 73 to 78 into the subject; or
[0509] (iii) implanting the capsule composition of embodiment 83 or 84 into the subject.
[0510] 88. A method of treating a human subject diagnosed with a mucopolysaccharidosis type 1 (MPS-1) disease, the method comprising:
[0511] (a) providing the capsule composition of embodiment 86; and
[0512] (b) placing the capsule composition in the body of the subject.
[0513] 89. The method of embodiment 88, wherein the disposing step comprises placing the capsule composition in the intraperitoneal space of the subject.
[0514] 90. The method of embodiment 88, wherein the disposing step comprises placing the capsule composition in a large pouch in the peritoneal cavity.
[0515] 91. The method of any one of embodiments 87 to 90, wherein the capsule composition produces a BBB transport IDUA fusion protein comprising, consisting essentially of, or consisting of SEQ ID NO:28 or SEQ ID NO:29.
[0516] Example
[0517] In order to more fully understand the disclosure described herein, the following examples are described. The embodiments described in this application are provided to illustrate the BBB transport fusion protein, genetically modified cells, implantable devices and compositions and methods provided herein, and should not be interpreted as limiting their scope in any way. The MPS-1 mice used in these embodiments were obtained from Charles River Laboratory (Wilmington, MA) and carried nonsense mutations (Ackson Laboratory stock number 017681) at Idua codon W392.
[0518] Example 1: Effect of fusing an exemplary IGF1R binding domain to hIDUA on hIDUA activity in vitro.
[0519] DNA expression vectors are engineered to encode six different hIDUA fusion enzymes containing BBB-penetrating sdAb (IGF1R4) fused to the N-terminus or C-terminus of the hIDUA open reading frame via a G4S linker unit of variable length repeated 3, 4 or 5 times. ARPE-19 cells are transfected with these expression vectors, and polyclonal colonies of stably expressing hIDUA fusion enzymes are produced for each of the six different transfections. Expression vectors and transfected cells are named based on the orientation of the coding sequence of the composite module relative to each other. For example, hIDUA-(G4S)3-IGF1R4 cell expression fusion enzyme, wherein IGF1R4 is fused to the C-terminus of hIDUA via a G4S linker repeated 3 times.
[0520] The in vitro IDUA activity of the hIDUA fusion protein secreted from six polyclonal colonies was evaluated by seeding cells from each polyclonal colony into a 6-well tissue culture plate at approximately 400,000 cells in 2 ml of fresh medium per well. Twenty to twenty-four hours later, the conditioned cell culture medium was collected and the IDUA protein concentration was determined using an IDUA activity assay and compared with a known standard (laronidase), essentially as described in Ou, L. et al., (2014). Standardization of α-L-iduronidase enzyme assay with Michaelis-Menten kinetics. Molecular Genetics and Metabolism, 111 (2), 113–115. Briefly, in a black 96-well plate, 8 ul of cell culture medium was added to 32 ul of 0.4 M sodium formate (pH 3.5). 20 ul of 700 um 4-methylumbelliferyl-α-L-iduronidone diluted in assay buffer was added to all wells. The plate was incubated at 37°C for 10 minutes. To stop the reaction, 100ul stop solution (0.5M NaOH+0.5M glycine) was added. α-L-Iduronidase catalyzes the cleavage of the non-fluorescent substrate (4MU-iduronide) into a fluorescent product (4-MU). In endpoint mode, fluorescence intensity was measured on a Biotek Cytation 3 at excitation and emission wavelengths of 365nm and 445nm, respectively (top reading). The enzyme activity level was compared to a standard curve generated with laronidase, and the results are shown in Figure 8. The polyclonal culture that produced the highest in vitro IDUA activity was the polyclonal culture expressing the IGF1R4-(G4S)4-hIDUA fusion enzyme.
[0521] ARPE-19 cells were newly transfected with the expression vector for this fusion, from which a polyclonal pool with higher hIDUA activity was identified. Cells from this pool were encapsulated in the inner compartment of a protected capsule at 50 million cells / ml, essentially as described in WO2020198696. A dose of 0.5 ml of capsule was implanted in the IP space of each of five MPS-1 mice. 28 days after administration, the mice were euthanized and the amount of hIDUA activity in liver and plasma tissue samples was assessed. Figure 8BThe measured hIDUA activity levels are shown compared to typical hIDUA levels observed in substantially similar experiments in which capsules encapsulating ARPE-19 cells genetically modified to express and secrete wild-type hIDUA were implanted. This comparison indicates that implanting MPS-1 mice with cells producing the IGF1R4-hIDUA fusion does not result in higher liver and plasma hIDUA activity compared to implanting cells producing wild-type hIDUA.
[0522] Example 2: Effect of fusing exemplary HSA and IGF1R binding domains to hIDUA on hIDUA activity in vitro.
[0523] DNA expression vectors were engineered to encode six different hIDUA fusion enzymes containing open reading frames of a BBB penetrating sdAb (IGF1R5), an anti-HSA sdAb (R28), and hIDUA in different orientations, with a (G4S)4 amino acid linker located between each of these open reading frames. The different orientations evaluated were: (i) 2 fusions in which the sdAbs were both fused to the N-terminus of hIDUA (N-terminal fusions); (ii) 2 fusions in which the sdAbs were flanked by hIDUA (flanking fusions); and (iii) 2 fusions in which the sdAbs were both fused to the C-terminus of hIDUA (C-terminal fusions). ARPE-19 cells were transfected with these expression vectors, and polyclonal colonies stably expressing the hIDUA fusion enzymes were generated for each of the six different transfections. The expression vectors and transfected cells were named based on the orientation of the coding sequences of the composite modules relative to each other. For example, IGF1R5-R28-hIDUA cells express a fusion enzyme in which IGF1R5 is located N-terminally to R28, which itself is located N-terminally to hIDUA.
[0524] The in vitro hIDUA activity of hIDUA fusion proteins secreted from 6 polyclonal colonies was evaluated as described in Example 1 and the results are shown in Fig. 9APolyclonal pools expressing N-terminal dual fusion enzymes (IGF1R5-R28-hIDUA and R28-IGF1R5-hIDUA) showed higher levels of hIDUA activity than cell lines expressing flanking fusions or C-terminal fusions, a result consistent with the hIDUA activity results obtained in Example 1, which showed that hIDUA activity was higher against single N-terminal fusions than against C-terminal fusions. Surprisingly, the orientation of the anti-HSA and anti-IGF1R sdAbs in the N-terminal fusions had a significant effect on hIDUA activity, with fusions containing R28 upstream of IGF1R5 producing approximately 50% higher hIDUA activity than fusions containing IGF1R-5 upstream of R28. The differences in activity between each of the six cell lines were statistically significant.
[0525] To evaluate whether the addition of the HSA binding domain affects the hIDUA activity of the fusion protein, the best performing dual fusion polyclonal pool (R28-(G4S) 4- IGF1R5-(G4S) 4- The in vitro hIDUA activity in the conditioned medium of cells in culture containing IGF1R4-(G4S)4-hIDUA was compared to the in vitro hIDUA activity in the conditioned medium of cells in culture containing IGF1R4-(G4S)4-hIDUA polyclonal pool used in the MPS-1 mouse experiments described in Example 1. Fig. 9B As shown, there was virtually no difference in the amount of hIDU A activity in the single N-terminal and double N-terminal fusion cultures.
[0526] Example 3: Effects of HSA and IGF1R binding domains on hIDUA activity in vivo.
[0527] The secreted R28-(G4S) 4- IGF1R5-(G4S) 4- Cells of a polyclonal pool of hIDUA fusion enzymes were encapsulated in the inner compartment of a protected capsule at 50 million cells / ml, essentially as described in WO2020198696. A dose of 0.5 ml capsule was implanted in the IP space of each of six MPS-1 mice (J). 21 days after administration, mice were euthanized and the amount of hIDUA activity in plasma and various systemic tissues was assessed.
[0528] Fig.10Shown are measured hIDUA activity levels compared to typical hIDUA levels observed in substantially similar experiments in which protected capsules were implanted encapsulating ARPE-19 cells genetically modified to express and secrete wild-type hIDUA. Mice implanted with cells expressing the R28-IGF1R5-hIDUA fusion enzyme had significantly higher hIDUA activity in tissues (except kidney) and plasma compared to mice implanted with cells expressing the wild-type hIDUA enzyme.
[0529] Example 4: Effects of implanting protected capsules producing exemplary BBB transport fusion proteins into MPS-1 mice on brain heparan sulfate levels.
[0530] Encapsulate the secreted R28-(G4S) 4- IGF1R5-(G4S) 4- The protected capsules of cells of the polyclonal pool of hIDUA fusion enzyme are implanted into the IP gap of each of six MPS-1 mice. Six untreated MPS-1 mice of a group were observed as controls. 21 days after administration, two groups of mice were euthanized, and the amount of heparan sulfate in two different brain regions (hippocampus and frontal lobe) was evaluated. In brief, the tissue homogenate of each brain region was obtained, and the tissue homogenate (10ul) was combined with an equal volume of heparinase cocktail (mixture of heparinase I, heparinase II and heparinase III in heparinase reaction buffer). Each heparinase and heparinase reaction buffer are from New England Biolabs, catalog numbers P0735S, P0736S, P0737S and B0735S. Reactants were incubated at 37°C for 3 days, and the obtained heparan sulfate disaccharide was quantified by LC / MS.
[0531] like Fig.11 As shown, MPS-1 mice implanted with cells secreting the hIDUA BBB transport fusion protein had a statistically significant reduction in heparan sulfate in both brain tissues compared to control mice.
[0532] Example 5: Double IDS fusions with exemplary HSA and IGF1R binding domains in different orientations.
[0533] DNA expression vectors were engineered to encode two different hIDS fusion enzymes containing open reading frames in different orientations for a BBB penetrating sdAb (IGF1R5), an anti-HSA sdAb (R28), and hIDS, with a (G4S)4 amino acid linker located between each of these open reading frames. The different orientations evaluated were R28-(G4S)4-IGF1R5-(G4S)4-hIDS (e.g., Formula I fusion) and IGF1R5-(G4S)4-R28-(G4S)4-hIDS (e.g., Formula II fusion). ARPE-19 cells were transfected with one of the two expression vectors, and polyclonal colonies stably expressing the hIDS fusion enzymes were generated for each of the two transfections.
[0534] The in vitro IDS activity of the hIDS fusion protein secreted from each polyclonal pool was assessed by seeding cells from each cell line into 6-well tissue culture plates at approximately 400,000 cells in 2 ml of fresh medium per well. Twenty to twenty-four hours later, the conditioned cell culture medium was collected and the IDS protein concentration was determined using a 2-step enzymatic IDS activity assay and compared with a known standard (iduronidase). Briefly, in a black 96-well plate, 3ul of cell culture medium was added to 15.6ul of water and 20ul of a buffer containing 20mM lead (II) acetate in 0.2M sodium acetate (pH 5.0). 1.4ul of 20mM substrate (2-sulfate 4-methylumbelliferyl-α-L-iduronidase reconstituted in DMSO) was added to all wells. The plate was incubated at 37°C for 10 minutes. To quench the first reaction, 40ul of 2x McIlvaine buffer (0.40M sodium phosphate, 0.20M citrate pH 4.5) supplemented with 5ug / mL laronidase was added to each well. The plate was incubated at 37°C for 10 minutes. To terminate the second reaction, 100ul of stop solution (0.5M NaOH+0.5M glycine) was added. In the first reaction step, the substrate (2-sulfate 4MU-α-iduronide) was hydrolyzed by iduronide 2-sulfatase (IDS) to product 4MU-iduronide. In the second reaction step, iduronic acid 2-sulfatase activity was quenched by adding excess phosphate, and α-L-iduronidase catalyzed the cleavage of the non-fluorescent product (4MU-iduronide) of the first reaction into a fluorescent product (4-MU). Fluorescence intensity was measured on a Biotek Cytation 3 in endpoint mode at excitation and emission wavelengths of 365 nm and 445 nm, respectively (top reading). Enzyme activity levels were compared to a standard curve generated with idursulfatase and the results are displayed in Fig.13The polyclonal pool expressing the R28-(G4S)4-IGF1R5-(G4S)4-hIDS (Formula I) dual fusion enzyme showed higher levels of hIDS activity than the cell line expressing the IGF1R5-(G4S)4-R28-(G4S)4-hIDS (Formula II) dual fusion, which is consistent with the hIDUA activity results obtained in Example 3, which showed that the hIDUA activity produced against the Formula I fusion (AB-L1-RB-L2-C) was higher than that against the Formula II fusion (RB-L1-AB-L2-C).
[0535] Example 6: Effects of implanting protected capsules producing exemplary BBB transport fusion proteins into MPS-1 mice on heparan sulfate in systemic tissues.
[0536] Encapsulate the secreted R28-(G4S) 4- IGF1R5-(G4S) 4- The protected capsules of cells of the polyclonal pool of hIDUA fusion enzyme are implanted into the IP gap of each of six MPS-1 mice. Six untreated MPS-1 mice of a group were observed as controls. 21 days after administration, these two groups of mice were euthanized, and the amount of heparan sulfate in various organs (liver, spleen, kidney, lung and heart) was evaluated. In brief, organ tissue homogenate was obtained, and tissue homogenate (10ul) was combined with an equal volume of heparinase mixture (mixture of heparinase I, heparinase II and heparinase III in heparinase reaction buffer). Each heparinase and heparinase reaction buffer are from New England Biolabs, catalog numbers P0735S, P0736S, P0737S and B0735S. Reactant was incubated at 37°C for 3 days, and the obtained heparan sulfate disaccharide was quantified by LC / MS.
[0537] like Fig.14 As shown, MPS-1 mice treated with the dual fusion enzyme (black bars) exhibited statistically significant reductions in heparan sulfate levels in each of liver, spleen, kidney, lung, and heart tissue samples relative to untreated mice (grey bars).
[0538] Example 7: Evaluation of the immunogenic potential of exemplary BBB transport fusion proteins.
[0539] The following molecules were evaluated for in silico immunogenicity by a commercial vendor (EpiVax, Providence, Rhode Island, USA): R28-(G4S)4-IGF1R5-(G4S)4-hIDUA fusion enzyme; (2) R28-H5-(G4S)4-IGF1R5-H2-(G4S)4-hIDUA fusion enzyme, wherein the R28-H5 component is a humanized R28 variant having an amino acid sequence (SEQ ID NO:5) and the IGF1R5-H2 component is a humanized IGF1R5 variant having an amino acid sequence (SEQ ID NO:12); (3) native human IDUA protein alone (i.e., not fused to any other molecule); and (4) individual parental and humanized sdAbs present in both fusion enzymes. Briefly, EpiVax evaluated the amino acid sequences of fusion constructs containing molecules against predicted T-cell epitopes as well as the amino acid sequences of individuals using its proprietary EpiMatrix algorithm. Each molecule was scored based on the total predicted T-cell epitope content and ranked against the EpiMatrix protein immunogenicity scale, where the molecule can be directly compared to proteins with known immunogenicity. As shown in the table just below, each of the fusion enzymes had a lower predicted immunogenicity score than native hIDUA alone.
[0540]
[0541] Example 8: In vivo comparison of exemplary humanized and camelid BBB transport fusion proteins.
[0542] Three groups of MPS-1 mice (n=6 mice per group) were implanted with protected capsules encapsulating the secreted humanized IDUA fusion protein [R28-H5-(G4S) 4- IGF1R5-H2-(G4S) 4- hIDUA or IGF1R5-H2-(G4S) 4-R28-H5-(G4S)4-hIDUA] or a polyclonal pool of camelid IDUA fusion proteins [R28-(G4S)4-IGF1R5-(G4S)4-hIDUA]. The IDUA amino acid sequence in each fusion protein is identical. A group of four untreated MPS-1 mice were observed as controls. All mouse cohorts were euthanized 28 days after administration and the amount of heparan sulfate in the midbrain was assessed. In brief, midbrain tissue homogenate was obtained and the tissue homogenate (10ul) was combined with an equal volume of heparinase mixture (a mixture of heparinase I, heparinase II and heparinase III in heparinase reaction buffer). Each heparinase and heparinase reaction buffer were from New England Biol abs, catalog numbers P0735S, P0736S, P0737S and B0735S. The reactions were incubated at 37°C for 3 days and the resulting heparan sulfate disaccharide was quantified by LC / MS. Fig.15 As shown, MPS-1 mice treated with any of the three dual fusion enzymes (grey bars) exhibited a statistically significant reduction in midbrain heparan sulfate levels relative to untreated mice (black bars). There were no statistically significant differences in midbrain heparan sulfate reductions between the treated mouse cohorts.
[0543] Equivalents and scope
[0544] This application mentions various granted patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any incorporated reference and this specification, the specification shall prevail. In addition, any specific embodiment of the present disclosure within the prior art may be explicitly excluded from any one or more claims. Because such embodiments are considered to be known to those of ordinary skill in the art, they may be excluded even if they are not explicitly set forth herein. Any specific embodiment of the present disclosure may be excluded from any claim for any reason, whether or not it involves the existence of prior art.
[0545] Those skilled in the art will recognize or be able to determine using only routine experimentation many equivalents to the specific embodiments described herein. The scope of the embodiments of the present invention described herein is not intended to be limited to the above description, drawings or examples, but as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications may be made to this specification without departing from the spirit or scope of the present disclosure, as defined in the following claims.
Claims
1. A fusion protein comprising a structure defined by the following from the N-terminus to the C-terminus: Formula I: AB-L1-RB-L2-C or Formula II: RB-L1-AB-L2-C, Wherein for each of Formula I and Formula II: AB contains a domain that binds to human serum albumin (HSA); L1 may be present or absent and comprises a first linker amino acid sequence; RB contains a domain that binds to the extracellular domain of human IGF1R (hIGF1R); L2 may be present or absent, and comprises a second linker amino acid sequence that is identical to or different from the first linker amino acid sequence; and C is a cargo moiety, optionally said cargo moiety comprises, consists essentially of, or consists of the amino acid sequence of a polypeptide.
2. The fusion protein of claim 1, which is defined by formula I: AB-L1-RB-L2-C.
3. The fusion protein of claim 1, wherein each of AB and RB has a molecular weight of less than about any of 75 kDa, 50 kDa or 25 kDa, and optionally the cargo portion has a molecular weight of about 1 kD to about 200 kD, or about 2 kD to about 100 kD.
4. The fusion protein according to claim 1, wherein (i) AB comprises a set of first, second and third amino acid sequences corresponding to the three complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region of an anti-HSA antibody, optionally wherein the set of first, second and third amino acid sequences is selected from: (a) GRTFIAYA (SEQ ID NO: 1), ITNFAGGTT (SEQ ID NO: 2), AADRSAQTMRQVRPVLPY (SEQ ID NO: 3); (b) GFLLRSNTM (SEQ ID NO: 41), IRPSGLT (SEQ ID NO: 42), HTRPPFQRDS (SEQ ID NO: 43); (c) GFLLRSNTM (SEQ ID NO: 41), IRPSGLT (SEQ ID NO: 42), ATRPPFQRDS (SEQ ID NO: 44); (d) GRTFDNYVM (SEQ ID NO: 45), ISGSGSIT (SEQ ID NO: 46), AAGSRRTYYREPKFYPS (SEQ ID NO: 47); (e) GSTFSSSSV (SEQ ID NO:48), ITSGGST (SEQ ID NO:49), NVAGRNWVPISRYSPGPY (SEQ ID NO:50); and (f) GSTFSSSSV (SEQ ID NO: 48), ITSGGST (SEQ ID NO: 49), AVAGRNWVPISRYSPGPY (SEQ ID NO: 51); or (ii) AB comprises, consists essentially of, or is composed of an amino acid sequence selected from the group consisting of composition: (a) QVQLVESGGGLVQAGGSLRLSCVASGRTFIAYAMGWFR QAPGKEREFVAAITNFAGGTTYYADSVKGRFTISRDNAKTTVYLQ MNSLKPEDTALYYCAADRSAQTMRQVRPVLPYWGQGTQVTVSS (SEQ ID NO: 4) or a conservatively substituted variant thereof; (b) QVQLVESGGGLVQPGGSLRLSCAASGRTFIAYAMGWFR QAPGKEREFVAAITNFAGGTTYYADSVKGRFTISRDNAKTTVYLQ MNSLRAEDTAVYYCAADRSAQTMRQVRPVLPYWGQGTLVTVSS (SEQ ID NO: 5) or a conservatively substituted variant thereof; (c) QVKLEESGGGLVQAGGSLRLSCVGPGFLLRSNTMGWYR QAPGKERELVAFIRPSGLTNYNDAVQGRFTISRDNAKNTVYLQMNALKPEDTAVYYCHTRPPFQRDSWGQGTQV TVSS (SEQ ID NO: 52) or a conservatively substituted variant thereof; (d) QVQLVESGGGLVQPGGSLRLSCAGPGFLLRSNTMGWYR QAPGKERELVAFIRPSGLTNYNDAVQGRFTISRDNAKNTVYLQMNSLRAEDTAVYYCHTRPPFQRDSWGQGTLV TVSS (SEQ ID NO: 53) or a conservatively substituted variant thereof; (e) QVQLVESGGGFVQAGGSLRLSCAASGRTFDNYVMAWFR QAPGKEREFVASISGSGSITNYANSVKDRFTISRDSAKNAIYLQMN SLKPEDTALYYCAAGSRRTYYREPKFYPSWGQGTQVTVSS (SEQ ID NO: 54) or a conservatively substituted variant thereof; (f) EVQLVESGGGLVQPGGSLRLSCAASGRTFDNYVMAWFR QAPGKGLEFVSSISGSGSITNYANSVKDRFTISRDNSKNTLYLQMN SLRAEDTAVYYCAAGSRRTYYREPKFYPSWGQGTLVTVSS (SEQ ID NO: 55) or a conservatively substituted variant thereof; (g) QVKLEESGGGLVQAGGSLKLSCAASGSTFSSSSVGWYRQ APGQQRELVAAITSGGSTNTADSVKGRFTMSRDNAKNTVYLQMR DLKPEDTAVYYCNVAGRNWVPISRYSPGPYWGQGTQVTVSS (SE Q ID NO: 56) or a conservatively substituted variant thereof; and (h) EVQLVESGGGLVQPGGSLRLSCAASGSTFSSSSVGWYRQ APGKGLELVSAITSGGSTNTADSVKGRFTISRDNSKNTLYLQMNS LRAEDTAVYYCNVAGRNWVPISRYSPGPYWGQGTLVTVSS (SEQ ID NO: 57) or a conservatively substituted variant thereof.
5. The fusion protein of claim 4, wherein the first amino acid sequence, the second amino acid sequence and the third amino acid sequence in AB are: GRTFIAYA (SEQ ID NO: 1) or a conservatively substituted variant thereof; ITNFAGGTT (SEQ ID NO: 2) or a conservatively substituted variant thereof; and AADRSAQTMRQVRPVLPY (SEQ ID NO: 3) or a conservatively substituted variant thereof.
6. The fusion protein of claim 1, wherein AB comprises, consists essentially of, or consists of an amino acid sequence from sdAb.
7. The fusion protein of claim 6, wherein AB consists essentially of or is selected from the following amino acid sequence: composition: (i) SEQ ID NO: 4; (ii) SEQ ID NO: 5; or (iii) the amino acid sequence of the heavy chain variable region of an antibody that cross-competes with the sdAb consisting of SEQ ID NO: 4 or SEQ ID NO: 5 for binding to HSA.
8. The fusion protein of claim 1, wherein the fusion protein binds to domain 1 (DI) or domain 2 (DII) of HSA via AB and does not substantially inhibit binding of human FcRn to HSA.
9. The fusion protein of claim 1, wherein the fusion protein dissociates via the AB domains with a dissociation constant (K) of less than about 0.1 nM to about 1,000 nM in the pH range of about 5.0 to about 7.4 as determined by surface plasmon resonance at 25°C. D ) binds to HSA with affinity, optionally wherein the K D It is about 0.5 nM to about 500 nM, about 1 nM to about 250 nM, about 5 nM to about 50 nM, about 10 nM to about 25 nM, or about 0.5 nM to about 1 nM.
10. The fusion protein of claim 1, wherein the fusion protein binds to at least one mammalian serum albumin ortholog via AB at a pH range of about 5.5 to about 7.4 at 25°C, optionally wherein the fusion protein binds via AB to two or more mammalian serum albumins selected from the group consisting of mouse serum albumin, rat serum albumin, hamster serum albumin, rabbit serum albumin, guinea pig albumin, porcine albumin, cat albumin, dog albumin, and non-human primate serum albumin, optionally wherein the non-human primate serum albumin is cynomolgus serum albumin or rhesus serum albumin.
11. The fusion protein of claim 1, wherein the fusion protein binds to hIGF1R expressed on the surface of human brain endothelial cells via the RB domain, optionally wherein the fusion protein binds to an epitope in the extracellular domain of hIGF1R comprising FENFLHNSIFVPR (SEQ ID NO: 6) via RB.
12. The fusion protein of claim 1, wherein the fusion protein does not substantially bind to human insulin receptor (h-IR), optionally wherein the fusion protein does not substantially inhibit the binding of insulin, insulin growth factor 1 (IGF1) or insulin growth factor 2 (IGF2) to hIGF1R.
13. The fusion protein of claim 1, wherein the fusion protein has a K of about 0.1 nM to about 1,000 nM via RB in the pH range of about 5.0 to about 7.4 as determined by surface plasmon resonance at 25°C. D Affinity binds to hIGF1R, optionally wherein the K D is any of (i) about 0.2 nM to about 500 nM, 250 nM, 100 nM, 50 nM, 25 nM or 10 nM; (ii) about 0.5 nM to about 250 nM, 100 nM, 50 nM, 25 nM, 10 nM or 5 nM; or (iii) about 1 nM to about 100 nM, 50 nM, 25 nM, 10 nM or 5 nM.
14. The fusion protein of claim 13, wherein the fusion protein is synthesized via RB with a K of 1 nM to 10 nM. D Binds to hIGF1R.
15. The fusion protein of claim 1, wherein the fusion protein binds to at least one mammalian IGF1R ortholog via RB at 25°C and in a pH range of about 5.0 to about 7.4, optionally wherein the fusion protein binds via RB to two or more mammalian IGF1R proteins selected from the group consisting of mouse IGF1R, rat IGF1R, hamster IGF1R, rabbit IGF1R, guinea pig IGF1R, dog IGF1R, cat IGF1R, and non-human primate IGF1R, optionally wherein the non-human primate IGF1R is cynomolgus monkey IGF1R or rhesus monkey IGF1R.
16. The fusion protein of claim 1, wherein (i) RB comprises a first amino acid sequence, a second amino acid sequence and a third amino acid sequence corresponding to the three complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region of an anti-hlGF1R antibody, optionally wherein the first amino acid sequence, the second amino acid sequence and the third amino acid sequence are selected from: (a) GRTIDNYA (SEQ ID NO: 7), IDWGDGGX, wherein X is A or T (SEQ ID NO: 8), AMARQSRVNLDVARYDY (SEQ ID NO: 9); (b) GRTIDNYA (SEQ ID NO: 7), IDWGDGGA (SEQ ID NO: 10), AMARQSRVNLDVARYDY (SEQ ID NO: 9); (c) EYPSNFYA (SEQ ID NO:58), VSRDGLTT (SEQ ID NO:59), AIVITGVWNKVDVNSRSYHY (SEQ ID NO:60); and (d) GGTVSPTA (SEQ ID NO: 61), ITWSRGTT (SEQ ID NO: 62), AASTFLRILPEESAYTY (SEQ ID NO: 63); or (ii) RB comprises, consists essentially of, or is composed of an amino acid sequence selected from the group consisting of composition: (a) QVKLEESGGGLVQAGGSLRLSCAASGRTIDNYAMAWSR QAPGKDREFVATIDWGDGGARYANSVKGRFTISRDNAKGTMYL QMNNLEPEDTAVYSCAMARQSRVNLDVARYDYWGQGTQVTVS S (SEQ ID NO: 11) or a conservatively substituted variant thereof; (b) QVQLVESGGGLVQPGGSLRLSCAASGRTIDNYAMAWVR QAPGKGLEWVATIDWGDGGTRYANSVKGRFTISRDNSKNTMYL QMNSLRAEDTAVYYCAMARQSRVNLDVARYDYWGQGTLVTVSS (SEQ ID NO: 12) or a conservatively substituted variant thereof; (c) QVKLEESGGGLVQAGGSLRLSCVASEYPSNFYAMSWFR QAPGKEREFVAGVSRDGLTTLYADSVKGRFTMSRDNAKNTVDL QMNSVKAEDTAVYYCAIVITGVWNKVDVNSRSYHYWGQGTQV TVSS (SEQ ID NO: 67) or a conservatively substituted variant thereof; (d) EVQLVESGGGLVQPGGSLRLSCAASEYPSNFYAMSWFRQ APGKEREFVSGVSRDGLTTLYADSVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCAIVITGVWNKVDVNSRSYHYWGQGTLVTVSS (SEQ ID NO: 68), or a conservatively substituted variant thereof; (e) QVKLEESGGGLVQAGGSLRLSCEVSGGTVSPTAMGWFR QAPGKEREFVGHITWSRGTTRVASSVKDRFTISRDSAKNTVYLQMNSLKSEDTAVYYCAASTFLRILPEESAYTYWGQGTQVTVSS (SEQ ID NO: 69) or a conservatively substituted variant thereof; and (f) QVQLVESGGGLVQPGGSLRLSCAVSGGTVSPTAMGWVR QAPGKGLEWVGHITWSRGTTRYASSVKGRFTISRDNSKNTVYLQ MNSLRAEDTAVYYCAASTFLRILPEESAYTYWGQGTLVTVSS (SE Q ID NO: 70) or a conservatively substituted variant thereof.
17. The fusion protein of claim 16, wherein the first amino acid sequence, the second amino acid sequence and the third amino acid sequence in RB are: GRTIDN YA (SEQ ID NO: 7), or a conservatively substituted variant thereof; IDWGDGGA (SEQ ID NO: 10), or a conservatively substituted variant thereof; and AMARQSRVNLDVARYDY (SEQ ID NO: 9), or a conservatively substituted variant thereof.
18. The fusion protein of claim 17, wherein RB consists essentially of or is composed of composition: (i) SEQ ID NO: 11; (ii) SEQ ID NO: 12; or (iii) an amino acid sequence of the heavy chain variable region of an antibody that cross-competes with the sdAb consisting of SEQ ID NO: 11 or SEQ ID NO: 12 for binding to hIGF1R.
19. The fusion protein of claim 1, wherein L1 and L2 are present, optionally wherein each of L1 and L2 is a linker peptide less than 50 amino acids in length, or between about 15 and 30 amino acids in length, or between about 20 and 25 amino acids in length.
20. The fusion protein of claim 19, wherein one or both of L1 and L2 consists essentially of or consists of (GGGGS)m, wherein m is 4 or 5.
21. The fusion protein of claim 20, wherein each of L1 and L2 consists essentially of or consists of: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 14).
22. The fusion protein of claim 1, wherein the cargo moiety is a cargo polypeptide selected from the group consisting of an enzyme, a growth factor, a cytokine, or an antibody or an antigen-binding fragment thereof, optionally wherein the cargo polypeptide comprises a mature amino acid sequence encoded by a wild-type human gene.
23. The fusion protein of claim 22, wherein the cargo polypeptide is an acid α-glucosidase protein (GAA), an α-galactosidase A (GLA) protein, an α-L-iduronidase (IDUA) protein, an α-N-acetyl-glucosaminidase (NAGLU) protein, a β-glucuronidase (GUSB) protein, a β-glucosidase (GBA) protein, an iduronate-2-sulfatase (IDS) protein, a heparan-α-glucosaminidase N-acetyltransferase (HGSNAT) protein, an N-acetylgalactosamine-6-sulfatase (GNS) protein, or an N-sulfoglucosamine sulfohydrolase (SGSH) protein, optionally wherein the cargo polypeptide is not an IDS protein.
24. The fusion protein of claim 22 or 23, wherein the cargo polypeptide is an IDUA protein, optionally wherein the IDUA protein consists essentially of or consists of composition: (i) amino acids 26, 27 or 28 to amino acid 653 of SEQ ID NO: 22; or (ii) amino acids 27-653 of SEQ ID NO:
22.
25. The fusion protein of claim 24, which has an IDUA enzyme activity within 80%-120% of the corresponding enzyme activity of the wild-type human IDUA protein.
26. The fusion protein of claim 22 or 23, wherein the cargo polypeptide is an IDS protein, optionally wherein the fusion protein comprises, consists essentially of, or consists of SEQ ID NO: 93 or SEQ ID NO:
94.
27. The fusion protein of claim 26, which has an IDS enzyme activity within 80%-120% of the corresponding enzyme activity of the wild-type human IDS protein.
28. The fusion protein of claim 1, comprising, consisting essentially of, or consisting of the amino acid sequence of the hIDUA fusion protein shown in Figure 3A, Figure 3B, Figure 3C, Figure 3D, Figure 3E, or Figure 3F, optionally wherein the fusion protein consists essentially of, or consists of, SEQ ID NO: 29, wherein each of m and n = 4.
29. A polynucleotide comprising a first nucleotide sequence encoding the fusion protein of claim 1, optionally wherein the polynucleotide is one strand of an isolated double-stranded DNA molecule.
30. The polynucleotide of claim 29, wherein the first nucleotide sequence is operably linked to a nucleotide sequence encoding a secretory signal sequence of the fusion protein, optionally wherein the secretory signal sequence comprises, consists essentially of, or consists of composition: SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85 or SEQ ID NO:
86.
31. The polynucleotide of claim 30, wherein the secretion signal sequence consists essentially of or consists of SEQ ID NO:
79.
32. The polynucleotide of claim 29, wherein the first nucleotide sequence is operably linked to a promoter sequence and a polyA signal sequence, optionally wherein the promoter sequence comprises, consists essentially of, or consists of SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34, and optionally wherein the polyA signal sequence comprises, consists essentially of, or consists of SEQ ID NO: 35, SEQ ID NO: 36, or SEQ ID NO:
37.
33. The polynucleotide of claim 32, comprising SEQ ID NO:
39.
34. A genetically modified mammalian cell transiently or stably transfected with the polynucleotide of claim 29, optionally wherein the cell is derived from a human cell.
35. The genetically modified mammalian cell of claim 34, wherein the polynucleotide is inserted into at least one location in the genome of the mammalian cell.
36. The genetically modified mammalian cell of claim 34, derived from a RPE cell, optionally an ARPE-19 cell.
37. The genetically modified mammalian cell of claim 34, which is derived from an induced pluripotent stem cell (iPSC) or a mesenchymal stem cell (MSC).
38. A composition comprising a plurality of genetically modified cells, wherein each of the plurality of genetically modified cells is a genetically modified cell as defined by claim 34, optionally wherein the plurality of genetically modified cells are obtained from a culture of a monoclonal cell line.
39. An implantable device comprising at least one cell-containing compartment comprising the genetically modified cells of claim 34 or the composition of claim 38; and further comprising at least one means for reducing a foreign body reaction (FBR) when the device is implanted in a subject, optionally wherein the device comprises a spherical two-compartment hydrogel capsule having a diameter of about 0.75 mm to about 2 mm.
40. The implantable device of claim 39, wherein the cell-containing compartment comprises a polymer composition, wherein the polymer composition comprises alginate covalently modified with a peptide, wherein the peptide consists essentially of or consists of GRGDSP (SEQ ID NO: 89), GGRGDSP (SEQ ID NO: 90), or GGGRGDSP (SEQ ID NO: 91).
41. The implantable device of claim 39, wherein the cell-containing compartment is surrounded by a barrier compartment comprising an alginate hydrogel and optionally a compound of formula (III) or a pharmaceutically acceptable salt thereof disposed on an outer surface of the barrier compartment, Wherein formula (III) is in A is alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -O-, -C(O)O-, -C(O)-, -OC(O)-, -N(R C )-、-N(R C )C(O)-、-C(O)N(R C )-、-N(R C )C(O)(C 1 -C 6 -alkylene)-, -N(R C )C(O)(C 1 -C 6 -alkenylene)-, -N(R C )N(R D )-、-NCN-、-C(=N(R C )(R D ))O-、-S-、-S(O) x -、-OS(O) x -、-N(R C )S(O) x -、-S(O) x N(R C )-、-P(R F ) y -、-Si(OR A ) 2 -、-Si(R G )(OR A )-、-B(OR A )- or a metal, each of which is optionally linked to an attachment group (e.g., an attachment group described herein) and optionally substituted by one or more R 1 replace; L 1 and L 3 Each of the R is independently a bond, an alkyl group or a heteroalkyl group, wherein each alkyl group and heteroalkyl group is optionally substituted by one or more R 2 replace; L 2 is the key; M is absent, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally replaced by one or more R 3 replace; P is absent, cycloalkyl, heterocyclyl, or heteroaryl, each of which is optionally replaced by one or more R 4 replace; Z is hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, -OR A 、-C(O)R A 、-C(O)OR A 、-C(O)N(R C )(R D )、-N(R C )C(O)R A 、-N(R C )(R D ), cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted by one or more R 5 replace; Each R A , R B , R C , R D , R E , R F and R G are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, halogen, azido, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted by one or more R 6 replace; or R C and R D Together with the nitrogen atom to which they are attached, they form a 6 substituted rings (e.g., 5-7 membered rings); Each R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, -OR A1 、-C(O)OR A1 、-C(O)R B1 、-OC(O)R B1 、-N(R C1 )(R D1 )、-N(R C1 )C(O)R B1 、-C(O)N(R C1 ), SR E1 、S(O) x R E1 、-OS(O) x R E1 、-N(R C1 )S(O) x R E1 、-S(O) x N(R C1 )(R D1 )、-P(R F1 ) y , cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally replaced by one or more R 7 replace; Each R A1 , R B1 , R C1 , R D1 , R E1 and R F1 are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted by one or more R 7 replace; Each R 7 are independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxy, cycloalkyl or heterocyclyl; x is 1 or 2; and y is 2, 3, or 4.
42. The implantable device of claim 41, wherein the barrier compartment comprises Or a chemically modified alginate or a pharmaceutically acceptable salt thereof.
43. A preparation of devices, wherein each device in the preparation is a device as described in claim 39.
44. A hydrogel capsule, include: (i) an interior compartment comprising a plurality of the genetically modified cells of claim 34 encapsulated in a first polymer composition, wherein the first polymer composition comprises a hydrogel-forming polymer, optionally wherein the concentration of the genetically modified cells in the interior compartment is at least 40 million cells / ml of the first polymer composition; and (ii) a barrier compartment surrounding the inner compartment and comprising a second polymer composition, wherein the second polymer composition comprises alginate covalently modified with at least one compound of formula (III) or a pharmaceutically acceptable salt thereof, optionally wherein the compound of formula (III) is selected from the compounds provided in the following table:
45. A capsule composition comprising a plurality of the hydrogel capsules of claim 44 in a pharmaceutically acceptable carrier.
46. The capsule composition of claim 45, wherein the genetically modified cells in the plurality of hydrogel capsules express and secrete an IDUA fusion protein consisting essentially of or consisting of SEQ ID NO: 29, wherein each of m and n = 4.
47. A pharmaceutical composition comprising the fusion protein of claim 1 and a pharmaceutically acceptable carrier.
48. The pharmaceutical composition of claim 47, wherein the fusion protein consists essentially of or consists of SEQ ID NO: 29, wherein each of m and n = 4.
49. A method of preventing or treating a disease or disorder of the central nervous system (CNS) of a subject, the method include: (i) administering the pharmaceutical composition of claim 47 to the subject; (ii) implanting a device or device formulation as claimed in any one of claims 39; or (iii) implanting the capsule composition of claim 45.
50. A method of treating a human subject diagnosed with mucopolysaccharidosis type 1 (MPS-1) disease, the method include: (i) providing the capsule composition according to claim 46; as well as (ii) disposing the capsule composition in the body of the subject, optionally wherein the disposing step comprises placing the capsule composition in the intraperitoneal space or in a large sac of the peritoneal cavity of the subject.
